var title_f27_7_27760="EMG repetitive stimulation";
var content_f27_7_27760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repetitive stimulation of deltoid muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Repetitive nerve stimulation in the brachial plexus and recording from the deltoid muscle reveals decrements in the motor action potential with sequential stimuli. This pattern is characteristic of myesthenia gravis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27760=[""].join("\n");
var outline_f27_7_27760=null;
var title_f27_7_27761="Blunt chest trauma algo ped";
var content_f27_7_27761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Blunt chest trauma in children ED management",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 588px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AP: anterior-posterior; CT: computed tomography; CXR: chest x-ray; ECG: electrocardiogram; ED: emergency department; FAST: Focused Assessment with Sonography in Trauma; OR: operating room; PA: posterior-anterior; PTX: pneumothorax; TEE: transesophageal echocardiography; US: ultrasound.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27761=[""].join("\n");
var outline_f27_7_27761=null;
var title_f27_7_27762="Flexible bronchoscope";
var content_f27_7_27762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram of a flexible bronchoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27762=[""].join("\n");
var outline_f27_7_27762=null;
var title_f27_7_27763="Single stage breast reconstruct";
var content_f27_7_27763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Single stage breast reconstruction in a patient with prior bilateral augmentation mammoplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left immediate single-stage breast reconstruction following mastectomy, utilizing a double lumen normal saline/silicone gel implant. Left panel: preoperative appearance; right panel, postoperative appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge de la Pedraja, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27763=[""].join("\n");
var outline_f27_7_27763=null;
var title_f27_7_27764="Fluticasone (topical): Pediatric drug information";
var content_f27_7_27764=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluticasone (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=see_link\">",
"    see \"Fluticasone (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/54/15204?source=see_link\">",
"    see \"Fluticasone (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9349371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cutivate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9349372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cutivate&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F990195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F990197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=see_link\">",
"      see \"Fluticasone (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Topical:",
"     <b>",
"      Note:",
"     </b>",
"     If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy of use &gt;4 weeks in pediatric patients have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Atopic dermatitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &ge;3 months, Children, and Adolescents: Cream: Apply sparingly to affected area once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;1 year and Adolescents: Lotion: Apply sparingly to affected area once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Corticosteroid-responsive dermatoses:",
"     </b>",
"     Infants &ge;3 months, Children, and Adolescents: Cream: Apply sparingly to affected area twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Atopic dermatitis:",
"     </b>",
"     Cream, lotion: Apply sparingly to affected area once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Corticosteroid-responsive dermatoses:",
"     </b>",
"     Cream, lotion, ointment: Apply sparingly to affected area twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F242556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as propionate: 0.05% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutivate&reg;: 0.05% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as propionate: 0.05% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutivate&reg;: 0.05% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as propionate: 0.005% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutivate&reg;: 0.005% (30 g, 60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9349374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10494303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply sparingly to affected area, gently rub in until disappears; do not use on open skin; avoid application on face, underarms, or groin area unless directed by physician; avoid contact with eyes; do not occlude area unless directed; do not apply to diaper area",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10494301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, ointment: Store at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not refrigerate; keep tightly closed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F990196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Relief of inflammation and pruritus associated with corticosteroid-responsive dermatoses (eg, atopic dermatitis) (medium potency topical corticosteroid) (FDA approved in ages &ge;3 months and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Relief of inflammation and pruritus associated with atopic dermatitis (FDA approved in ages &ge;1 year and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Relief of inflammation and pruritus associated with corticosteroid-responsive dermatoses (medium potency topical corticosteroid) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9349367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cutivate&reg; may be confused with Ultravate&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively, [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9349426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dryness, eczema infection, exacerbation of eczema, pruritus, rash (erythematous; children), skin irritation, telangiectasia (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness of fingers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acneiform eruptions, atrophy, blurred vision, Cushing syndrome, dermatitis, edema, folliculitis, hemorrhage, hyperglycemia, immunosuppression, leukopenia, secondary infection, sepsis, skin discoloration, thrombocytopenia, urticaria, viral warts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reported with other topical corticosteroids (in decreasing order of occurrence): Hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin atrophy, striae, hypertrichosis, miliaria, pustular psoriasis from chronic plaque psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10494271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluticasone or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10494274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; these adverse effects (as well as intracranial hypertension) may occur with topical use and have been reported in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Enhanced tumor growth has been reported in mice exposed concurrently to low-level ultraviolet (UV) radiation and topical fluticasone lotion and lotion vehicle alone; clinical applicability of these results to humans is unknown; enhanced tumor growth in humans has not been reported; however, patients should minimize UV light exposure when using fluticasone topical products; avoid excessive or unnecessary exposure to natural and artificial sunlight, including sunbathing, tanning booths, sun lamps, etc.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10494272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse systemic effects may occur when topical steroids are used on large areas of the body, denuded areas, for prolonged periods of time, with an occlusive dressing, and/or in infants or small children; infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to a larger skin surface area to body mass ratio; use with caution in pediatric patients. HPA axis suppression occurred in two children (2 and 5 years old) of 43 pediatric patients treated topically with fluticasone cream for 4 weeks; application covered at least 35% of body surface area. HPA axis suppression was not reported with use of fluticasone lotion for at least 3-4 weeks in young pediatric patients (4 months to &lt;6 years) during clinical trials; however, it cannot be ruled out when topical fluticasone is used in any patient and especially with longer use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not use for the treatment of rosacea, perioral dermatitis, or in the presence of skin atrophy or infection at treatment site. Cutivate&reg; lotion and cream contain imidurea, an excipient; imidurea releases trace amounts of formaldehyde which may cause allergic sensitization, irritation, or may prevent healing or worsen dermatitis; avoid use in patients with sensitivity to formaldehyde; discontinue if irritation occurs and institute appropriate therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9349429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9349428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9349376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9349377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with systemic corticosteroids in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10494302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10494308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/54/15204?source=see_link\">",
"      see \"Fluticasone (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform physician if allergic to formaldehyde. Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval. Notify physician immediately if allergic symptoms develop. Report signs of infection. Avoid excessive or unnecessary exposure to sunlight and artificial light sources (sunbathing, sun lamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15].",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Schaffer ET, Fitzgerald JF, Molleston JP, et al, \"Comparison of Oral Prednisone and Topical Fluticasone in the Treatment of Eosinophilic Esophagitis: A Randomized Trial in Children,\"",
"      <i>",
"       Clin Gastroenterol Hepatol",
"      </i>",
"      , 2008, 6(2):165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/7/27764/abstract-text/18237866/pubmed\" id=\"18237866\" target=\"_blank\">",
"        18237866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15934 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27764=[""].join("\n");
var outline_f27_7_27764=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349371\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349372\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990195\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990197\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242556\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349374\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494303\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494301\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990196\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349367\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349426\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494271\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494274\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494272\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349429\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349428\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349376\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349377\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494302\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494308\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15934\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15934|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/3/30773?source=related_link\">",
"      Fluticasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/5/28756?source=related_link\">",
"      Fluticasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/45/32468?source=related_link\">",
"      Fluticasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26120?source=related_link\">",
"      Fluticasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12822?source=related_link\">",
"      Fluticasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25047?source=related_link\">",
"      Fluticasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=related_link\">",
"      Fluticasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/54/15204?source=related_link\">",
"      Fluticasone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_7_27765="Discharge planning for high-risk newborns";
var content_f27_7_27765=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Discharge planning for high-risk newborns",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27765/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27765/contributors\">",
"     Jane Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27765/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27765/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27765/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27765/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27765/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/7/27765/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For neonates who require a lengthy birth hospitalization, shortening the duration of neonatal hospitalization as much as possible is beneficial because it decreases the risk of hospital-acquired neonatal morbidity, shortens the period of separation of the parents from the infant, and lowers medical costs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, infants who require neonatal intensive care remain at increased risk for morbidity and mortality following discharge from the neonatal intensive care unit (NICU). These include infants who were born preterm, require technological support, have complicated family issues, or have an irreversible condition that may result in early death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comprehensive discharge planning is required to minimize the risk of morbidity and mortality from premature discharge and prevent prolongation of the hospital stay in an infant ready for discharge. This includes assessment of the neonate's medical status and readiness for discharge, completion of routine predischarge screening and care, parental education, and specific planning for follow-up and home care.",
"   </p>",
"   <p>",
"    Discharge planning for high-risk newborns will be presented here. The focus is primarily on premature infants as they represent the majority of NICU graduates. The care of the neonatal intensive care unit graduate is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=see_link\">",
"     \"Care of the neonatal intensive care unit graduate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discharge planning helps to ensure a smooth transition from the NICU to home. On the other hand, premature discharge home may place the infant at increased risk for morbidity and mortality. As a result, the American Academy of Pediatrics (AAP) published discharge guidelines in 2008 for the infant cared for in the NICU [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discharge planning should be developed and implemented by a multidisciplinary team consisting of physicians, nurses, respiratory therapists, occupational",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical therapists, and social workers. The process can begin soon after an infant is admitted to the NICU and is continued through regularly scheduled planning sessions during hospitalization.",
"   </p>",
"   <p>",
"    The following are the components of discharge planning. The successful completion of all of these is necessary prior to discharge.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of the neonate's clinical status and readiness for discharge based on:",
"     </li>",
"     <li>",
"      Parental readiness and education",
"     </li>",
"     <li>",
"      Predischarge screening and care",
"     </li>",
"     <li>",
"      Review of the hospital course",
"     </li>",
"     <li>",
"      Development of a home care plan including, if needed, arrangement for home medical equipment and supplies",
"     </li>",
"     <li>",
"      Communication and follow-up arrangements with the designated primary care provider",
"     </li>",
"     <li>",
"      Plan for monitoring growth and development after discharge",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEONATAL MEDICAL READINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants ready for discharge must be medically stable and without any acute illness. In preterm infants, discharge is considered only if an infant demonstrates physiologic stability by showing competency in all of the following functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain normal body temperature in an open crib with normal ambient temperature (24 to 25&ordm;C).",
"     </li>",
"     <li>",
"      Demonstrate maturity of respiratory control without episodes of apnea and bradycardia. The length of time before discharge that an infant should be free from apnea and bradycardia is controversial. However, five to eight days of observation after the discontinuation of caffeine therapy probably offers a sufficient margin of safety [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link&amp;anchor=H17699592#H17699592\">",
"       \"Management of apnea of prematurity\", section on 'Management overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Demonstrate mature oral feeding skills (breast or bottle) that will allow enough nutritional intake to promote appropriate growth.",
"     </li>",
"     <li>",
"      Demonstrate a consistent pattern of appropriate weight gain. There is a lack of clarity on how best to define optimal rates of growth for preterm infants; a goal of at least 15",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day is generally used in infants who weigh less than 2 kg, and a total between 15 to 20",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      for heavier infants. The growth should be parallel to the normal growth curve. If the other criteria are met, attaining a specific weight is not necessary for discharge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link&amp;anchor=H7#H7\">",
"       \"Growth management in preterm infants\", section on 'Discharge planning'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link&amp;anchor=H3#H3\">",
"       \"Growth management in preterm infants\", section on 'Normative growth data'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, the infant is discharged before one of the above competencies is met, provided there is a suitable plan for home care and monitoring that is agreed upon by both the health care team and the family. This may require additional support (eg, equipment and personal) at home, which will also need to be arranged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PARENTAL READINESS AND EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parents should demonstrate consistent involvement in their infant's care, and readiness and competency to provide home care. An individualized teaching plan should be developed to allow parents to acquire the knowledge and skills needed to care for their infant at home. This includes demonstration of feeding techniques, positioning, medication administration, and respiratory treatments, if needed.",
"   </p>",
"   <p>",
"    All parents should be trained in cardiopulmonary resuscitation. Some may need additional training in gastrostomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tracheostomy care and in the use of cardiorespiratory monitoring equipment.",
"   </p>",
"   <p>",
"    Parents also should be counseled about the importance of a safe sleeping environment including supine position and discouragement of devices such as wedges or sleep positioners and sleeping in car seats, swings, or slings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/6\">",
"     6",
"    </a>",
"    ]. Techniques used to enhance parental education include repeated demonstrations, parental rooming-in, and telephone assessment after discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The home environment should be assessed before discharge for adequate safety. Arrangements should be made for parents to participate in an ongoing family support program, if available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ROUTINE PREDISCHARGE SCREENING AND CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following routine screening and care should be completed prior to discharge:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All newborns require routine screening for metabolic and genetic disorders and hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H9#H9\">",
"       \"Screening tests in children and adolescents\", section on 'Hearing screen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The American Academy of Pediatrics (AAP) recommends that medically stable preterm infants should receive full immunization based upon their chronological age consistent with the schedule and dose recommended for normal full-term infants (",
"      <a class=\"graphic graphic_figure graphicRef82617 \" href=\"UTD.htm?24/55/25463\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Vaccination in preterm infants appears to be safe as illustrated by a prospective study of 473 very low birth weight infants (birth weight below 1500 g) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/14\">",
"       14",
"      </a>",
"      ]. Adverse events at the time of vaccination (mean gestational age of 37 weeks) included",
"      <span class=\"nowrap\">",
"       apnea/bradycardia",
"      </span>",
"      in 11 percent of patients, and local",
"      <span class=\"nowrap\">",
"       reactions/fever",
"      </span>",
"      in 3 percent. Infants with",
"      <span class=\"nowrap\">",
"       apnea/bradycardia",
"      </span>",
"      were more likely to have a lower gestational age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40964?source=see_link\">",
"     Palivizumab",
"    </a>",
"    should be given to eligible infants during respiratory syncytial virus season, and parents and other care providers who will be in close contact with the infant should receive appropriate influenza vaccination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=see_link&amp;anchor=H104282430#H104282430\">",
"     \"Respiratory syncytial virus infection: Prevention\", section on 'Prematurity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants at risk for developing retinopathy of prematurity (ROP) should have routine ophthalmologic screening. Examinations should continue until the infant's retinal vessels are mature and no longer at risk for developing ROP. After the retinal vessels are mature, follow-up with a pediatric ophthalmologist should be scheduled before the end of the first year of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H18#H18\">",
"       \"Retinopathy of prematurity\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to performing earlier screening for intraventricular hemorrhage, imaging may be recommended prior to discharge to detect periventricular leukomalacia or white matter injury in at-risk infants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link\">",
"       \"Periventricular leukomalacia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In specific cases, laboratory studies to document anemia or nutritional deficiencies (such as calcium, phosphate and vitamin D) may be appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link\">",
"       \"Anemia of prematurity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=see_link\">",
"       \"Calcium and phosphorus requirements of newborn infants\"",
"      </a>",
"      .).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REVIEW OF HOSPITAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants with a complicated hospital course and ongoing health issues, a thorough review of the hospitalization will facilitate the discharge and help make the transition of care to the outpatient setting. The results of diagnostic studies, such as cranial ultrasound examinations and echocardiograms, including those that require outpatient follow-up, should be reviewed. If possible, subspecialty consultants who will provide follow-up care should see the infant prior to hospital discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HOME HEALTH CARE PLAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plan for continuing home health care should be developed and implemented prior to discharge. Arrangements should be made for special medical equipment and services needed at home. They may include oxygen, mechanical ventilation, cardiorespiratory monitoring, or feeding pumps for transabdominal enteral nutrition. Arrangements can be made for home nursing. For infants with substantial health care needs, additional caregivers (eg, grandparents or child care providers) can be identified and trained.",
"   </p>",
"   <p>",
"    A social work evaluation should be performed in order to assist with social or financial needs. Loss of work and increased health care expenses may burden parents with financial difficulties. Referrals to the following programs after discharge can provide additional support and assistance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Women, Infants, and Children (WIC) program provides financial assistance for nutritional support for mothers and infants.",
"     </li>",
"     <li>",
"      Early Intervention Programs provide various therapies, such as physical and speech therapy, and support services at little or no cost to parents. Referring infants to local Early Intervention Programs prior to discharge can help decrease delays in resuming therapies once the infant is out of the hospital.",
"     </li>",
"     <li>",
"      Family support groups provide psychosocial support and advice for families.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants with an incurable terminal disorder have additional home care issues that must be considered and planned for, including referral to a hospice organization that will provide medical home visits, home-nursing visits and respite care, pain and comfort management, and provision of bereavement support for the family. If appropriate, a letter stating the infant's status with instructions not to resuscitate should be provided to the family to give to other caregivers or emergency medical workers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PRIMARY CARE PROVIDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pediatric care provider who will provide follow-up care after discharge should be identified by the parents early in the infant's hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. The neonatologist or hospital-based physician should establish contact with this physician prior to discharge. A full review of the infant's hospital course should be summarized in a report that is sent to the pediatric care provider and other specialists who will be involved in the infant's care after discharge.",
"   </p>",
"   <p>",
"    Collaborative arrangements can be made for primary care, specialty care (eg, pulmonology, cardiology, surgery), and neurodevelopmental follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/1\">",
"     1",
"    </a>",
"    ]. A plan for nutritional support and monitoring of growth also should be established. Neurodevelopmental follow-up in a special program should be arranged for extremely preterm and other high-risk infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=see_link\">",
"     \"Care of the neonatal intensive care unit graduate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A visit should be scheduled within two to four days of discharge and arrangements made for ongoing care, including subspecialty care if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GROWTH MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm infants are at risk for poor growth after discharge from the NICU. They must be closely monitored and may require interventions to promote better growth. Infants with chronic disease, such as chronic lung disease, short bowel syndrome, cholestatic jaundice, or osteopenia also may need nutrient supplementation. Consultation with a neonatal dietitian may be helpful to make feeding adjustments and for parental education. Excessive velocity of weight gain should also be avoided, as these infants are at risk for later obesity, diabetes, and cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27765/abstract/16\">",
"     16",
"    </a>",
"    ]. The specific details of monitoring growth and nutrient supplementation are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=see_link\">",
"     \"Growth management in preterm infants\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who require neonatal intensive care remain at increased risk for morbidity and mortality following discharge from the neonatal intensive care unit (NICU). These infants require comprehensive discharge planning to ensure a smooth transition from the NICU to the home and reduce morbidity and mortality after discharge.",
"   </p>",
"   <p>",
"    The components of discharge planning that need to be met prior to discharge include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic stability of the infant indicating that the neonate is ready for discharge. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Neonatal medical readiness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parental readiness and acquisition of the skills required for home care of their infant. &nbsp;(See",
"      <a class=\"local\" href=\"#H4\">",
"       'Parental readiness and education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Completion of routine predischarge screening and care. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Routine predischarge screening and care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Review of the hospital course (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Review of hospital course'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Development of a home care plan and if necessary, arrangements for additional medical support and equipment. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Home health care plan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ongoing communication and follow-up arrangements with primary care provider and specialists, if indicated. &nbsp;(See",
"      <a class=\"local\" href=\"#H8\">",
"       'Primary care provider'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plan for monitoring growth and development. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Growth monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/1\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn. Hospital discharge of the high-risk neonate. Pediatrics 2008; 122:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/2\">",
"      Brooten D, Kumar S, Brown LP, et al. A randomized clinical trial of early hospital discharge and home follow-up of very-low-birth-weight infants. N Engl J Med 1986; 315:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/3\">",
"      Eichenwald EC, Aina A, Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics 1997; 100:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/4\">",
"      Darnall RA, Kattwinkel J, Nattie C, Robinson M. Margin of safety for discharge after apnea in preterm infants. Pediatrics 1997; 100:795.",
"     </a>",
"    </li>",
"    <li>",
"     Eichenwald EC. Apnea of Prematurity. In: Primary Care of the Premature Infant, Brodsky D, Ouellette MA (Eds), Saunders Elsevier, Philadelphia 2008. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/6\">",
"      Task Force on Sudden Infant Death Syndrome. SIDS and Other Sleep-Related Infant Deaths: Expansion of Recommendations for a Safe Infant Sleeping Environment. Pediatrics 2011; 128:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/7\">",
"      Kotagal UR, Perlstein PH, Gamblian V, et al. Description and evaluation of a program for the early discharge of infants from a neonatal intensive care unit. J Pediatr 1995; 127:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/8\">",
"      Kun S, Warburton D. Telephone assessment of parents' knowledge of home-care treatments and readmission outcomes for high-risk infants and toddlers. Am J Dis Child 1987; 141:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/9\">",
"      Kaye CI, Committee on Genetics, Accurso F, et al. Newborn screening fact sheets. Pediatrics 2006; 118:e934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/10\">",
"      Kaye CI, Committee on Genetics, Accurso F, et al. Introduction to the newborn screening fact sheets. Pediatrics 2006; 118:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/11\">",
"      American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. Pediatrics 2007; 120:898.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Infectious Disease American Academy of Pediatrics. Immunization in special clinical circumstances. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering, LK (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/13\">",
"      Saari TN, American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 2003; 112:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/14\">",
"      Furck AK, Richter JW, Kattner E. Very low birth weight infants have only few adverse events after timely immunization. J Perinatol 2010; 30:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/15\">",
"      Casiro OG, McKenzie ME, McFadyen L, et al. Earlier discharge with community-based intervention for low birth weight infants: a randomized trial. Pediatrics 1993; 92:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27765/abstract/16\">",
"      Casey PH. Growth of low birth weight preterm children. Semin Perinatol 2008; 32:20.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4974 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27765=[""].join("\n");
var outline_f27_7_27765=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEONATAL MEDICAL READINESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PARENTAL READINESS AND EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ROUTINE PREDISCHARGE SCREENING AND CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REVIEW OF HOSPITAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HOME HEALTH CARE PLAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRIMARY CARE PROVIDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GROWTH MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4974\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4974|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/55/25463\" title=\"figure 1\">",
"      Childhood immunization schedule 0 to 6 yrs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40567?source=related_link\">",
"      Calcium and phosphorus requirements of newborn infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11738?source=related_link\">",
"      Care of the neonatal intensive care unit graduate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23912?source=related_link\">",
"      Growth management in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=related_link\">",
"      Periventricular leukomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=related_link\">",
"      Respiratory syncytial virus infection: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_7_27766="Echocardiographic evaluation of the right ventricle";
var content_f27_7_27766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of the right ventricle",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27766/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27766/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27766/contributors\">",
"     Bryan Ristow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27766/contributors\">",
"     Xiushui Ren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27766/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27766/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27766/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27766/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/7/27766/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging the right ventricle is an essential and highly informative portion of the comprehensive echocardiographic evaluation. Patients with an abnormality of the left heart on echocardiographic examination often have concomitant right ventricular abnormalities.",
"   </p>",
"   <p>",
"    The normal right ventricle can be recognized by a number of echocardiographic features. Its free wall is &lt;0.4 mm thick, its apex is heavily trabeculated and dominated by the septal marginal trabeculation or moderator band, and its most active contraction occurs along its longitudinal axis. This latter feature creates a striking annular plane motion recognized best in the apical four chamber and subcostal views. In all views, the body of the right ventricle is visually subordinate to the companion left ventricle.",
"   </p>",
"   <p>",
"    The echocardiographic evaluation of the right ventricle will be reviewed here. The evaluation of the right ventricle using other imaging modalities as well as evaluation of non-right ventricular structures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link&amp;anchor=H2#H2\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Radionuclide ventriculography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link&amp;anchor=H12#H12\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\", section on 'Echocardiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13240?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of the left ventricle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHIC EVALUATION OF THE RIGHT VENTRICLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the right ventricle (RV) involves evaluation of wall thickness, shape, ventricular cavity size and content, as well as regional and global contractile function. A complete RV examination should include both qualitative and quantitative parameters, including RV size, right atrial (RA) size, RV systolic function (with at least one of the following: fractional area change [FAC], and tricuspid annular plane systolic excursion [TAPSE]; with or without RV index of myocardial performance [RIMP]), and pulmonary artery systolic pressure (PASP) with an estimate of RA pressure on the basis of inferior vena cava (IVC) size and collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Wall thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV hypertrophy is recognized by inspecting the wall of the right ventricular outflow tract in the precordial views, the free wall in the apical view, and the diaphragmatic wall in the subcostal view. Generally, the RV free wall in diastole is approximately 3 to 4 mm thick; if it exceeds 5 mm it is considered hypertrophied (",
"    <a class=\"graphic graphic_waveform graphicRef73683 \" href=\"UTD.htm?41/21/42325\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71065 \" href=\"UTD.htm?28/2/28719\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RV wall thickness, when inspected or measured in the subcostal view, allows differentiation of the wall thickness from cavity trabeculations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/4\">",
"     4",
"    </a>",
"    ]. Contrast enhancement of M-mode or two dimensional images can aid in measuring wall thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Shape",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the elliptical shape of the left ventricle (LV), the complex structure of the RV limits quantitation of its volume. The shape of the RV has been described as a pyramid with a triangular base; however, this description fails to take into account its crescentic shape in cross section or its outflow tract. A \"teapot\" configuration has been proposed as a model that includes the outflow tract, but this is difficult to represent mathematically. The tomographic nature of echocardiography makes it impractical to image this irregularly shaped organ in a single, encompassing plane. Three-dimensional approaches may circumvent this limitation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have attempted to measure the size or volume of the RV, but no method has gained wide acceptance. Three dimensional methods may, however, provide the flexibility required to adequately measure this structure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of approaches for determining RV size using M-mode or two dimensional echocardiography have been used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection of the RV and LV from the standard precordial long axis M-mode view. Problems inherent in this approach include misrepresentation of chamber size if the narrower portion of the chamber is recorded.",
"     </li>",
"     <li>",
"      Measurement of the RV directly from two dimensional images (preferred technique).",
"     </li>",
"     <li>",
"      Qualitative inspection of four views of the RV obtained from the two dimensional echocardiogram (which also serves to avoid overlooking cavity enlargement):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the long and short axis precordial views, where the RV outflow tract is seen coursing over the LV outflow tract and aortic root, the RV appears to be crescent shaped and its size, if normal, it appears considerably smaller than the LV.",
"     </li>",
"     <li>",
"      The second view is the short axis through the LV minor axis. Right ventricular dilation can be strongly suspected if its size appears to be the same or larger than the LV (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52660 \" href=\"UTD.htm?8/12/8387\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When RV dilation is suspected, particular attention is paid to the apical four chamber view in which the LV forms the cardiac apex and the normal RV appears to be the smaller of the two chambers. If the RV forms or even shares the apex, RV dilation is suspected. In frank RV enlargement it appears to dominate, and in extreme cases, the LV appears slit-like by comparison (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67160 \" href=\"UTD.htm?43/32/44559\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Society of Echocardiography reference limits for normal RV linear dimensions in the apical four chamber view are basal RV diameter 2.0 to 2.8 cm, mid RV diameter 2.7 to 3.3 cm, and base-to-apex length 7.1 to 7.9 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/8\">",
"     8",
"    </a>",
"    ]. Severe enlargement is basal diameter &ge;3.9 cm, mid diameter &ge;4.2 cm, and length &ge;9.2 cm. Normal right ventricular outflow tract diameter is 2.5 to 2.9 cm above the aortic valve, and severe dilatation is &ge;3.6 cm.",
"   </p>",
"   <p>",
"    The American Society of Echocardiography published reference range for the apical four-chamber RV end-diastolic and end-systolic area is 11 to 28 cm2 and 7.5 to 16 cm2, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiographic measures of RV size are significantly different in men and women as demonstrated in a study using 2-D and 3-D echocardiography. The authors found that RV end-diastolic volume using 3-D echocardiography was larger in men compared to women (129",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    25 versus 102",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    33 mL, p&lt;0.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/7\">",
"     7",
"    </a>",
"    ]. Good correlation has been found between magnetic resonance and 3-D echocardiographic measurements of the RV: normal indexed RV end-diastolic volume is 39 to 92",
"    <span class=\"nowrap\">",
"     ml/m2",
"    </span>",
"    and normal RV end-systolic volume is 23-43",
"    <span class=\"nowrap\">",
"     ml/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Contractility",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective approach for evaluating RV function is to observe the motion of the base of the right heart. The descent of the RV base towards the fixed location of the apex is easily seen as vigorous motion of the AV groove [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/10\">",
"     10",
"    </a>",
"    ]. This motion can be appreciated in the subcostal and four chamber views, and, if depressed, is a sensitive indicator of right ventricular systolic dysfunction. Normal descent of the tricuspid annulus toward the apex is 1.6 to 2.0 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/1\">",
"     1",
"    </a>",
"    ]. Annular excursion less than 1.6 cm has been associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/8\">",
"     8",
"    </a>",
"    ]. Doppler tissue imaging of the tricuspid annulus has also yielded similar results in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Right ventricular contractile function is also evaluated by direct visual inspection of the two dimensional echocardiogram. Since the wall of the RV is thin, careful adjustments of instrument gain and settings, and judicious selection of transducers may be needed to accurately detect RV inward systolic motion or wall thickening.",
"   </p>",
"   <p>",
"    The ratio of the RV volume to that of the LV obtained in the single plane area length four chamber view is 0.6, but increases to greater than 1.1 in a group of patients with cor pulmonale [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ejection fraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systolic and diastolic right ventricular \"volumes\" (minus the RVOT volume) computed by the area length algorithm using values obtained by tracing the outline of the cavity in the four chamber view in systole and diastole. The RVEF ejection fraction is calculated as follows:",
"   </p>",
"   <p>",
"    RVEF = (RV end-diastolic volume - RV end systolic volume) &divide; RV end-diastolic volume",
"   </p>",
"   <p>",
"    The area length method correlates reasonably well with the EF obtained by radionuclide blood pool. One study was able to replicate quantitative angiography of the RV volume in children by adding the area length volume of the apical view to the volume from the subcostal view [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative method of measuring RV contractile function is the RV fractional area change as measured in the apical four chamber view. Normal RV fractional area change is 32 to 60 percent, mildly reduced is 25 to 31 percent, moderately reduced is 18 to 24 percent, and severely reduced is &le;17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27766/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONDITIONS ASSOCIATED WITH RIGHT VENTRICULAR PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The right ventricle dilates in response to a number of situations and conditions, many of which have characteristics that permit echocardiographic differentiation (",
"    <a class=\"graphic graphic_table graphicRef69418 \" href=\"UTD.htm?42/1/43036\">",
"     table 1",
"    </a>",
"    ). RV pathology can be due to volume or pressure overload from a variety of etiologies (eg, valvular disease, congenital heart disease, etc). In addition, primary myopathic processes or tumors can result in RV pathology. Complete discussions of the following conditions are presented separately:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3009950\">",
"    <span class=\"h2\">",
"     Conditions associated with RV volume overload",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial septal defect (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=see_link\">",
"       \"Identification and assessment of atrial septal defects in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link\">",
"       \"Management of atrial septal defects in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patent foramen ovale (rare to cause volume overload) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link\">",
"       \"Patent foramen ovale\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Valvular regurgitation (tricuspid or pulmonic regurgitation) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=see_link\">",
"       \"Etiology, clinical features, and evaluation of tricuspid regurgitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30471?source=see_link\">",
"       \"Management and prognosis of tricuspid regurgitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20567?source=see_link&amp;anchor=H17589234#H17589234\">",
"       \"Echocardiographic evaluation of the pulmonic valve and pulmonary artery\", section on 'Pulmonic valve regurgitation'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3009958\">",
"    <span class=\"h2\">",
"     Conditions associated with RV pressure overload",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary hypertension (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eisenmenger syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=see_link\">",
"       \"Evaluation and prognosis of Eisenmenger syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link\">",
"       \"Medical management of Eisenmenger syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute or chronic thromboembolic disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of acute pulmonary embolism\", section on 'Symptoms / Signs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=see_link\">",
"       \"Overview of the treatment of chronic thromboembolic pulmonary hypertension\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Right ventricular outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link\">",
"       \"Clinical manifestations and diagnosis of pulmonic stenosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"       \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary artery stenosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of pulmonic stenosis\", section on 'Supravalvular pulmonic stenosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Transposition of the great arteries (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=see_link\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3009966\">",
"    <span class=\"h2\">",
"     Cardiomyopathic conditions associated with RV pathology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RV ischemia or infarction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"       \"Right ventricular myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dilated cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"       \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link&amp;anchor=H6#H6\">",
"       \"Echocardiographic recognition of cardiomyopathies\", section on 'Right ventricle'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Endomyocardial fibrosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=see_link\">",
"       \"Endomyocardial fibrosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3010190\">",
"    <span class=\"h2\">",
"     Tumors involving the RV",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac myxomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link&amp;anchor=H14#H14\">",
"       \"Cardiac tumors\", section on 'Myxomas'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other primary cardiac tumors (eg, sarcomas, fibromas, rhabdomyomas) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"       \"Cardiac tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Metastatic lesions (eg, melanoma, renal cell carcinoma) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link&amp;anchor=H34#H34\">",
"       \"Cardiac tumors\", section on 'Secondary cardiac tumors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=see_link\">",
"       \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1602520\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal right ventricle can be recognized by a number of echocardiographic features. Its free wall is &lt;0.4 mm thick, its apex is heavily trabeculated and dominated by the septal marginal trabeculation or moderator band, and its most active contraction occurs along its longitudinal axis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of the right ventricle (RV) involves evaluation of wall thickness, shape, ventricular cavity size and content, as well as regional and global contractile function. A complete RV examination should include both qualitative and quantitative parameters, including RV size, right atrial (RA) size, RV systolic function (with at least one of the following: fractional area change [FAC], and tricuspid annular plane systolic excursion [TAPSE]; with or without RV index of myocardial performance [RIMP]), and pulmonary artery systolic pressure (PASP) with an estimate of RA pressure on the basis of inferior vena cava (IVC) size and collapse. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Echocardiographic evaluation of the right ventricle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An effective approach for evaluating RV function is to observe the motion of the base of the right heart. The descent of the RV base towards the fixed location of the apex is easily seen as vigorous motion of the AV groove. This motion can be appreciated in the subcostal and four chamber views, and, if depressed, is a sensitive indicator of right ventricular systolic dysfunction. Normal descent of the tricuspid annulus toward the apex is 1.6 to 2.0 cm, and annular excursion less than 1.6 cm has been associated with a poor prognosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Contractility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/1\">",
"      Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/2\">",
"      Schnittger I, Gordon EP, Fitzgerald PJ, Popp RL. Standardized intracardiac measurements of two-dimensional echocardiography. J Am Coll Cardiol 1983; 2:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/3\">",
"      Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/4\">",
"      Cooper MJ, Teitel DF, Silverman NH, Enderlein M. Comparison of M-mode echocardiographic measurement of right ventricular wall thickness obtained by the subcostal and parasternal approach in children. Am J Cardiol 1984; 54:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/5\">",
"      Lange PE, Seiffert PA, Pries F, et al. Value of image enhancement and injection of contrast medium for right ventricular volume determination by two-dimensional echocardiography in congenital heart disease. Am J Cardiol 1985; 55:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/6\">",
"      Wann LS, Stickels KR, Bamrah VS, Gross CM. Digital processing of contrast echocardiograms: a new technique for measuring right ventricular ejection fraction. Am J Cardiol 1984; 53:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/7\">",
"      Kjaergaard J, Sogaard P, Hassager C. Quantitative echocardiographic analysis of the right ventricle in healthy individuals. J Am Soc Echocardiogr 2006; 19:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/8\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/9\">",
"      Gopal AS, Chukwu EO, Iwuchukwu CJ, et al. Normal values of right ventricular size and function by real-time 3-dimensional echocardiography: comparison with cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2007; 20:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/10\">",
"      Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984; 107:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/11\">",
"      Isaaz K, Munoz del Romeral L, Lee E, Schiller NB. Quantitation of the motion of the cardiac base in normal subjects by Doppler echocardiography. J Am Soc Echocardiogr 1993; 6:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/12\">",
"      Himelman RB, Struve SN, Brown JK, et al. Improved recognition of cor pulmonale in patients with severe chronic obstructive pulmonary disease. Am J Med 1988; 84:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27766/abstract/13\">",
"      Silverman NH, Hudson S. Evaluation of right ventricular volume and ejection fraction in children by two-dimensional echocardiography. Pediatr Cardiol 1983; 4:197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5291 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27766=[""].join("\n");
var outline_f27_7_27766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1602520\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECHOCARDIOGRAPHIC EVALUATION OF THE RIGHT VENTRICLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Wall thickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Shape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Contractility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ejection fraction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONDITIONS ASSOCIATED WITH RIGHT VENTRICULAR PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3009950\">",
"      Conditions associated with RV volume overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3009958\">",
"      Conditions associated with RV pressure overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3009966\">",
"      Cardiomyopathic conditions associated with RV pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3010190\">",
"      Tumors involving the RV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1602520\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5291|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/2/28719\" title=\"diagnostic image 1\">",
"      Echocardiogram short axis with RV pressure overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/12/8387\" title=\"diagnostic image 2\">",
"      Echocardiogram short axis with RV volume overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/32/44559\" title=\"diagnostic image 3\">",
"      Echocardiogram apical 4-chamber showing right heart enlargement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5291|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/1/43036\" title=\"table 1\">",
"      Etiologies of right ventricular pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5291|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/21/42325\" title=\"waveform 1\">",
"      M-mode of right ventricular hypertrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=related_link\">",
"      Clinical manifestations and diagnosis of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20567?source=related_link\">",
"      Echocardiographic evaluation of the pulmonic valve and pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=related_link\">",
"      Endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=related_link\">",
"      Etiology, clinical features, and evaluation of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5896?source=related_link\">",
"      Identification and assessment of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30471?source=related_link\">",
"      Management and prognosis of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=related_link\">",
"      Management of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34293?source=related_link\">",
"      Overview of the treatment of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13240?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of the left ventricle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_7_27767="Port placement left adrenalectomy";
var content_f27_7_27767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61077%7ESURG%2F67773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61077%7ESURG%2F67773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Port placement left adrenalectomy*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peritoneal cavity is accessed with a Veres technique through a midclavicular, subcostal site. Three additional 5 mm ports are placed that include a flank port in the mid-axillary line between the subcostal margin and the iliac crest, an epigastric port and a medial subcostal port. Once the adrenal gland is resected, it is captured in a laparoscopic bag that is placed through the 12 mm subcostal port site and removed by extending this incision, as needed.",
"    <div class=\"footnotes\">",
"     * Port placement and technique may vary amongst laparoscopic surgeons.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Port placement right adrenalectomy*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 587px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peritoneal cavity is accessed with a Veres technique through a midclavicular, subcostal site. Three additional 5 mm ports are placed that include a flank port in the mid-axillary line between the subcostal margin and the iliac crest, an epigastric port and a medial subcostal port. One additional port may be needed to retract the liver. Once the adrenal gland is resected, it is captured in a laparoscopic bag that is placed through the 12 mm subcostal port site and removed by extending this incision, as needed.",
"    <div class=\"footnotes\">",
"     * Port placement and technique may vary amongst laparoscopic surgeons.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27767=[""].join("\n");
var outline_f27_7_27767=null;
var title_f27_7_27768="Tuberculous lymphadenitis";
var content_f27_7_27768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tuberculous lymphadenitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27768/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27768/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27768/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27768/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/7/27768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous lymphadenitis is among the most frequent presentations of extrapulmonary tuberculosis (TB). Tuberculous lymphadenitis in the cervical region is known as scrofula [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/1\">",
"     1",
"    </a>",
"    ]. This syndrome can also be caused by nontuberculous mycobacteria.",
"   </p>",
"   <p>",
"    TB is responsible for up to 43 percent of peripheral lymphadenopathy in the developing world [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/2\">",
"     2",
"    </a>",
"    ]. In rural India, the prevalence of tuberculous lymphadenitis in children up to 14 years of age is approximately 4.4 cases per 1000 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/3\">",
"     3",
"    </a>",
"    ]. In the United States, about 20 percent of patients with TB have extrapulmonary disease, and lymphadenitis is a presenting symptom in about 30 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The human immunodeficiency virus (HIV) epidemic has been associated with an increase in the total incidence of TB and an increased proportion of miliary, disseminated, and extrapulmonary TB cases including lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34150?source=see_link\">",
"     \"Epidemiology and pathology of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to tuberculous lymphadenitis will be reviewed here. Other issues related to tuberculosis are discussed separately (see related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated peripheral tuberculous lymphadenopathy is usually due to reactivation of disease at a site seeded hematogenously during primary TB infection, perhaps years earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been postulated that cervical TB lymphadenitis occurs as a result of TB infection involving the tonsils, adenoids and Waldeyer's ring, leading to cervical lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/2\">",
"     2",
"    </a>",
"    ]. Abdominal TB lymphadenopathy may occur via ingestion of sputum or milk infected with Mycobacterium tuberculosis or M. bovis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22378?source=see_link\">",
"     \"Microbiology and pathogenesis of tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16614?source=see_link\">",
"     \"Mycobacterium bovis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Though most cases of TB lymphadenitis occur in the setting of reactivation of latent infection, miliary dissemination with prominent lymph node involvement in the setting of primary infection can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of TB lymphadenitis varies between developed and developing countries.",
"   </p>",
"   <p>",
"    In developed countries, most cases of TB lymphadenitis occur among adult immigrants from TB endemic countries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. This was illustrated by case series of TB lymphadenitis in France and Germany in which about 70 percent of cases occurred in immigrants; in the German study, two-thirds of patients had immigrated &gt;3 years prior to diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In the United States, the rate of TB lymphadenitis is higher among Asian Pacific Islanders and in females [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/2,5,15\">",
"     2,5,15",
"    </a>",
"    ]. Rarely, TB lymphadenitis can also occur in travelers to endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. TB lymphadenitis occurs more frequently in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, TB lymphadenitis was considered a disease of childhood; however, the peak age of onset in developed countries has shifted from childhood to ages 20 to 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/18\">",
"     18",
"    </a>",
"    ]. In contemporary series, the median age has been approximately 40 years in developed countries (range 1 to 88 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/12,14,19\">",
"     12,14,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developing countries where TB is endemic, extrapulmonary TB occurs in up to 60 percent of HIV-infected patients with TB and is frequently accompanied by signs of pulmonary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Most extrapulmonary TB cases (including TB lymphadenitis) occur among patients with HIV at CD4 counts &lt;300",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (usually below 100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/7,23\">",
"     7,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations depend on the site of the lymphadenopathy and the immune status of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/8,10,15,16\">",
"     8,10,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common presentation is isolated chronic nontender lymphadenopathy in a young adult without systemic symptoms. The mass may be present for up to 12 months before diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/16,24\">",
"     16,24",
"    </a>",
"    ]. Physical examination reveals a firm discrete mass or matted nodes fixed to surrounding structures; the overlying skin may be indurated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/8\">",
"     8",
"    </a>",
"    ]. Uncommon findings include fluctuance, draining sinus, or erythema nodosum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cervical lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical lymphadenopathy is the most common manifestation of TB lymphadenitis; in contemporary series it represents 63 to 77 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/12,19\">",
"     12,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most frequently a unilateral mass appears in the anterior or posterior cervical triangles; submandibular and supraclavicular lymph node involvement also occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/16,20,24,25\">",
"     16,20,24,25",
"    </a>",
"    ]. Bilateral disease is uncommon (up to 26 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/16,26\">",
"     16,26",
"    </a>",
"    ]. Although most patients have disease at only one site, multiple nodes may be involved at that site [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/15,24\">",
"     15,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other involved nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other sites of TB lymphadenitis include the axillary, inguinal, mesenteric, mediastinal, and intramammary lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/8,10,27\">",
"     8,10,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tuberculous mediastinal lymphadenopathy can present with dysphagia, esophageal perforation, vocal cord paralysis due to recurrent laryngeal nerve involvement, or pulmonary artery occlusion mimicking pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tuberculous peritoneal lymphadenopathy most commonly involves lymph nodes in the periportal region, followed by peripancreatic and mesenteric lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/10\">",
"     10",
"    </a>",
"    ]. Hepatic lymph node involvement can lead to jaundice, portal vein thrombosis, and portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/32\">",
"     32",
"    </a>",
"    ]. Extrinsic compression of renal arteries due to tuberculous abdominal lymphadenopathy can result in renovascular hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HIV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with TB lymphadenitis in the setting of HIV infection, there may be a significant mycobacterial load with concomitant systemic findings including fever, sweats, and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/20\">",
"     20",
"    </a>",
"    ]. Abnormal chest radiography is frequently observed, and such patients are more likely to have disseminated TB with lymphadenitis at more than one site [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/10,20\">",
"     10,20",
"    </a>",
"    ]. Patients with mediastinal and hilar node involvement are likely to have active pulmonary TB and may have symptoms including dyspnea and tachypnea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of isolated peripheral lymphadenopathy is extensive and includes malignancy (eg, Hodgkin lymphoma and non-Hodgkin lymphoma) and other infections (eg, nontuberculous mycobacteria [M. scrofulaceum, M. avium complex, M. kansasii], cat scratch disease, fungal infection, sarcoidosis, and bacterial adenitis). Kikuchi's disease can cause a necrotizing lymphadenitis and mimic tuberculosis cervical lymphadenopathy; indistinct margins of necrotic foci demonstrated on CT scan may be an independent predictor of Kikuchi&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The most likely alternative diagnoses depend on the clinical setting including the patient's age, ethnic background, immune status, and presenting clinical features.",
"   </p>",
"   <p>",
"    It is difficult to differentiate TB from other causes of lymphadenitis on clinical grounds. One study found no distinguishing clinical features between patients with lymphadenitis due to TB or nontuberculous mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/37\">",
"     37",
"    </a>",
"    ]. Another report noted the same results regardless of HIV status [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of TB lymphadenitis is established by histopathology examination along with AFB smear and culture of lymph node material. Chest imaging should also be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Material for histopathology evaluation may be obtained by fine needle aspiration (FNA) or excisional biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Fine needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration (FNA) is appropriate for initial evaluation of cervical lymphadenopathy to evaluate for TB lymphadenitis. The yield of FNA appears to be highest in the setting of HIV infection and in regions where the prevalence of TB is high [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/16,20,38-40\">",
"     16,20,38-40",
"    </a>",
"    ]. In these circumstances the burden of organisms is likely to be high. In a series of 1193 patients evaluated for TB lymphadenitis in Hong Kong, for example, FNA had good sensitivity and specificity (77 and 93 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FNA is a relatively safe and inexpensive procedure, with few complications when a 21 to 23 gauge needle is used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/16\">",
"     16",
"    </a>",
"    ]. Specimens should be submitted for microscopy, culture, cytology and polymerase chain reaction (PCR) testing (where available). Some studies have suggested that PCR can increase the sensitivity of FNA for TB diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/42\">",
"     42",
"    </a>",
"    ], while others did not observe an increased diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/43\">",
"     43",
"    </a>",
"    ]. Culture permits susceptibility testing and therefore provides important therapeutic information even in the setting of positive PCR results. For circumstances in which the culture is negative or there is discrepancy between the clinical impression and excisional biopsy histology, PCR should be pursued if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excisional biopsy for histopathologic and microbiological evaluations has the highest diagnostic yield and should be pursued in cases where fine needle aspiration is not diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/25,41\">",
"     25,41",
"    </a>",
"    ]. In a series of 47 patients evaluated for TB lymphadenitis in San Francisco, for example, the diagnosis of TB was established by excisional biopsy in all cases; FNA was definitive in only 62 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An excisional biopsy is preferred; incisional biopsy may result in sinus tract formation. For mediastinal lymph node biopsy, mediastinoscopy may be required. Specimens should be submitted for histology, culture and PCR testing (where available).",
"   </p>",
"   <p>",
"    The finding of caseating granulomas on histopathology is highly suggestive of TB although is not diagnostic since other diseases can also have similar histology [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/25\">",
"     25",
"    </a>",
"    ]. Some studies have suggested PCR can facilitate diagnosis of TB in lymph node tissues for which histology findings are not specific and acid-fast organisms are not seen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/44\">",
"     44",
"    </a>",
"    ], while others did not observe an increased diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/43\">",
"     43",
"    </a>",
"    ]. In one study, fluorescent in situ hybridization (FISH) assays on lymph node tissue demonstrated higher sensitivity and specificity than histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chest imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients (90 to 100 percent) with tuberculous lymphadenitis have no evidence of active pulmonary TB on chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]. Pleural thickening and apical fibrosis suggestive of previous TB may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/8,20\">",
"     8,20",
"    </a>",
"    ]. Chest x-ray abnormalities have been described more frequently among patients with HIV infection in some series. One report of 10 HIV-infected patients described abnormal radiography on presentation with TB lymphadenitis in 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest imaging suggestive of active pulmonary TB should prompt further evaluation, as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Neck imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck imaging modalities include ultrasonography, computed tomography, and magnetic resonance imaging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasonography &mdash; In a study comparing lymph node metastases with TB lymphadenitis, the latter was associated with a higher incidence of abnormal surrounding soft tissue, cystic necrosis, matting, posterior enhancement, and a heterogeneous rather than a homogenous pattern [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computed tomography &mdash; Computed tomography (CT) can be a useful tool to distinguish between TB lymphadenitis and lymphoma. In one Chinese series including 26 patients with TB lymphadenitis and 43 patients with lymphoma, lower paraaortic node involvement was more common in lymphoma; TB more often involved upper paraaortic, lesser omental, mesenteric, and anterior para-renal lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/9\">",
"       9",
"      </a>",
"      ]. Peripheral enhancement (often with a multilocular appearance) was also a feature of TB lymphadenopathy; homogeneous attenuation was more common in the setting of lymphomatous adenopathy.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging &mdash; In a report of magnetic resonance imaging (MRI) evaluation among nine Chinese patients with TB lymphadenitis, three patterns of disease were noted: discrete nodes, matted nodes, and confluent masses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/47\">",
"       47",
"      </a>",
"      ]. Necrotic foci, when present, were more frequently peripheral rather than central.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other diagnostic tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of TB lymphadenitis is established by histopathology examination and AFB smear and culture of lymph node material as discussed above. Additional diagnostic tools that may be useful in the setting of suspected TB lymphadenitis are outlined below. Further discussion of issues related to diagnosis of TB is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sputum smear and culture &mdash; Positive sputum cultures are uncommon (0 to 14 percent) in the setting of TB lymphadenitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/12,16,48\">",
"       12,16,48",
"      </a>",
"      ]. Chest radiography findings consistent with active pulmonary TB should prompt sputum cultures; if positive, evaluation for miliary TB should be pursued. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchoscopy &mdash; In the setting of isolated intrathoracic lymphadenopathy, bronchoscopy may be useful to establish a diagnosis of TB if sputum studies are negative [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) &ndash; This modality may be useful in the setting of isolated intrathoracic lymphadenopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. In one report of 24 patients with isolated intrathoracic lymphadenopathy and a high clinical suspicion for tuberculosis, material obtained by EBUS-TBNA confirmed the diagnosis in 79 percent of cases (sensitivity and specificity 95 and 100 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blood culture &mdash; Blood cultures for M. tuberculosis are rarely positive, but may be positive in disseminated TB especially in patients with HIV and other forms of immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       Tuberculin skin test",
"      </a>",
"      &mdash; The tuberculin skin test (TST) is positive in the majority (74 to 100 percent) of patients with TB lymphadenitis (in the absence of HIV infection), although positive TST is not sufficient to establish the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/8,12,14,16,17,20\">",
"       8,12,14,16,17,20",
"      </a>",
"      ]. A negative TST is not helpful in excluding the diagnosis, especially in immunosuppressed individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interferon-Gamma Release Assays (IGRA) &mdash; In a report including 44 patients with suspected tuberculous cervical lymphadenitis, the diagnosis was confirmed in 21 patients; IGRA demonstrated a sensitivity and specificity of 86 and 87 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV testing &mdash; Patients with suspected or proven TB should undergo HIV testing [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of TB lymphadenitis consists of antimycobacterial therapy. In some circumstances excisional biopsy in theory may be sufficient for treatment of immunocompetent patients with localized disease, though in general all patients should also receive antimycobacterial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Thoracic Society (ATS), Centers for Disease Control (CDC), and the Infectious Diseases Society of America (IDSA) have published recommendations for the treatment of tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/55\">",
"     55",
"    </a>",
"    ]. In general, treatment for adults with TB lymphadenitis consists of two months of rifampicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    (given daily) followed by four months of rifampicin and isoniazid (given either daily or three times weekly) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/56\">",
"     56",
"    </a>",
"    ]. Dosing, monitoring and further details related to antimycobacterial regimens for TB are presented separately, as are issues related to patients with HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended duration of therapy for HIV seronegative adults is six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/55,57,58\">",
"     55,57,58",
"    </a>",
"    ]. In a randomized trial comparing a six month regimen (four drugs for four months followed by two drugs for two months) with a nine month regimen (four drugs for four months followed by two drugs for five months), there was no difference in treatment failure or remission at five years between the two regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative regimens for drug-susceptible M. tuberculosis have also been evaluated, including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two months of rifampicin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      (two times weekly) followed by four months of rifampicin and isoniazid (two times weekly)",
"     </li>",
"     <li>",
"      Six month regimen of daily rifampicin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these regimens were comparable to each other in a trial of 277 patients with TB lymphadenitis in India (90 percent of patients had fully susceptible M. tuberculosis), the two drug regimen is not generally recommended.",
"   </p>",
"   <p>",
"    The optimal duration of therapy in children is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/59\">",
"     59",
"    </a>",
"    ]. The relapse rate in children after six months of therapy is not well established; nine months of therapy may be appropriate pending further study.",
"   </p>",
"   <p>",
"    Longer duration of therapy also may be appropriate for patients with HIV infection with evidence of suboptimal response, who cannot tolerate first line medications, or who have infection due to resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/55\">",
"     55",
"    </a>",
"    ]. In such situations, selection and duration of therapy should be individualized in consultation with infectious disease expertise. Treatment of drug-resistant tuberculosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB lymphadenitis tends to respond slowly to effective treatment. This may include enlargement of nodes while on treatment or after cessation of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Paradoxical reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimycobacterial therapy may prompt a paradoxical reaction or increase in lymph node size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enlargement of additional lymph nodes during or after cessation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/12,48\">",
"     12,48",
"    </a>",
"    ]. This is attributable to an immune response to dying M. tuberculosis organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/60\">",
"     60",
"    </a>",
"    ]. Clinical manifestations may include lymph node enlargement (12 percent), fluctuance (11 percent), overlying erythema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spontaneous discharge (7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/48,61\">",
"     48,61",
"    </a>",
"    ]. Constitutional symptoms are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In HIV negative patients, such paradoxical reactions occur in up to 23 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/12,48,60,62\">",
"     12,48,60,62",
"    </a>",
"    ]. Predictors include male gender and presence of local erythema at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In HIV positive patients, paradoxical reactions are more common in some but not all reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. It may be more temporally associated with the initiation of anti-retroviral therapy (ART) than anti-tuberculosis therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/63\">",
"     63",
"    </a>",
"    ]. There appears to be no association between baseline CD4 counts or CD4 response to ART [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis includes treatment failure due to resistance or non-compliance, another infection, or an alternative diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no consensus guidelines for management. Options include observation, aspiration, surgical excision, or a trial of nonsteroidal antiinflammatory agents or corticosteroids.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    has also been used in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fine needle aspiration (FNA) for acid fast bacillus microscopy and culture may be pursued to distinguish between a paradoxical reaction and treatment failure. Repeated FNA has been used in an attempt to prevent fistula formation and as an alternative to steroid therapy or to prevent the need for surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 235 HIV seronegative patients, spontaneous resolution of paradoxical lymph node enlargement occurred in 56 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/60\">",
"     60",
"    </a>",
"    ]. In a second study including both HIV-infected and non-infected patients, spontaneous resolution occurred in all patients in mean period of 2.5 months; some patients underwent aspiration or excision [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Relapse rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse rates of up to 3.5 percent have been reported in patients treated for TB lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/58\">",
"     58",
"    </a>",
"    ]. A minority (7 to 11 percent) of patients have residual lymph nodes present at the end of the treatment course [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27768/abstract/58,61,67\">",
"     58,61,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculous lymphadenitis is among the most frequent presentations of extrapulmonary tuberculosis (TB). TB lymphadenitis in the cervical region is known as scrofula. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated peripheral tuberculous lymphadenopathy is usually due to reactivation of disease at a site seeded hematogenously during primary TB infection, perhaps years earlier. Miliary dissemination with prominent lymph node involvement in the setting of primary infection can also occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Previously, TB lymphadenitis was considered a disease of childhood; however, in reports from developed countries, the peak age of onset has shifted from childhood to ages 20 to 40 years. In developed countries, most cases of TB lymphadenitis occur among immigrants from TB endemic countries. In regions where TB is endemic, extrapulmonary TB occurs in approximately 60 percent of HIV-infected patients with TB and is frequently accompanied by signs of pulmonary involvement. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations depend on the site of the lymphadenopathy and the immune status of the patient. The most common presentation is isolated chronic nontender lymphadenopathy in a young adult without systemic symptoms, most commonly in the cervical region. Physical examination reveals a firm discrete mass or matted nodes fixed to surrounding structures; the overlying skin may be indurated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with TB lymphadenitis in the setting of HIV infection, there may be a significant mycobacterial load with concomitant systemic findings including fever, sweats, and weight loss. Abnormal chest radiography is frequently observed, and such patients are more likely to have disseminated TB with lymphadenitis at more than one site. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HIV coinfection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of TB lymphadenitis is established by histopathology examination along with AFB smear and culture of lymph node material. FNA is appropriate for initial evaluation of cervical lymphadenopathy to evaluate for TB lymphadenitis. The yield of FNA appears to be highest in the setting of HIV infection and in regions where the prevalence of TB is high. Specimens should be submitted for microscopy, culture, cytology and PCR testing (where available). Excisional biopsy for histopathologic and microbiological evaluations has the highest diagnostic yield and should be pursued in cases where fine needle aspiration is not diagnostic, or for persistent disease despite appropriate therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest imaging should be pursued in the setting of suspected TB lymphadenitis. Many patients with tuberculous lymphadenitis have no evidence of active pulmonary TB on chest x-ray; abnormalities have been described more frequently among patients with HIV infection in some series. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment for HIV seronegative adults with TB lymphadenitis we suggest the following regimen: two months of rifampicin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      (given daily) followed by four months of rifampicin and isoniazid (given either daily or three times weekly) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The preferred duration of therapy for adults is six months. The optimal duration of therapy in children is uncertain, as the relapse rate after six months of therapy is not well established; nine months of therapy may be appropriate pending further study. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/1\">",
"      Fontanilla JM, Barnes A, von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis 2011; 53:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/2\">",
"      Dandapat MC, Mishra BM, Dash SP, Kar PK. Peripheral lymph node tuberculosis: a review of 80 cases. Br J Surg 1990; 77:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/3\">",
"      Narang P, Narang R, Narang R, et al. Prevalence of tuberculous lymphadenitis in children in Wardha district, Maharashtra State, India. Int J Tuberc Lung Dis 2005; 9:188.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control. Reported Tuberculosis in the United States, 2006. Atlanta, GA: U.S. Department of Health and Human Services, CDC, September 2007. (file://www.cdc.gov/tb/).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/5\">",
"      Rieder HL, Snider DE Jr, Cauthen GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990; 141:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/6\">",
"      Peto HM, Pratt RH, Harrington TA, et al. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis 2009; 49:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/7\">",
"      Hill AR, Premkumar S, Brustein S, et al. Disseminated tuberculosis in the acquired immunodeficiency syndrome era. Am Rev Respir Dis 1991; 144:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/8\">",
"      Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine (Baltimore) 1984; 63:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/9\">",
"      Yang ZG, Min PQ, Sone S, et al. Tuberculosis versus lymphomas in the abdominal lymph nodes: evaluation with contrast-enhanced CT. AJR Am J Roentgenol 1999; 172:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/10\">",
"      Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore) 1991; 70:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/11\">",
"      Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/12\">",
"      Geldmacher H, Taube C, Kroeger C, et al. Assessment of lymph node tuberculosis in northern Germany: a clinical review. Chest 2002; 121:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/13\">",
"      Fain O, Lortholary O, Djouab M, et al. Lymph node tuberculosis in the suburbs of Paris: 59 cases in adults not infected by the human immunodeficiency virus. Int J Tuberc Lung Dis 1999; 3:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/14\">",
"      Wark P, Goldberg H, Ferson M, et al. Mycobacterial lymphadenitis in eastern Sydney. Aust N Z J Med 1998; 28:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/15\">",
"      Castro DJ, Hoover L, Castro DJ, Zuckerbraun L. Cervical mycobacterial lymphadenitis. Medical vs surgical management. Arch Otolaryngol 1985; 111:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/16\">",
"      Artenstein AW, Kim JH, Williams WJ, Chung RC. Isolated peripheral tuberculous lymphadenitis in adults: current clinical and diagnostic issues. Clin Infect Dis 1995; 20:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/17\">",
"      Thompson MM, Underwood MJ, Sayers RD, et al. Peripheral tuberculous lymphadenopathy: a review of 67 cases. Br J Surg 1992; 79:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/18\">",
"      Perlman DC, D'Amico R, Salomon N. Mycobacterial Infections of the Head and Neck. Curr Infect Dis Rep 2001; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/19\">",
"      Mert A, Tabak F, Ozaras R, et al. Tuberculous lymphadenopathy in adults: a review of 35 cases. Acta Chir Belg 2002; 102:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/20\">",
"      Shriner KA, Mathisen GE, Goetz MB. Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. Clin Infect Dis 1992; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/21\">",
"      Atomiya AN, Uip DE, Leite OH. Evaluation of disease patterns, treatment and prognosis of tuberculosis in AIDS patient. Braz J Infect Dis 2002; 6:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/22\">",
"      Lee MP, Chan JW, Ng KK, Li PC. Clinical manifestations of tuberculosis in HIV-infected patients. Respirology 2000; 5:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/23\">",
"      Jones BE, Young SM, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/24\">",
"      Shikhani AH, Hadi UM, Mufarrij AA, Zaytoun GM. Mycobacterial cervical lymphadenitis. Ear Nose Throat J 1989; 68:660, 662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/25\">",
"      Lee KC, Tami TA, Lalwani AK, Schecter G. Contemporary management of cervical tuberculosis. Laryngoscope 1992; 102:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/26\">",
"      Agarwal AK, Sethi A, Sethi D, et al. Tubercular cervical adenitis: clinicopathologic analysis of 180 cases. J Otolaryngol Head Neck Surg 2009; 38:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/27\">",
"      Yilmaz F, Yagmur Y, Uzunlar AK. Tuberculosis in an intramammary lymph node. Eur J Surg 2000; 166:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/28\">",
"      Popli MB. Dysphagia: a rare presentation of tuberculous mediastinal lymphadenitis. Australas Radiol 1998; 42:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/29\">",
"      Ohtake M, Saito H, Okuno M, et al. Esophagomediastinal fistula as a complication of tuberculous mediastinal lymphadenitis. Intern Med 1996; 35:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/30\">",
"      Rafay MA. Tuberculous lymphadenopathy of superior mediastinum causing vocal cord paralysis. Ann Thorac Surg 2000; 70:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/31\">",
"      Drake WM, Elkin SL, al-Kutoubi A, et al. Pulmonary artery occlusion by tuberculous mediastinal lymphadenopathy. Thorax 1997; 52:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/32\">",
"      Caroli-Bosc FX, Conio M, Maes B, et al. Abdominal tuberculosis involving hepatic hilar lymph nodes. A cause of portal vein thrombosis and portal hypertension. J Clin Gastroenterol 1997; 25:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/33\">",
"      Puri S, Khurana SB, Malhotra S. Tuberculous abdominal lymphadenopathy causing reversible renovascular hypertension. J Assoc Physicians India 2000; 48:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/34\">",
"      Centers for Disease Control (CDC). Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR Morb Mortal Wkly Rep 1989; 38:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/35\">",
"      Kamath MP, Bhojwani K, Naik R, et al. Tuberculosis mimicking Kikuchi's disease. Ear Nose Throat J 2006; 85:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/36\">",
"      Lee S, Yoo JH, Lee SW. Kikuchi disease: differentiation from tuberculous lymphadenitis based on patterns of nodal necrosis on CT. AJNR Am J Neuroradiol 2012; 33:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/37\">",
"      Chao SS, Loh KS, Tan KK, Chong SM. Tuberculous and nontuberculous cervical lymphadenitis: a clinical review. Otolaryngol Head Neck Surg 2002; 126:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/38\">",
"      Pithie AD, Chicksen B. Fine-needle extrathoracic lymph-node aspiration in HIV-associated sputum-negative tuberculosis. Lancet 1992; 340:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/39\">",
"      Ellison E, Lapuerta P, Martin SE. Fine needle aspiration diagnosis of mycobacterial lymphadenitis. Sensitivity and predictive value in the United States. Acta Cytol 1999; 43:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/40\">",
"      Jha BC, Dass A, Nagarkar NM, et al. Cervical tuberculous lymphadenopathy: changing clinical pattern and concepts in management. Postgrad Med J 2001; 77:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/41\">",
"      Lau SK, Wei WI, Hsu C, Engzell UC. Efficacy of fine needle aspiration cytology in the diagnosis of tuberculous cervical lymphadenopathy. J Laryngol Otol 1990; 104:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/42\">",
"      Singh KK, Muralidhar M, Kumar A, et al. Comparison of in house polymerase chain reaction with conventional techniques for the detection of Mycobacterium tuberculosis DNA in granulomatous lymphadenopathy. J Clin Pathol 2000; 53:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/43\">",
"      Linasmita P, Srisangkaew S, Wongsuk T, et al. Evaluation of Real-time Polymerase Chain Reaction for Detection of the 16S Ribosomal RNA Gene of Mycobacterium tuberculosis and the Diagnosis of Cervical Tuberculous Lymphadenitis in a Country With a High Tuberculosis Incidence. Clin Infect Dis 2012; 55:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/44\">",
"      Tarng DC, Su WJ, Huang TP. PCR diagnosis on formalin-fixed, paraffin-embedded tissues with acid-fast stain and culture negativity in chronic dialysis patients of cervico-mediastinal tuberculous lymphadenitis. Nephrol Dial Transplant 1998; 13:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/45\">",
"      Rodriguez-Nu&ntilde;ez J, Avelar FJ, Marquez F, et al. Mycobacterium tuberculosis complex detected by modified fluorescent in situ hybridization in lymph nodes of clinical samples. J Infect Dev Ctries 2012; 6:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/46\">",
"      Ying M, Ahuja AT, Evans R, et al. Cervical lymphadenopathy: sonographic differentiation between tuberculous nodes and nodal metastases from non-head and neck carcinomas. J Clin Ultrasound 1998; 26:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/47\">",
"      King AD, Ahuja AT, Metreweli C. MRI of tuberculous cervical lymphadenopathy. J Comput Assist Tomogr 1999; 23:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/48\">",
"      Polesky A, Grove W, Bhatia G. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. Medicine (Baltimore) 2005; 84:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/49\">",
"      Raffy O, Sleiman C, Roue C. Fibreoptic bronchoscopy for diagnosis of isolated tuberculous mediastinal lymphadenopathy. Thorax 1996; 51:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/50\">",
"      Baran R, Tor M, Tahao��lu K, et al. Intrathoracic tuberculous lymphadenopathy: clinical and bronchoscopic features in 17 adults without parenchymal lesions. Thorax 1996; 51:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/51\">",
"      Hassan T, McLaughlin AM, O'Connell F, et al. EBUS-TBNA performs well in the diagnosis of isolated thoracic tuberculous lymphadenopathy. Am J Respir Crit Care Med 2011; 183:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/52\">",
"      Navani N, Molyneaux PL, Breen RA, et al. Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study. Thorax 2011; 66:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/53\">",
"      Gopinath K, Kumar S, Singh S. Prevalence of mycobacteremia in Indian HIV-infected patients detected by the MB/BacT automated culture system. Eur J Clin Microbiol Infect Dis 2008; 27:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/54\">",
"      Song KH, Jeon JH, Park WB, et al. Usefulness of the whole-blood interferon-gamma release assay for diagnosis of extrapulmonary tuberculosis. Diagn Microbiol Infect Dis 2009; 63:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/55\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/56\">",
"      Jawahar MS, Rajaram K, Sivasubramanian S, et al. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens. Trop Med Int Health 2005; 10:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/57\">",
"      Yuen AP, Wong SH, Tam CM, et al. Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. Otolaryngol Head Neck Surg 1997; 116:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/58\">",
"      van Loenhout-Rooyackers JH, Laheij RJ, Richter C, Verbeek AL. Shortening the duration of treatment for cervical tuberculous lymphadenitis. Eur Respir J 2000; 15:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/59\">",
"      McMaster P, Isaacs D. Critical review of evidence for short course therapy for tuberculous adenitis in children. Pediatr Infect Dis J 2000; 19:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/60\">",
"      Cho OH, Park KH, Kim T, et al. Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis. J Infect 2009; 59:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/61\">",
"      Campbell IA. The treatment of superficial tuberculous lymphadenitis. Tubercle 1990; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/62\">",
"      Carvalho AC, De Iaco G, Saleri N, et al. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis 2006; 42:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/63\">",
"      Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/64\">",
"      Wendel KA, Alwood KS, Gachuhi R, et al. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/65\">",
"      Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/66\">",
"      Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008; 47:e83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27768/abstract/67\">",
"      Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. British Thoracic Society Research Committee. Br Med J (Clin Res Ed) 1985; 290:1106.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8001 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-A161942C46-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27768=[""].join("\n");
var outline_f27_7_27768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cervical lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other involved nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HIV coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Fine needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chest imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Neck imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Paradoxical reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Relapse rates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34150?source=related_link\">",
"      Epidemiology and pathology of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22378?source=related_link\">",
"      Microbiology and pathogenesis of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16614?source=related_link\">",
"      Mycobacterium bovis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_7_27769="High altitude disease: Unique pediatric considerations";
var content_f27_7_27769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   High altitude disease: Unique pediatric considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27769/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27769/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27769/contributors\">",
"     Peter Hackett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27769/contributors\">",
"     Scott A Gallagher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27769/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27769/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/7/27769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every year the beauty and recreational opportunities of the mountains attract millions of visitors from lowland elevations to high-altitude destinations worldwide. Resort towns in the Western United States alone attract over 30 million visitors annually, generally to sleeping elevations of 2000 to 3000 m (6500 to 9750 feet). Many more millions visit cities at these elevations, including several large cities in South America and Asia situated above 3000 m (9750 feet) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of these destinations can be reached within a day using modern means of transportation. Many of these mountain travelers are children.",
"   </p>",
"   <p>",
"    Rapid ascents to high altitude place the unacclimatized child at risk for developing high altitude illness (HAI). Clinicians working in mountainous areas must familiarize themselves with the presentation and management of HAI in children, while all health care workers who advise travelers need to understand the best prevention strategies and treatment options.",
"   </p>",
"   <p>",
"    This topic will review the unique pediatric aspects of high altitude illness. The different types of HAI, their pathophysiology, and methods for prevention and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"     \"Acute mountain sickness and high altitude cerebral edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"     \"High altitude pulmonary edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link\">",
"     \"High altitude, air travel, and heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HIGH ALTITUDE PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diminished inspired partial pressure of oxygen (PIO2) at altitude is the direct result of lower barometric pressure. As PIO2 decreases, so does the partial pressure of alveolar oxygen (PAO2), arterial PO2 (PaO2), and arterial oxygen saturation (SpO2), resulting in tissue hypoxia. This form of hypoxia is termed hypobaric hypoxia, and it represents the initial cause of high altitude illness (HAI). The physiology of HAI is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link&amp;anchor=H2#H2\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\", section on 'High altitude physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Susceptibility of infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain anatomic and physiologic factors make infants and young children more susceptible to hypoxia than adults, primarily through ventilation-perfusion mismatch [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/2\">",
"     2",
"    </a>",
"    ]. These factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Predisposition for paradoxical inhibition of respiratory drive up to one to two months of age",
"     </li>",
"     <li>",
"      More compliant rib cage",
"     </li>",
"     <li>",
"      Reduced surfactant (pre-term infants)",
"     </li>",
"     <li>",
"      Increased proportion of the pulmonary vascular bed with muscular arterioles in early infancy",
"     </li>",
"     <li>",
"      Increased airway reactivity in response to hypoxia",
"     </li>",
"     <li>",
"      Lung volume at end expiration similar to closing volume in early infancy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced upper and lower internal diameters of the airways",
"     </li>",
"     <li>",
"      Fewer alveoli in early infancy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This susceptibility to hypoxia may translate into a greater frequency of high altitude illness at very high altitudes (above 3500 m [11,375 ft]) in infants and children when compared to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, most healthy children can travel safely to altitudes lower than 3500 m and are not at greater risk than adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2847584\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for high altitude illness that are common to children and older patients include rapid rate of ascent, the absolute altitude achieved, the degree of physical exertion, and cold weather. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link&amp;anchor=H15#H15\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors found more commonly in children include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concurrent (viral) upper respiratory or other infection (eg, otitis media) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/8-12\">",
"       8-12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Congenital cardiopulmonary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/13,14\">",
"       13,14",
"      </a>",
"      ] (eg, unilateral absence of pulmonary artery) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]; pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/8\">",
"       8",
"      </a>",
"      ]; cardiac shunts (atrial septal defect, ventricular septal defect, patent foramen ovale)",
"     </li>",
"     <li>",
"      Down syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic diseases that compromise respiratory function (eg, bronchopulmonary dysplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/17\">",
"       17",
"      </a>",
"      ], cystic fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/18\">",
"       18",
"      </a>",
"      ], sickle cell anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/19\">",
"       19",
"      </a>",
"      ], severe scoliosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/20\">",
"       20",
"      </a>",
"      ], neuromuscular disease, obstructive sleep apnea)",
"     </li>",
"     <li>",
"      Full-term infants less than six weeks of age (premature infants less than 46 weeks postconceptual age) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/17,21\">",
"       17,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Full-term infants up to one year of age with a history of oxygen requirement or pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/17,21\">",
"       17,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Premature infants beyond 46 weeks post conceptual age with a history of oxygen requirement, bronchopulmonary dysplasia, or pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/17,21\">",
"       17,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Susceptibility to re-ascent (patient lives at very high altitude [above 3000 m, 11,325 ft], travels to low altitude for a short time period [eg, several weeks or less], and then returns home) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/14,22\">",
"       14,22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231531\">",
"    <span class=\"h2\">",
"     Recommendations for ascent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy children should ascend to high altitudes slowly and only if rapid descent is possible in the event of problems. Children have ascended safely as far as 15,000 to 18,000 ft (4570 to 5500 m), higher altitudes have been achieved by teenagers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/23\">",
"     23",
"    </a>",
"    ]. If the child has had a recent upper respiratory infection, lower respiratory infection, or otitis media, extra caution should be exercised during rapid ascent above 2000 m (6500 ft). (See",
"    <a class=\"local\" href=\"#H2847584\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Infants and children with certain underlying diseases are at particular risk for significant complications, including exacerbation of their underlying condition or life-threatening high altitude pulmonary edema (HAPE):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with sickle cell disease who live at sea level should ascend cautiously if at all, as sickle cell crisis can occur at altitudes as low as 1500 m (4900 ft) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/24\">",
"       24",
"      </a>",
"      ]; symptoms are common at 2300 m (7500 ft). Patients with sickle cell trait may become symptomatic from splenic sequestration or infarct at altitudes over 2500 m (8000 ft) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asthmatic patients may find that their symptoms improve because of a relative lack of allergens at high altitudes. While theoretically bronchospasm induced by cold or exercise may worsen [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/28\">",
"       28",
"      </a>",
"      ], asthmatics appear to have no higher risk of altitude illness than non-asthmatics [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/25,29,30\">",
"       25,29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with chronic lung disease, such as cystic fibrosis or bronchopulmonary dysplasia, are at increased risk of significant hypoxemia and should undergo oxygen saturation monitoring during altitude travel. [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Again, ascent should be slow and cautious. One author suggests that children who are able to play and run without shortness of breath at home are unlikely to have problems lower than 3650 m (12,000 ft) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/25\">",
"       25",
"      </a>",
"      ]. Supplemental oxygen may enable these children to travel to altitudes between 2000 to 3000 m (6500 to 9750 ft) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13205892\">",
"       'High altitude pulmonary edema'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link&amp;anchor=H3#H3\">",
"       \"High altitude pulmonary edema\", section on 'Epidemiology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants and children with cardiac lesions involving an increase in pulmonary blood flow or pulmonary hypertension also are at increased risk for HAPE. Isolated absence of the right pulmonary artery has been associated with development of HAPE at relatively low altitudes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/15,29,33,34\">",
"       15,29,33,34",
"      </a>",
"      ]. Thus, these patients should avoid exposure to high altitude. Children with other cardiac defects that increase pulmonary flow, such as atrial and ventricular septal defects and patent ductus arteriosus, may be at increased risk for HAPE as well [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13205892\">",
"       'High altitude pulmonary edema'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link&amp;anchor=H3#H3\">",
"       \"High altitude pulmonary edema\", section on 'Epidemiology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with trisomy 21 have increased pulmonary vascular reactivity and a higher risk of pulmonary hypertension than normal children, in addition to their increased risk of congenital cardiac defects. They also are more likely to have obstructive apnea and hypoventilation. These factors may be responsible for a higher risk of HAPE development, even at low altitudes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infants under six weeks of age and those under one year of age with a history of oxygen requirement or pulmonary hypertension have several unique physiologic limitations that place them at risk for pulmonary hypertension and right heart failure when rapidly exposed to high altitude (3000 to 5000 m [9840 to 16,400 ft]) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/17,35\">",
"       17,35",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Susceptibility of infants and children'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2845974\">",
"       'High altitude cerebral edema'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2845376\">",
"    <span class=\"h1\">",
"     HIGH ALTITUDE ILLNESS IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mountain sickness (AMS) is the most common of the altitude illnesses. The risk of AMS depends upon individual susceptibility, the elevation reached, and the rate of ascent. Thus, while AMS is uncommon below 2000 m (6500 ft), it is quite common (approximately 25 percent incidence in adults and children) at sleeping elevations between 2000 and 3000 m (6500 to 9750 ft), where some cities and the majority of ski resorts in the western United States are located (",
"    <a class=\"graphic graphic_table graphicRef63999 \" href=\"UTD.htm?8/24/8588\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50199 \" href=\"UTD.htm?0/4/71\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Small observational studies suggest that acute mountain sickness may occur more frequently in children and adolescents than in adults at elevations above 3500 m [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/6,7,36\">",
"     6,7,36",
"    </a>",
"    ]. However, in most instances, pediatric high altitude illness can be prevented with appropriate precautions or treated before serious illness, such as high altitude pulmonary or cerebral edema, occurs.",
"   </p>",
"   <p>",
"    The epidemiology of AMS in adults is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute mountain sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute mountain sickness (AMS) and high altitude cerebral edema (HACE) are generally considered to represent two points along a single spectrum of disease, with the same underlying pathophysiology. Although some aspects of this pathophysiology remain unclear, the concept that",
"    <span class=\"nowrap\">",
"     AMS/HACE",
"    </span>",
"    represents a continuum, and that AMS can progress to fatal HACE, fits with clinical experience and is helpful for management. However, especially in young children and infants, recognition of AMS is hampered by the difficulty in recognizing symptoms (eg, headache) in a nonverbal child. Certain pediatric patients (eg, infants under six weeks of age, children with congenital heart disease, cystic fibrosis, Down syndrome) also have a greater susceptibility for life-threatening disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Susceptibility of infants and children'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of AMS in young children are nonspecific and include decreased playfulness, fussiness, poor sleep, vomiting, and decreased appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/31,37,38\">",
"     31,37,38",
"    </a>",
"    ]. The Children's Lake Louise AMS score has been used to assess fussiness and changes in appetite, playfulness, and sleep in the context of recent ascent to a higher altitude (",
"    <a class=\"graphic graphic_table graphicRef66807 \" href=\"UTD.htm?26/10/26796\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/37\">",
"     37",
"    </a>",
"    ]. When used by parents, this score showed high agreement between mothers and fathers for the identification of AMS in young children.",
"   </p>",
"   <p>",
"    In older children and adolescents, signs of high altitude illness are similar to adults and can be identified using the Lake Louise AMS score (",
"    <a class=\"graphic graphic_table graphicRef74655 \" href=\"UTD.htm?41/23/42364\">",
"     table 4",
"    </a>",
"    ). The most common symptom of AMS is headache, which may be accompanied or followed by shortness of breath, dizziness, poor sleep, anorexia, fatigue, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/39\">",
"     39",
"    </a>",
"    ]. The presentation and diagnosis of AMS in adults is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'Presentation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of AMS is usually delayed for 6 to 12 hours following arrival at high altitude, but can occur as rapidly as 1 to 2 hours or as late as 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/40\">",
"     40",
"    </a>",
"    ]. Symptoms are often most severe after the first night, generally resolve in one day if there is no further ascent, and do not recur at the same altitude. AMS may reappear upon ascent to higher altitudes. On occasion, symptoms of AMS may persist for weeks despite no further ascent. In such cases, descent is required if there is no improvement with standard treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'AMS treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supplemental oxygen may be used to support the clinical diagnosis of AMS. Providing 2 to 4",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    of oxygen by nasal cannula for 15 to 20 minutes prior to other interventions should markedly improve headache and other symptoms, as does a brief excursion to a lower altitude. The onset of symptoms more than two days after arrival at a given altitude, absence of headache, dyspnea at rest, and failure to improve rapidly with supplemental oxygen should prompt the clinician to search for an alternative diagnosis. No radiographic or laboratory testing is typically required, unless the diagnosis of AMS is unclear. Other etiologies to consider include carbon monoxide poisoning, migraine, dehydration, exhaustion, hyponatremia, viral syndrome, and bacterial infection (eg, pneumonia).",
"   </p>",
"   <p>",
"    AMS alone does not cause an elevation in body temperature and an appropriate evaluation for fever based upon age and immunization status is warranted in febrile children at altitude. AMS is often a diagnosis of exclusion in this group. The clinician should pay close attention to the child's signs and response to oxygen, and when in doubt should err on the side of a longer observation period before attributing symptoms to a condition other than AMS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link&amp;anchor=H15#H15\">",
"     \"Fever without a source in children 3 to 36 months of age\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2845974\">",
"    <span class=\"h3\">",
"     High altitude cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;High altitude cerebral edema (HACE) is a rare life-threatening altitude disease that theoretically may occur in children. In adults, HACE generally occurs in individuals with acute mountain sickness (AMS)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high altitude pulmonary edema (HAPE) at elevations over 3000 to 3500 m (9750 to 11,375 ft) and is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"     \"Acute mountain sickness and high altitude cerebral edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link&amp;anchor=H3#H3\">",
"     \"High altitude pulmonary edema\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2845239\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of AMS in children follows the same principles as in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/41\">",
"     41",
"    </a>",
"    ]. Treatment of acute mountain sickness (AMS) is based upon symptom severity. Mild illness can be treated conservatively with symptomatic care (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for headache,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    for vomiting), while moderate symptoms may require specific medication (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 5",
"    </a>",
"    ), supplemental oxygen (if available), and if symptoms persist or worsen, descent. In the field, portable hyperbaric therapy may be available when supplemental oxygen is in short supply or unavailable. Children with signs of HACE should undergo immediate descent and if available, receive supplemental oxygen therapy and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is important that group members and the afflicted individual remain alert for any symptoms or signs of worsening disease, particularly at elevations where AMS may rapidly progress to high altitude cerebral edema (above 4000 m [13,000 ft]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'AMS treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'HACE treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Prevention and pharmacologic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acclimatization and slow ascent are by far the best ways to avoid acute mountain sickness (AMS). Travelers who ascend to high altitudes in order to ski, hike, or climb should be encouraged to limit their activity for the first few days at altitude. Adequate hydration also is important although overhydration should be avoided so that hyponatremia does not develop. A recommended approach to prevent AMS (and other altitude-related syndromes) is for climbers to ascend no more than 300 m (1000 ft) per day if they are already above 2440 to 3050 m (8000 to 10,000 ft). This approach is particularly important in individuals in whom AMS or other altitude problems have occurred with previous climbs; such individuals are more likely to suffer from these disorders on subsequent exposure to high altitude.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4877893\">",
"    <span class=\"h4\">",
"     Acetazolamide prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic pharmacologic therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    has not been studied in children who undergo rapid ascent. One prospective observational study of 48 older children and adolescents with rapid ascent to 3450 m found that 18 (38 percent) developed symptoms of acute mountain sickness over 72 hours, but that no patient required specific pharmacologic treatment or evacuation to a lower altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/42\">",
"     42",
"    </a>",
"    ]. This study suggests that prophylactic therapy for acute mountain sickness may be unnecessary in most healthy older children and adolescents who are not acclimated.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    is used, duration of treatment depends upon the ascent profile. Individuals ascending to a fixed sleeping altitude (eg, recreational skiers) may start acetazolamide the day before ascent and continue treatment for 48 hours. If further ascent is planned, acetazolamide can be continued until maximum elevation is attained. Acetazolamide can also be taken episodically to speed acclimatization at any point while gaining altitude or to treat mild AMS. Symptoms do not recur when the drug is discontinued. Although the danger of AMS passes after a few days of acclimatization, acetazolamide may still be useful for sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H28#H28\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'Pharmacologic prevention of AMS/HACE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H30#H30\">",
"     \"Acute mountain sickness and high altitude cerebral edema\", section on 'Acetazolamide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pediatric dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    for prevention of AMS is 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose twice a day (maximum single dose 125 mg) (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 5",
"    </a>",
"    ). Acetazolamide should not be given to children with sulfonamide allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2845163\">",
"    <span class=\"h2\">",
"     Other altitude-related illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;High altitude retinal hemorrhage and high altitude periodic breathing of sleep are other types of altitude illness that may occur in children. In addition, children are more prone to hypothermia because of the larger surface area to mass ratio and the decreased glycogen stores available for increased energy needs in cold weather. Young children are also prone to frostbite if proper attention to appropriate clothing and limitation of cold exposure is not provided by caregivers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations of hypothermia in children\", section on 'Pediatric considerations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=see_link&amp;anchor=H5#H5\">",
"     \"Frostbite\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29659530\">",
"    <span class=\"h3\">",
"     High altitude retinal hemorrhage (HARH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;High altitude retinal hemorrhage (HARH) is a relatively common finding at altitudes above 4270 to 4570 m (14,000 to 15,000 ft), but it usually is asymptomatic and thus, unrecognized unless the macula is involved. The usual complaint is blurring of vision and funduscopy shows flame-like retinal hemorrhages.",
"    <strong>",
"    </strong>",
"    As with all other forms of altitude disease, slow ascent is preventative, and descent is the best treatment. No medications have been found to prevent or treat HARH. Any individual with hemorrhage affecting vision probably should descend. The retinal hemorrhages resolve slowly over the course of several weeks to months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link&amp;anchor=H14#H14\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\", section on 'Other altitude-related illnesses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29659538\">",
"    <span class=\"h3\">",
"     High altitude periodic breathing of sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic breathing of sleep at high altitude is a form of Cheyne-Stokes respiration that occurs almost exclusively during non-REM sleep and can awaken subjects if the hyperventilation phase is strong enough. Children may be less disposed to this illness than adults. As an example, an observational study of 20 children between 9 and 12 years of age and their fathers which compared respiratory inductive plethysmography, pulse oximetry, and end-tidal CO2 measurements during sleep at 3450 m (11,218 ft) versus 490 m (1593 ft), children were noted to have markedly less periodic breathing but similar hyperventilation and decrease in nocturnal oxygen saturation compared with adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, 50 percent of children met criteria for altitude mountain sickness versus 30 percent of adults during the course of the study. This finding suggests that the more stable breathing pattern displayed by these children is related to a lower apnea threshold for CO2 and does not render them more tolerant of high altitude. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link&amp;anchor=H14#H14\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\", section on 'Other altitude-related illnesses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206928\">",
"    <span class=\"h1\">",
"     HIGH ALTITUDE PULMONARY HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious high altitude pulmonary hypertension is rare in healthy infants and children. However, infants less than six weeks of age are at particular risk for pulmonary hypertension and progression to right heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/43\">",
"     43",
"    </a>",
"    ]. This entity has been described in up to 1 percent of infants of lowland parents who are born or arrive at high altitude (3000 to 5000 m [9840 to 16,400 ft]) and remain there for more than a month; it occurs almost exclusively in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/29\">",
"     29",
"    </a>",
"    ]. Because of the risk of this disorder, exposure to prolonged high altitude should be avoided in infants younger than six weeks of age who normally live at low altitude or whose gestation primarily occurred at low altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants between six weeks and one year of age may have a higher incidence of pulmonary hypertension with hypoxia, patent ductus arteriosus (PDA), and patent foramen ovale (PFO) with prolonged exposure to high altitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/17,44\">",
"     17,44",
"    </a>",
"    ]. Those infants who will be remaining indefinitely at altitude warrant physical examination and an initial measurement of pulse oximetry followed by regular monitoring at well child visits. Patients with physical findings suggesting pulmonary hypertension (eg, systolic ejection murmur with a single or narrowly split second heart sound) or other structural heart disease should have an electrocardiogram. An echocardiogram is also necessary if clinical findings suggest structural heart disease or pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13205892\">",
"    <span class=\"h1\">",
"     HIGH ALTITUDE PULMONARY EDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;High altitude pulmonary edema (HAPE) is a form of noncardiogenic pulmonary edema that may be fatal. The syndrome generally occurs among individuals who rapidly ascend to altitudes above 12,000 to 13,000 ft (3660 to 3960 m). However, it may also occur at lower altitudes (5900 to 11,000 ft [1800 to 3350 m]) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As illustrated by the following studies, children who live at high altitudes and then temporarily descend are at risk for HAPE. Children with a viral upper respiratory tract infection who travel to or live at high altitude may have a slightly increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/9,10,32,33,45-47\">",
"     9,10,32,33,45-47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 39 episodes in 32 patients hospitalized for HAPE in Leadville, Colorado, the highest permanent community in the United States at an altitude of 10,152 ft (3094 m) above sea level, 25 of the 32 patients were under 15 years of age, and all but two victims were permanent residents of Leadville [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/46\">",
"       46",
"      </a>",
"      ]. The majority of episodes followed a brief descent to lower altitudes; in three patients, the descent period was only 24 hours. A decrease in the incidence of HAPE was noted with increasing age, suggesting that an undefined response of the pediatric pulmonary vasculature to altitude may contribute to childhood frequency of HAPE.",
"     </li>",
"     <li>",
"      Similar childhood predominance of HAPE also was described in a study of 97 victims in the Andes; children between the ages of two and 12 years had more severe pulmonary edema than did older patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study reported cardiac catheterization results for seven children who lived in Leadville, Colorado and who had recovered from HAPE [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/9\">",
"       9",
"      </a>",
"      ]. Three children had HAPE in association with a viral upper respiratory tract infection without any prior descent. These patients had a greater mean pulmonary artery pressure in response to hypoxia.",
"     </li>",
"     <li>",
"      Upper respiratory infection (colds, bronchitis, or otitis media) in the period immediately preceding ascent also appears to predispose children who live at low altitude to development of HAPE; this phenomenon may be related to the release of inflammatory mediators during infection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13205997\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young children, HAPE presents as increasing respiratory distress over one to two days, but may develop more precipitously. Young children and infants may manifest only pallor and depressed consciousness or other nonspecific symptoms such as increased fussiness, crying, decreased appetite, decreased playfulness, disrupted sleep, and possibly vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/11,29,37,38\">",
"     11,29,37,38",
"    </a>",
"    ]. In infants, increased pulmonary artery pressure and fetal shunting, with or without HAPE, can cause severe hypoxemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link&amp;anchor=H2#H2\">",
"     \"High altitude pulmonary edema\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older children and adolescents, HAPE may present as an insidious cough, breathlessness out of proportion to work, breathlessness that does not respond to rest, and production of frothy, often rusty, sputum. Physical findings at this time include rapid breathing, cyanosis, elevated jugular venous pressure, and diffuse crackles on auscultation of the lungs. When available, chest radiograph reveals diffuse interstitial changes typical of noncardiogenic pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HAPE may appear insidiously over the course of several hours or days, but may also present explosively. It can occur without preceding AMS. In addition, certain individuals develop HAPE upon repeated ascents above the same altitude and may, therefore, have an altitude threshold beyond which they are susceptible to HAPE. Individuals who have experienced HAPE in the past appear to be at risk for recurrence.",
"   </p>",
"   <p>",
"    Of note, HAPE alone does not cause an elevation in body temperature over 38&ordm;C, and young children with a higher fever should be assessed based upon age and immunization status. However, respiratory infection and HAPE can coexist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link&amp;anchor=H15#H15\">",
"     \"Fever without a source in children 3 to 36 months of age\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis in children includes pneumonia, undetected intracardiac shunts, and in infants opening of fetal shunts (eg, ductus arteriosus) in response to high altitude pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=see_link\">",
"     \"Pathophysiology of left to right shunts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206004\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of high altitude pulmonary edema (HAPE) in lowland children who ascend to high altitude targets the same goal as in older patients; the prompt reduction of pulmonary artery (PA) pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/41\">",
"     41",
"    </a>",
"    ]. Options include limiting physical exertion and cold exposure, providing supplemental oxygen via tank or concentrator, evacuation to a lower altitude, simulating descent using hyperbaric therapy, and giving appropriate medications. Descent (simulated or actual) and supplemental oxygen are often effective alone and appear to be superior to any pharmacologic therapy. In some resort areas, children with HAPE are treated as outpatients with supplemental oxygen and remain at the same altitude with their families. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link&amp;anchor=H9#H9\">",
"     \"High altitude pulmonary edema\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who normally reside at high altitude and manifest severe hypoxia or other signs suggestive of high altitude pulmonary edema warrant an electrocardiogram and echocardiography to look for pulmonary hypertension or a structural cardiac abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13206044\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with acute mountain sickness, slow ascent is the best method to prevent high altitude pulmonary edema (HAPE). Individuals with previous HAPE should be encouraged to ascend slowly and be prepared to descend quickly if symptoms of HAPE appear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link&amp;anchor=H22#H22\">",
"     \"High altitude pulmonary edema\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"     Nifedipine",
"    </a>",
"    is the preferred drug for the prevention of HAPE, but is used only in high-risk individuals (eg, adults with pulmonary hypertension who cannot avoid high altitude travel) and only when acclimatization is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/30\">",
"     30",
"    </a>",
"    ]. Ideally, treatment is started 24 hours prior to ascent and continued for five days at the destination altitude (",
"    <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"     table 5",
"    </a>",
"    ). In higher-risk scenarios, treatment may be continued for a longer period. The use of nifedipine for prevention of HAPE in children has not been studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link&amp;anchor=H24#H24\">",
"     \"High altitude pulmonary edema\", section on 'Prophylactic medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20743462\">",
"    <span class=\"h1\">",
"     TRAVEL ADVICE FOR PARENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4876887\">",
"    <span class=\"h2\">",
"     Healthy infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy infants over six weeks of age and young children, including those with well-controlled asthma, typically tolerate travel to altitude well and rarely experience any serious high altitude illness. Clinicians should strongly discourage high altitude travel for infants under six weeks of age who were born at or whose gestations was primarily at low elevation (&lt;1500 m [5000 ft]) because they are at risk for abrupt severe hypoxia, pulmonary hypertension, high altitude pulmonary edema, and right-sided heart failure. (See",
"    <a class=\"local\" href=\"#H2847584\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2845974\">",
"     'High altitude cerebral edema'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following measures reduce the risk or enable easy management of high altitude illness in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Gradual ascent",
"      </strong>",
"      &ndash; As a general guideline, individuals who normally reside below 1500 m (5000 ft) elevation should avoid an abrupt ascent to sleeping altitudes above 2800 m (9200 ft). This is best accomplished by spending one night at an intermediate altitude (particularly when traveling to an elevation that caused symptoms previously). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention and pharmacologic prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link&amp;anchor=H22#H22\">",
"       \"High altitude illness: Physiology, risk factors, and general prevention\", section on 'Gradual ascent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"       Acetazolamide",
"      </a>",
"      <strong>",
"       prophylaxis",
"      </strong>",
"      &ndash; Most experts do not routinely prescribe acetazolamide prophylaxis in otherwise healthy children or adults who are gradually ascending to high altitudes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/21\">",
"       21",
"      </a>",
"      ]. Prophylaxis is indicated in situations where gradual ascent is not possible (eg, rapid ascent by airplane to a destination above 2800 m [9100 ft]) and in children who have had acute mountain sickness when previously exposed to a similar altitude and rate of ascent. (See",
"      <a class=\"local\" href=\"#H4877893\">",
"       'Acetazolamide prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Availability of descent",
"      </strong>",
"      &ndash; Descent from altitude should be readily available if serious high altitude illness occurs. Destinations for which rapid descent is difficult or requires initial ascent should be avoided.",
"     </li>",
"     <li>",
"      <strong>",
"       Medical resources",
"      </strong>",
"      &ndash; Resort communities generally have health care providers with expertise in high altitude illness who are excellent resources for parents. If altitude illness is diagnosed in these settings, it can usually be managed so that the family trip does not have to be disrupted. Clinicians should counsel parents against destinations that are remote and lacking with respect to emergency rescue or medical care capabilities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With proper training most parents can use the Children&rsquo;s Lake Louise score (",
"    <a class=\"graphic graphic_table graphicRef66807 \" href=\"UTD.htm?26/10/26796\">",
"     table 3",
"    </a>",
"    ) to recognize acute mountain sickness, even in preverbal children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/38\">",
"     38",
"    </a>",
"    ]. Awareness and application of this score can help parents decide when to decrease activity, seek medical care",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    provide treatment for mild acute mountain sickness (eg, descent or, in children without sulfonamide allergy,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose every 12 hours, maximum dose: 250 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/21\">",
"     21",
"    </a>",
"    ]. Parents should also know to seek immediate medical attention for altered mental status, respiratory distress, dizziness, or ataxia.",
"   </p>",
"   <p>",
"    Children who develop mild acute mountain sickness that resolves with descent or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"     acetazolamide",
"    </a>",
"    therapy do not require specific evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who normally reside at altitude and manifest severe hypoxia or other signs suggestive of high altitude pulmonary edema warrant an electrocardiogram and echocardiography to look for pulmonary hypertension or a structural cardiac abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4876894\">",
"    <span class=\"h2\">",
"     Susceptible infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents of children with the following conditions should be advised to avoid travel to high altitude (&gt;2000 m [6500 ft]) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/17,21\">",
"     17,21",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H2847584\">",
"     'Risk factors'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Full-term infants less than six weeks of age (premature infants less than 46 weeks postconceptual age) or full-term infants up to one year of age with a history of oxygen requirement or pulmonary hypertension",
"     </li>",
"     <li>",
"      Premature infants beyond 46 weeks post conceptual age with a history of oxygen requirement, bronchopulmonary dysplasia, or pulmonary hypertension",
"     </li>",
"     <li>",
"      Congenital heart disease with pulmonary hypertension, cyanosis, or intracardiac shunts",
"     </li>",
"     <li>",
"      Sickle cell disease",
"     </li>",
"     <li>",
"      Down syndrome with cardiac shunts or pulmonary hypertension",
"     </li>",
"     <li>",
"      Active respiratory disease such as pneumonia, bronchiolitis, or cystic fibrosis with exacerbation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with stable cystic fibrosis may be able to travel to high altitude if pulse oximetry monitoring is performed during travel and supplemental oxygen can be provided. Assessment of FEV1 and hypoxia inhalation testing can be performed in children over six years of age and can help identify those children who warrant supplemental oxygen during the trip [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/30\">",
"     30",
"    </a>",
"    ]. Almost all resort areas have home oxygen companies that honor prescriptions for oxygen written by licensed providers. Parents should ensure strict adherence to established chest physiotherapy, mucolytic, and antibiotic regimens during the trip.",
"   </p>",
"   <p>",
"    Children with neuromuscular disorders or conditions causing restrictive lung disease (eg, severe kyphoscoliosis) should undergo assessment by a pediatric pulmonologist prior to travel to determine the need for supportive measures while at high altitude, such as supplemental oxygen (continuous or nocturnal) or nighttime bilevel positive airway pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27769/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/18/23842?source=see_link\">",
"       \"Patient information: Altitude sickness (including mountain sickness) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascent above 2000 m (6500 ft) may be associated with high altitude illness in children. However most healthy children do well without any serious effects at altitudes less than 3500 m (11,375 ft). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'High altitude physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healthy children should ascend to very high altitudes (over 3500 m [11,375 ft]) slowly and only if rapid descent is possible in the event of problems. (See",
"      <a class=\"local\" href=\"#H1231531\">",
"       'Recommendations for ascent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children at particular risk for serious high altitude illness include infants under six weeks of age; infants up to one year of age with a history of oxygen requirement or pulmonary hypertension, including premature infants; children who live at very high altitude and undergo a temporary descent; and children with Down syndrome, congenital heart disease, cystic fibrosis or neuromuscular problems compromising ventilation. (See",
"      <a class=\"local\" href=\"#H2847584\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2845974\">",
"       'High altitude cerebral edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of high altitude illness are nonspecific in young children and infants and require a high index of suspicion for detection (",
"      <a class=\"graphic graphic_table graphicRef66807 \" href=\"UTD.htm?26/10/26796\">",
"       table 3",
"      </a>",
"      ). Improvement of symptoms after administration of supplemental oxygen (eg, 2 to 4",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      by nasal cannula for 15 to 20 minutes) or a brief descent supports the diagnosis of acute mountain sickness (AMS). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of AMS in older children and adolescents are similar to what is seen in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link&amp;anchor=H6#H6\">",
"       \"Acute mountain sickness and high altitude cerebral edema\", section on 'Presentation and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of AMS is based upon symptom severity and follows the same principles as in adults (",
"      <a class=\"graphic graphic_table graphicRef76719 \" href=\"UTD.htm?40/16/41229\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2845239\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In young children, high altitude pulmonary edema (HAPE) presents as increasing respiratory distress over one to two days, but may develop more precipitously. In some young children and infants, primary signs may not include tachypnea, but oxygen saturation will always be low (&lt;90 percent). (See",
"      <a class=\"local\" href=\"#H13205892\">",
"       'High altitude pulmonary edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of HAPE in older children and adolescents are similar to what is seen in adults. Children with high altitude pulmonary edema warrant immediate supplemental oxygen, descent or both . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link&amp;anchor=H5#H5\">",
"       \"High altitude pulmonary edema\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13206004\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acclimatization and slow ascent are the most effective ways to avoid AMS and HAPE in otherwise healthy children. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention and pharmacologic prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13206044\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healthy children generally tolerate travel to altitude well and rarely experience any serious high altitude illness. The clinician should advise parents that resort communities generally have health care providers with expertise in altitude-related problems who are excellent sources for parents and children if they feel their child might be experiencing high altitude illness. (See",
"      <a class=\"local\" href=\"#H20743462\">",
"       'Travel advice for parents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hackett PH, Roach RC. High altitude medicine. In: Wildnerness Medicine, 5th, Auerbach PS.  (Ed), Mosby, Philadelphia 2007. p.2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/2\">",
"      Poets CF, Samuels MP, Southall DP. Potential role of intrapulmonary shunting in the genesis of hypoxemic episodes in infants and young children. Pediatrics 1992; 90:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/3\">",
"      Samuels MP. The effects of flight and altitude. Arch Dis Child 2004; 89:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/4\">",
"      Mortola JP, Fisher JT, Smith B, et al. Dynamics of breathing in infants. J Appl Physiol 1982; 52:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/5\">",
"      Hislop AA, Haworth SG. Airway size and structure in the normal fetal and infant lung and the effect of premature delivery and artificial ventilation. Am Rev Respir Dis 1989; 140:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/6\">",
"      Moraga FA, Osorio JD, Vargas ME. Acute mountain sickness in tourists with children at Lake Chungar&aacute; (4400 m) in northern Chile. Wilderness Environ Med 2002; 13:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/7\">",
"      Moraga FA, Pedreros CP, Rodr&iacute;guez CE. Acute mountain sickness in children and their parents after rapid ascent to 3500 m (Putre, Chile). Wilderness Environ Med 2008; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/8\">",
"      Durmowicz AG. Pulmonary edema in 6 children with Down syndrome during travel to moderate altitudes. Pediatrics 2001; 108:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/9\">",
"      Fasules JW, Wiggins JW, Wolfe RR. Increased lung vasoreactivity in children from Leadville, Colorado, after recovery from high-altitude pulmonary edema. Circulation 1985; 72:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/10\">",
"      Durmowicz AG, Noordeweir E, Nicholas R, Reeves JT. Inflammatory processes may predispose children to high-altitude pulmonary edema. J Pediatr 1997; 130:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/11\">",
"      Duster MC, Derlet MN. High-altitude illness in children. Pediatr Ann 2009; 38:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/12\">",
"      Choudhuri JA, Ogden LG, Ruttenber AJ, et al. Effect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics 2006; 117:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/13\">",
"      Lovering AT, Romer LM, Haverkamp HC, et al. Excessive gas exchange impairment during exercise in a subject with a history of bronchopulmonary dysplasia and high altitude pulmonary edema. High Alt Med Biol 2007; 8:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/14\">",
"      Das BB, Wolfe RR, Chan KC, et al. High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch Pediatr Adolesc Med 2004; 158:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/15\">",
"      Rios B, Driscoll DJ, McNamara DG. High-altitude pulmonary edema with absent right pulmonary artery. Pediatrics 1985; 75:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/16\">",
"      Sebbane M, Wuyam B, Pin I, et al. Unilateral agenesis of the pulmonary artery and high-altitude pulmonary edema (HAPE) at moderate altitude. Pediatr Pulmonol 1997; 24:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/17\">",
"      Niermeyer S. Going to high altitude with a newborn infant. High Alt Med Biol 2007; 8:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/18\">",
"      Oades PJ, Buchdahl RM, Bush A. Prediction of hypoxaemia at high altitude in children with cystic fibrosis. BMJ 1994; 308:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/19\">",
"      Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics 2008; 121:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/20\">",
"      Hultgren HN, Honigman B, Theis K, Nicholas D. High-altitude pulmonary edema at a ski resort. West J Med 1996; 164:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/21\">",
"      Yaron M, Niermeyer S. Travel to high altitude with young children: an approach for clinicians. High Alt Med Biol 2008; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/22\">",
"      KHOURY GH, HAWES CR. Primary pulmonary hypertension in children living at high altitude. J Pediatr 1963; 62:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/23\">",
"      Cosby RL, Sophocles AM, Durr JA, et al. Elevated plasma atrial natriuretic factor and vasopressin in high-altitude pulmonary edema. Ann Intern Med 1988; 109:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/24\">",
"      Rennie D, Morrissey J. Retinal changes in Himalayan climbers. Arch Ophthalmol 1975; 93:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/25\">",
"      Neumann K. Children at altitude. Travel Med Infect Dis 2007; 5:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/26\">",
"      Cook AL. Splenic infarction in a high-altitude traveler with undiagnosed sickle cell trait. Wilderness Environ Med 2008; 19:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/27\">",
"      L&oacute;pez de Guimaraes D, Menacho L&oacute;pez J, Villanueva Palacios J, Mosquera V&aacute;squez V. [Splenic infarction at high altitude, Huaraz-Peru (3,100 masl)]. Rev Gastroenterol Peru 2009; 29:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/28\">",
"      Harris MD, Terrio J, Miser WF, Yetter JF 3rd. High-altitude medicine. Am Fam Physician 1998; 57:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/29\">",
"      Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol 2001; 2:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/30\">",
"      Luks AM, Swenson ER. Travel to high altitude with pre-existing lung disease. Eur Respir J 2007; 29:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/31\">",
"      Carpenter TC, Niermeyer S, Durmowicz AG. Altitude-related illness in children. Curr Probl Pediatr 1998; 28:181.",
"     </a>",
"    </li>",
"    <li>",
"     Smith KM. High altitude illness and dysbarism. In: Pediatric Emergency Medicine: Concepts and Clinical Practice, Barkin RM.  (Ed), Mosby, St. Louis 1997. p.511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/33\">",
"      Hultgren HN. High-altitude pulmonary edema: current concepts. Annu Rev Med 1996; 47:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/34\">",
"      Hackett PH, Creagh CE, Grover RF, et al. High-altitude pulmonary edema in persons without the right pulmonary artery. N Engl J Med 1980; 302:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/35\">",
"      Pollard AJ, Murdoch DR, B&auml;rtsch P. Children in the mountains. BMJ 1998; 316:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/36\">",
"      Kohler M, Kriemler S, Wilhelm EM, et al. Children at high altitude have less nocturnal periodic breathing than adults. Eur Respir J 2008; 32:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/37\">",
"      Yaron M, Waldman N, Niermeyer S, et al. The diagnosis of acute mountain sickness in preverbal children. Arch Pediatr Adolesc Med 1998; 152:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/38\">",
"      Yaron M, Niermeyer S, Lindgren KN, Honigman B. Evaluation of diagnostic criteria and incidence of acute mountain sickness in preverbal children. Wilderness Environ Med 2002; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/39\">",
"      Theis MK, Honigman B, Yip R, et al. Acute mountain sickness in children at 2835 meters. Am J Dis Child 1993; 147:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/40\">",
"      Major SA, Hogan RJ, Yeates E, Imray CH. Peripheral arterial desaturation is further exacerbated by exercise in adolescents with acute mountain sickness. Wilderness Environ Med 2012; 23:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/41\">",
"      Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med 2010; 21:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/42\">",
"      Bloch J, Duplain H, Rimoldi SF, et al. Prevalence and time course of acute mountain sickness in older children and adolescents after rapid ascent to 3450 meters. Pediatrics 2009; 123:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/43\">",
"      Sui GJ, Liu YH, Cheng XS, et al. Subacute infantile mountain sickness. J Pathol 1988; 155:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/44\">",
"      Miao CY, Zuberbuhler JS, Zuberbuhler JR. Prevalence of congenital cardiac anomalies at high altitude. J Am Coll Cardiol 1988; 12:224.",
"     </a>",
"    </li>",
"    <li>",
"     Bezruchka, S. Altitude Illness: Prevention and Treatment, The Mountaineers, Seattle 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/46\">",
"      Scoggin CH, Hyers TM, Reeves JT, Grover RF. High-altitude pulmonary edema in the children and young adults of Leadville, Colorado. N Engl J Med 1977; 297:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27769/abstract/47\">",
"      Hultgren HN, Marticorena EA. High altitude pulmonary edema. Epidemiologic observations in Peru. Chest 1978; 74:372.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6590 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-90821EDB07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27769=[""].join("\n");
var outline_f27_7_27769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HIGH ALTITUDE PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Susceptibility of infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2847584\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231531\">",
"      Recommendations for ascent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2845376\">",
"      HIGH ALTITUDE ILLNESS IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute mountain sickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2845974\">",
"      - High altitude cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2845239\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Prevention and pharmacologic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4877893\">",
"      Acetazolamide prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2845163\">",
"      Other altitude-related illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29659530\">",
"      - High altitude retinal hemorrhage (HARH)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29659538\">",
"      - High altitude periodic breathing of sleep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13206928\">",
"      HIGH ALTITUDE PULMONARY HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13205892\">",
"      HIGH ALTITUDE PULMONARY EDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13205997\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13206004\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13206044\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20743462\">",
"      TRAVEL ADVICE FOR PARENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4876887\">",
"      Healthy infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4876894\">",
"      Susceptible infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6590|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/24/8588\" title=\"table 1\">",
"      Physiologic effects of high altitude",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/4/71\" title=\"table 2\">",
"      High altitude sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/10/26796\" title=\"table 3\">",
"      Fussiness and pediatric symptom scores acute mountain sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/23/42364\" title=\"table 4\">",
"      Lake Louise AMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/16/41229\" title=\"table 5\">",
"      Pharmacologic treatment of high altitude illness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=related_link\">",
"      Acute mountain sickness and high altitude cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16056?source=related_link\">",
"      Clinical manifestations of hypothermia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37671?source=related_link\">",
"      Frostbite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=related_link\">",
"      High altitude pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=related_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=related_link\">",
"      Pathophysiology of left to right shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/18/23842?source=related_link\">",
"      Patient information: Altitude sickness (including mountain sickness) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_7_27770="Central and lateral compartment lymphadenectomy (neck dissection) for differentiated thyroid cancer";
var content_f27_7_27770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Central and lateral compartment lymphadenectomy (neck dissection) for differentiated thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27770/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27770/contributors\">",
"     Rebecca S Sippel, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27770/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/7/27770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/7/27770/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/7/27770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27139731\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiated thyroid cancers, including papillary and follicular, account for &gt;90 percent of thyroid cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/1\">",
"     1",
"    </a>",
"    ]. While metastatic disease to regional nodes is frequently identified in patients with papillary thyroid cancer, it is very uncommon in patients with follicular cancer. (See",
"    <a class=\"local\" href=\"#H1137809\">",
"     'Incidence of metastatic disease to regional nodes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1138017\">",
"    <span class=\"h1\">",
"     ANATOMIC NECK LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic neck levels and the nodal contents include (",
"    <a class=\"graphic graphic_figure graphicRef58086 \" href=\"UTD.htm?14/53/15193\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Level I &ndash; Submental (IA) and submandibular lymph nodes (IB)",
"     </li>",
"     <li>",
"      Level II &ndash; Upper third of the jugular lymph nodes from the hyoid bone to the base of the skull. This includes those lymph nodes located anterior (IIA) and posterior (IIB) to the spinal accessory nerve.",
"     </li>",
"     <li>",
"      Level III &ndash; Middle third of jugular lymph nodes, located between the cricoid cartilage and the hyoid bone.",
"     </li>",
"     <li>",
"      Level IV &ndash; Lower third of jugular lymph nodes, located from the clavicle to the cricoid cartilage.",
"     </li>",
"     <li>",
"      Level V &ndash; Posterior triangle lymph nodes, located posterior to the sternocleidomastoid muscle, including spinal accessory nodes, above the cricoid cartilage (VA), supraclavicular, and transverse cervical nodes, and below the cricoid cartilage (VB).",
"     </li>",
"     <li>",
"      Level VI &ndash; Central neck lymph nodes located between the carotid arteries from the innominate artery to the hyoid bone. This includes the pretracheal, prelaryngeal, and paratracheal lymph nodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The anatomy of the thyroid gland is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44310?source=see_link\">",
"     \"Surgical anatomy of the thyroid gland\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18534097\">",
"    <span class=\"h1\">",
"     DEFINITION OF NECK DISSECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neck dissection is defined as compartment-oriented removal of all of the fibroadipose tissue and lymphatic tissues en bloc from a given compartment (ie, central, lateral) within the neck, while preserving critical structures (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef87027 \" href=\"UTD.htm?1/9/1173\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/2\">",
"     2",
"    </a>",
"    ]. &ldquo;Berry picking&rdquo; is not compartment-oriented dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The central neck dissection entails removal of the lymph nodes from level VI, including the prelaryngeal and pretracheal nodes, and at least one paratracheal lymph node basin. Central neck dissection may be unilateral or bilateral.",
"     </li>",
"     <li>",
"      The lateral neck dissection includes the removal of the lymph nodes from level II through V.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1137809\">",
"    <span class=\"h1\">",
"     INCIDENCE OF METASTATIC DISEASE TO REGIONAL NODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic disease to regional lymph nodes is common in patients with papillary thyroid cancer, particularly in autopsy series, where rates can exceed 90 percent. Palpable nodal disease is present in approximately 5 to 10 percent of patients with papillary thyroid cancer; a preoperative neck ultrasound can detect lymph node disease in up to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard histologic techniques (hematoxylin and eosin stain) typically reveal positive lymph nodes in 20 to 50 percent of patients undergoing an elective node dissection for papillary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/8\">",
"     8",
"    </a>",
"    ]. However, after immunohistochemical evaluation (ie, cytokeratin stain), up to 90 percent of patients will have microscopic metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. It appears that many patients have microscopic regional lymph node disease that never becomes clinically apparent. (See",
"    <a class=\"local\" href=\"#H27139738\">",
"     'Significance of lymph node involvement'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of papillary thyroid cancer\", section on 'Prognostic features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, less than 5 percent of patients with follicular thyroid cancer develop nodal metastatic disease; the hematogenous rather than the lymphatic route is the primary pathway for metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of follicular thyroid cancer\", section on 'Metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1138097\">",
"    <span class=\"h1\">",
"     PATTERN OF NODAL METASTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary thyroid cancer typically spreads in a stepwise fashion from the thyroid to the central neck and then laterally to the jugular chain nodes (",
"    <a class=\"graphic graphic_figure graphicRef58086 \" href=\"UTD.htm?14/53/15193\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ). If there is nodal involvement identified in the lateral neck, it is presumed that there is disease in the central neck as well. Level III and level IV are the most common sites of nodal metastatic disease in the lateral neck compartment; disease is rarely identified in level I [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &ldquo;Skip&rdquo; metastasis, in which lateral neck involvement is seen in the absence of central neck nodal disease, occurs in up to 8 percent of patients and is most commonly seen in superior pole thyroid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/14\">",
"     14",
"    </a>",
"    ]. If nodal disease is identified in the lateral neck, a central and lateral neck dissection should both be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27139738\">",
"    <span class=\"h1\">",
"     SIGNIFICANCE OF LYMPH NODE INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central neck, or level VI, lymph nodes are typically the first site of regional spread of papillary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/10\">",
"     10",
"    </a>",
"    ]. The prognosis of differentiated thyroid cancer remains excellent even in patients with lymph node involvement (&gt;90 percent 10-year survival) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. However, metastatic disease to regional lymph nodes at the time of presentation does appear to increase the risk of cervical recurrence, especially when macroscopic, but does not appear to have a significant impact on overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of papillary thyroid cancer\", section on 'Pathologic features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of follicular thyroid cancer\", section on 'Lymph node involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27139745\">",
"    <span class=\"h2\">",
"     Local nodal metastasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph node involvement in papillary thyroid cancer can be macroscopic (identified on preoperative imaging or intraoperative inspection) or microscopic (identified on pathologic review only). Cervical lymph node metastasis from papillary thyroid cancer is associated with several well-described factors including multifocality, extrathyroidal extension, larger tumor size, younger age, aggressive variants, and the presence of BRAF mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19166492\">",
"    <span class=\"h2\">",
"     Local nodal recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macroscopic lymph node involvement is associated with a high rate of local recurrence (10 to 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/16,17,23-26\">",
"     16,17,23-26",
"    </a>",
"    ]. Lymph node factors associated with a higher risk of local recurrence include more than five positive lymph nodes, lymph node ratio, and the presence of extranodal extension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/16,27\">",
"     16,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between microscopic nodal disease detected following a prophylactic neck dissection and recurrence of local lymph node disease is unresolved, as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/15,23,24,28\">",
"     15,23,24,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 134 patients with papillary thyroid cancer undergoing a thyroidectomy with a neck dissection, 17 (12.7 percent) developed a local recurrence (LR) in cervical lymph nodes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/15\">",
"       15",
"      </a>",
"      ]. LR was significantly higher for patients undergoing a therapeutic neck dissection (TND) for suspicious lymphadenopathy (n = 42) compared with patients undergoing an elective neck dissection (END) with no lymphadenopathy (23.8 [10 patients] versus 7.6 [7 patients] percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients with suspicious lymphadenopathy had histologically positive nodes.",
"     </li>",
"     <li>",
"      Microscopic disease was identified in 62 of 92 patients (67.4 percent) undergoing an END.",
"     </li>",
"     <li>",
"      Of the 62 patients with microscopic nodal disease, the LR rate was 11.3 percent.",
"     </li>",
"     <li>",
"      Of the 30 patients with histologically negative nodes, there were no local recurrences.",
"     </li>",
"     <li>",
"      Of the 104 patients with histologically positive nodes (macroscopic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      microscopic), the LR rate was 16.3 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 545 patients with papillary thyroid cancer, 118 patients (21.6 percent) were identified with macroscopic regional lymph node metastasis, and the overall 10-year probability of developing LR in regional nodes was 7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients with macroscopic disease treated with a bilateral central and lateral compartment lymphadenectomy had a significantly lower probability of LR compared with patients treated with any other type of nodal resection (10 versus 30 percent).",
"      <br/>",
"      <br/>",
"      For patients without macroscopic nodal disease treated with either no lymphadenectomy, bilateral central and lateral lymphadenectomy, or another type of lymph node resection (eg, unilateral, berry picking) the LR rate ranged from 0 to 5 percent.",
"     </li>",
"     <li>",
"      In a retrospective review of 235 patients with papillary thyroid cancer without macroscopic regional disease, patients undergoing an END had a similar LR rate compared with patients undergoing observation of the nodes (0.43 versus 0.65 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/23\">",
"       23",
"      </a>",
"      ]. In contrast, 24 patients with macroscopic disease undergoing a TND had a LR rate of 16.7 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27139752\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic disease to regional lymph nodes for patients &lt;45 years of age is not an independent risk factor for disease-specific survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/15,18,29-34\">",
"     15,18,29-34",
"    </a>",
"    ]. For example, the 5- and 10-year disease-specific survival rates were similar for patients with lymph node metastasis from papillary thyroid cancer compared with patients with no metastasis detected by LND (98 versus 100 percent, and 95 versus 100 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/15\">",
"     15",
"    </a>",
"    ]. In a retrospective review of 11,453 patients with papillary thyroid cancer, Kaplan-Meier age-stratified subgroup analysis found age &gt;45 years to be associated with a higher mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/18\">",
"     18",
"    </a>",
"    ]. In particular, the four-year disease specific survival was significantly worse for patients &gt;45 years old with positive nodes in the lateral and mediastinal compartments (Level II-VA and",
"    <span class=\"nowrap\">",
"     VB/VII)",
"    </span>",
"    compared with the positive nodes in the central compartment (Level VI, p&lt;0.01). The four-year disease specific survival for patients &lt;45 years old was 99 percent, independent of the presence or absence of lymph node involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of papillary thyroid cancer\", section on 'Prognostic features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of follicular thyroid cancer\", section on 'Prognostic features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28440921\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR NECK DISSECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15405244\">",
"    <span class=\"h2\">",
"     Therapeutic neck dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neck dissection for differentiated thyroid cancer (papillary and follicular) is performed as a therapeutic procedure when nodal disease is identified or suspected based upon the clinical examination or ultrasound evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/8,35,36\">",
"     8,35,36",
"    </a>",
"    ]. A therapeutic neck dissection can be performed at the time of the initial thyroid cancer diagnosis, as a delayed procedure, at the time of a local nodal recurrence in the absence of widespread or distant disease, or as reoperation in a previously dissected compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The consensus guidelines from the American Thyroid Association (ATA) and the National Comprehensive Cancer Network recommend a central or lateral therapeutic neck dissection in patients with evidence (clinical or ultrasound) of nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/8,39\">",
"     8,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H11#H11\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Therapeutic'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15405236\">",
"    <span class=\"h2\">",
"     Prophylactic central neck dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prophylactic central neck dissection (level VI) for patients with papillary thyroid cancer is controversial, and there is limited evidence to support a prophylactic lateral neck dissection (level II to V) in this clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/25,26,28,36,40-47\">",
"     25,26,28,36,40-47",
"    </a>",
"    ]. In addition, patients with follicular thyroid cancer have a low risk of nodal disease (&lt;5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/12\">",
"     12",
"    </a>",
"    ]) and a prophylactic neck dissection is not performed.",
"   </p>",
"   <p>",
"    Since the risks of transient complications are high, especially when performed in a low volume setting, and the benefits of prophylactic central neck dissection appear small, we do not recommend the routine performance of central neck dissection in all patients with papillary thyroid cancer. Instead, a selective approach should be taken, based upon patient risk factors and the experience level of the surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the ATA consensus guidelines that a prophylactic central neck dissection (ipsilateral or bilateral) may be performed for patients with advanced papillary thyroid cancer (T3 or T4 lesions) or who are otherwise high risk. A near-total or total thyroidectomy without prophylactic central node dissection may be adequate for patients with small (T1 or T2) lesions (",
"    <a class=\"graphic graphic_table graphicRef73748 \" href=\"UTD.htm?1/45/1758\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there are no randomized trials, a prophylactic central node dissection may avoid a reoperation for patients with other high-risk features, such as carriers of BRAF mutations and those with extrathyroidal tumor extension. While a comprehensive bilateral central node dissection may improve survival compared with historic controls and reduce the risk of nodal recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], it may increase morbidity when performed by less experienced surgeons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H12#H12\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Prophylactic'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19167149\">",
"    <span class=\"h2\">",
"     Prophylactic lateral neck dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral neck lymph nodal involvement occurs in approximately 20 to 30 percent of patients with thyroid cancer",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/50\">",
"     50",
"    </a>",
"    ]. Regional nodal disease is generally identified by ultrasound preoperatively or as a component of the postoperative follow-up routine. The lateral neck compartment is not entered during a total thyroidectomy, and therefore, there is no added risk to doing a lateral neck dissection in a delayed fashion if disease is identified after the initial operation. &nbsp;",
"   </p>",
"   <p>",
"    While microscopic disease is common in the lateral neck, there have been no data to show that routine lateral neck dissection benefits patients&rsquo; long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/16,36\">",
"     16,36",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    Therefore, there",
"    <strong>",
"    </strong>",
"    is no role for this procedure, which has no demonstrated survival advantage and can have considerable morbidity. We do not recommend it. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27139780\">",
"    <span class=\"h1\">",
"     STAGING EVALUATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preoperative ultrasound to assess for regional nodal disease in the neck is an essential part of the staging work-up of all patients with a preoperative diagnosis of thyroid cancer (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73138 \" href=\"UTD.htm?2/8/2178\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scans and MRI scans are used selectively in the preoperative evaluation of patients with thyroid cancer, and are most beneficial in patients with extensive nodal involvement, or in patients with thick necks in whom the resolution of ultrasound may be limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The staging of thyroid cancer and a review of the utility of ultrasonography are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14599?source=see_link\">",
"     \"Clinicopathologic staging of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Lymphadenopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=see_link\">",
"     \"Ultrasound-guided thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At thyroidectomy, it is not uncommon for central compartment nodal disease to be evident, ie to have been missed on preoperative staging. Thus, at thyroidectomy, the surgeon should always inspect the central compartment nodes and be prepared to perform CND if they appear abnormal. Suspected lymph node metastasis may be confirmed by intraoperative frozen section examination. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1138723\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1138731\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroidectomy and neck dissection are both considered clean operations and the risk of infection is less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/53\">",
"     53",
"    </a>",
"    ]. Prophylactic antibiotics may be routinely administered at a thyroidectomy, but are not proven to benefit this population due to the low risk of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1138747\">",
"    <span class=\"h2\">",
"     Venous thrombosis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing a regional thyroid lymphadenectomy are at a very low risk for developing a deep venous thrombosis (DVT). The reported risk of DVT in this population is 0.16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/54\">",
"     54",
"    </a>",
"    ]. The risk of bleeding complications is significantly higher (0.96 percent), therefore the risks and benefits of DVT prophylaxis must be balanced carefully in this population. Prevention of DVT is discussed in detail separately. For low or average risk patients, we use a preoperative subcutaneous dose of unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in addition to intermittent pneumatic compression devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2892454\">",
"    <span class=\"h2\">",
"     Preoperative localization of recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative localization of recurrent disease is a useful adjunct for a reoperative neck dissection, because, in the reoperative setting, failure to find and resect lymph node imbedded in scar is a real risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/55\">",
"     55",
"    </a>",
"    ]. A prospective study of 10 patients with isolated, nonpalpable recurrences found that injection of blue dye under ultrasound guidance was feasible and detected nodes as small as 6 mm without complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/56\">",
"     56",
"    </a>",
"    ]. Another prospective study of 15 consecutive patients found that colloidal charcoal injected under ultrasound guidance 1 to 15 days before the operation could be identified in or near 16 of 19 (84 percent) recurrent lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/57\">",
"     57",
"    </a>",
"    ]. Charcoal was absent in one patient, hematoma from the injection impaired surgical dissection in one patient, and 18 lesions (95 percent) were surgically removed. Recurrent carcinoma was identified in 16 lesions and benign lymphadenitis was identified in the other two lesions. While technically feasible, prospective studies are needed to determine if resection of small recurrent lesions will positively influence survival or adversely affect risk of complications.",
"   </p>",
"   <p>",
"    We perform surgical removal when feasible in order to avoid complications from continued tumor growth, to facilitate surveillance of thyroglobulin levels, and to minimize the amount of radioactive iodine that patients receive. Due to the risks of reoperation, we usually do not consider operative intervention until the lesion is &gt;7 mm in size. For lesions &lt;1.5 cm, we utilize the blue dye technique or same-day ultrasonographic skin marking to facilitate intraoperative localization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2892462\">",
"    <span class=\"h1\">",
"     INTRA-OPERATIVE MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique for intra-operative nerve monitoring is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Intraoperative neuromonitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intra-operative ultrasound can aid in tumor identification, particularly in the clinical setting of a reoperation where recurrence may not be identifiable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Using preoperative and intra-operative ultrasound and localization techniques can direct the dissection and minimize the risks in the reoperative setting, and reported outcomes in small series reveal a low rate of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/55-61\">",
"     55-61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7046574\">",
"     'Postoperative mortality and morbidity rates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27139831\">",
"    <span class=\"h1\">",
"     CENTRAL COMPARTMENT NECK DISSECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard approach to initial neck dissection for patients with thyroid cancer is compartment oriented. The positioning, type of incision, exposure, drains, and closure are the same as described for a thyroidectomy. Alternatively, in the reoperative setting, a fresh incision can be made directly over a localized level VI lymph node in order to avoid extensive dissection and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link\">",
"     \"Initial and reoperative thyroidectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general principles for performing a central compartment neck dissection include (",
"    <a class=\"graphic graphic_figure graphicRef86364 \" href=\"UTD.htm?2/50/2852\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1140098\">",
"    <span class=\"h2\">",
"     Extent of central neck dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central compartment neck dissection extends superiorly to the hyoid bone and inferiorly to the innominate (brachiocephalic) artery (",
"    <a class=\"graphic graphic_figure graphicRef58086 \" href=\"UTD.htm?14/53/15193\">",
"     figure 1",
"    </a>",
"    ). The lateral border of dissection is the ipsilateral carotid artery, the anterior border is the superficial layer of the deep cervical fascia, and the posterior border is the deep layer of the deep cervical fascia, which may be deep to the carotid artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27139898\">",
"    <span class=\"h2\">",
"     Technique for central neck dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic landmarks are the same for initial and reoperative thyroid-related procedures; however, the landmarks may be distorted and challenging to identify if the neck dissection is performed after a previous operation in that compartment, such as thyroidectomy, parathyroidectomy, carotid endarterectomy, cervical disc surgery, or lymphadenectomy. Hence, the procedure should be performed by a surgeon skilled in reoperative thyroid operations. The approach to thyroidectomy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the central compartment neck dissection includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identifying the recurrent laryngeal nerve (RLN) at the posterior suspensory ligament of Berry (lateral thyrohyoid ligament) (",
"      <a class=\"graphic graphic_figure graphicRef74541 \" href=\"UTD.htm?23/37/24146\">",
"       figure 5",
"      </a>",
"      ). The RLN lies lateral to the ligament. Preserve the RLN caudally along its entire course.",
"     </li>",
"     <li>",
"      Dissecting the fibroadipose tissues anterior and medial to the RLN and its branches, medially to laterally, using an en bloc technique and gentle traction on the specimen.",
"     </li>",
"     <li>",
"      Dissecting the tissues posterior to the recurrent laryngeal nerve laterally and inferiorly, sweeping the mass of lymphatic and fibroareolar tissues medially and inferiorly from the level of the hyoid bone superiorly to the innominate artery inferiorly.",
"     </li>",
"     <li>",
"      Identifying the upper (embryologically superior) parathyroid gland, typically 1 to 2 cm cranial to the junction of the recurrent laryngeal nerve with the inferior thyroid artery, and within 1 cm of the entry point for the recurrent laryngeal nerve into the ligament of Berry and the cricoid cartilage (",
"      <a class=\"graphic graphic_figure graphicRef56752 \" href=\"UTD.htm?9/47/9972\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Identifying the superior thyroid artery, which provides the arterial supply for most of the upper parathyroid glands. Preserve the parathyroid gland and its vascular pedicle [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/62\">",
"       62",
"      </a>",
"      ]. The vascular pedicle may also arise from the inferior thyroid artery. Also, preserve the adjacent superior laryngeal nerve and its branches.",
"     </li>",
"     <li>",
"      Identifying the inferior parathyroid gland, located anterior to the recurrent laryngeal nerve. The inferior gland is most often found in the thyrothymic tract, or just inside the thyroid capsule on the inferior portion of the thyroid lobes. Free the gland from its medial fibroareolar attachments and sweep it laterally on its vascular pedicle. The blood supply is generally from the inferior thyroid artery, which is nearly always available.",
"     </li>",
"     <li>",
"      Preserving the inferior parathyroid gland. Every attempt should be made to preserve the parathyroid gland in situ, if feasible. Often, the lower parathyroid gland can be mobilized laterally and preserved with its inferior pedicle. However, when there is bulky central neck nodal disease, this can be challenging. If a parathyroid gland becomes dusky in color, indicating devascularization, an autotransplantation can be performed after confirming that it is indeed a parathyroid gland by histology. Most surgeons agree it is difficult to preserve the lower parathyroid glands in situ, and advocate routine autotransplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link&amp;anchor=H16#H16\">",
"       \"Initial and reoperative thyroidectomy\", section on 'Parathyroid autotransplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dissecting caudally towards the sternal notch. If available, the Harmonic scalpel cutting and coagulation device may facilitate the separation of central compartment contents from the lateral strap muscle fibers, as well as help in the management of associated small blood vessels. Identify and preserve the RLN along its course from the ligament of Berry to the thoracic outlet while resecting all lymphatic tissues anterior to it.",
"     </li>",
"     <li>",
"      Include the thymic tissue with the specimen, especially if abnormal nodes are palpated within the gland.",
"     </li>",
"     <li>",
"      Do",
"      <strong>",
"       not",
"      </strong>",
"      &ldquo;berry pick&rdquo;. Isolated lymph node removal of only the visible or clinical involved nodes violates the principles of compartment-oriented dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27139926\">",
"    <span class=\"h1\">",
"     THERAPEUTIC LATERAL COMPARTMENT NECK DISSECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A compartment-oriented dissection is the standard of care when performing a lateral neck dissection; there is no role for &ldquo;berry picking&rdquo; of lymph nodes (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef86365 \" href=\"UTD.htm?30/22/31076\">",
"     figure 7",
"    </a>",
"    ). In previously unoperated compartments, the positioning, type of incision, exposure, drains, and closure for a lateral neck dissection are the same as described for a thyroidectomy. In most cases, lateral compartment neck dissection does not mean a radical or modified radical neck dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link\">",
"     \"Initial and reoperative thyroidectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A",
"    <strong>",
"     radical neck dissection",
"    </strong>",
"    includes the removal of all nodal and fibrofatty tissue from levels I to V, including sacrificing the sternocleidomastoid muscle, the spinal accessory nerve, and the internal jugular vein. &nbsp;",
"   </p>",
"   <p>",
"    A",
"    <strong>",
"     modified radical neck dissection",
"    </strong>",
"    involves removal of levels I to V, but includes the preservation of one or more of the sternocleidomastoid muscle, the spinal accessory nerve, and the internal jugular vein. For most patients with thyroid cancer, removal of the affected lymph node regions does not require sacrifice of any of these structures. In addition, it is uncommon that a patient with thyroid cancer requires removal of level I lymph nodes. Therefore, most patients undergo a compartment-oriented selective lateral neck dissection. The extent of the dissection and which compartments are removed is based upon the extent of disease and surgeon preference, and is discussed in the following section. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16738719\">",
"    <span class=\"h2\">",
"     Extent of lateral compartmental dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extensiveness of a lateral compartment lymph node dissection is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/64\">",
"     64",
"    </a>",
"    ]. The extent of dissection generally depends upon the location of the nodal disease (eg, most commonly level III and IV) (see",
"    <a class=\"local\" href=\"#H1138097\">",
"     'Pattern of nodal metastasis'",
"    </a>",
"    above). No randomized trials have been performed to determine the appropriate extent of the lateral compartmental dissection.",
"   </p>",
"   <p>",
"    The consensus statement from the American Thyroid Association recommends that a comprehensive lateral neck dissection for thyroid cancer include removal of levels IIA, III, IV, and VB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/65\">",
"     65",
"    </a>",
"    ]. The highest rates of positive nodal involvement include levels III (77 percent), IV (62 percent), IIA (49 percent), and VB (40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some authors support a comprehensive nodal dissection of levels II to V for all patients with thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/65,67\">",
"     65,67",
"    </a>",
"    ], we advocate a more selective approach with a compartment-oriented dissection determined by the extent of nodal involvement identified on preoperative imaging and intraoperative assessment. We routinely resect levels III, IV, and the anterior portion of level VB in all lateral neck dissections, and only include levels I, II, and the remainder of level VB in the presence of involved nodes in the adjacent compartment (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Using a selective approach, a level II neck dissection is required in approximately 21 percent of patients undergoing a therapeutic neck dissection, and patients with level II disease typically have positive level III lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/13\">",
"     13",
"    </a>",
"    ]. Most positive level II nodes are located in level IIA, and without clinical or radiographic involvement, level IIB dissection is unnecessary in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/66,68\">",
"     66,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A level II node dissection may be omitted if there is no clinical or histologic evidence of positive level III nodes. Based upon a retrospective review of 52 patients with papillary thyroid cancer with no clinical suspicion of positive level II nodes, occult disease was identified in 19 percent (10 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/69\">",
"     69",
"    </a>",
"    ]. Occult disease was identified only in those patients with imaging suspicious for level III or IV nodal involvement or histologic evidence of positive lymph nodes in level III.",
"   </p>",
"   <p>",
"    Level VA nodes are positive in 12 to 40 percent of patients, but involvement of level VB is rare (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/67,69\">",
"     67,69",
"    </a>",
"    ]. The border between levels III, IV, and V is somewhat arbitrary, likely contributing to the variable rate of dissection and node positivity. If there is no evidence of posterior nodal involvement in level V, we confine our dissection anterior to the spinal accessory nerve in order to avoid injury to the nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27139949\">",
"    <span class=\"h2\">",
"     Technique for a selective lateral neck dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic landmarks are the same for initial and reoperative thyroid-related procedures; however, the landmarks may be distorted and challenging to identify if the neck dissection is performed after a previous lateral neck operation.",
"   </p>",
"   <p>",
"    The approach to the lateral compartment neck dissection includes (",
"    <a class=\"graphic graphic_figure graphicRef58086 \" href=\"UTD.htm?14/53/15193\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef86365 \" href=\"UTD.htm?30/22/31076\">",
"     figure 7",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113141971\">",
"    <span class=\"h3\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incision for a lateral neck dissection depends upon the operative setting and surgeon preference(",
"    <a class=\"graphic graphic_figure graphicRef88332 \" href=\"UTD.htm?19/20/19778\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113141996\">",
"    <span class=\"h3\">",
"     Dissection of Level III and Level IV",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Begin the dissection inferiorly at the level of the clavicle. Continue the dissection along the internal jugular vein to the anterior scalene muscle.",
"     </li>",
"     <li>",
"      Identify the fibroareolar plane posteriorly.",
"     </li>",
"     <li>",
"      Use sharp dissection techniques, and avoid using electrocautery in the vicinity of major neurovascular structures (eg, jugular vein, vagus nerve).",
"     </li>",
"     <li>",
"      Preserve the thoracic duct as it empties into the internal jugular vein, near the junction with the subclavian vein. A simulated Valsalva maneuver, performed by suspending mechanical ventilation and applying manual compression to the ventilation bag, can facilitate identification of the duct and recognition of an injury. If the thoracic duct is divided, it should be ligated.",
"     </li>",
"     <li>",
"      Identify the vagus nerve within the carotid sheath, posterior and medial to the internal jugular vein. The vagus nerve is spared while dissecting along the vein.",
"     </li>",
"     <li>",
"      Continue the dissection superiorly and laterally, identifying and preserving the phrenic nerve, located just posterior to the plane of dissection and anterior to the scalene muscle (",
"      <a class=\"graphic graphic_figure graphicRef52752 \" href=\"UTD.htm?16/21/16725\">",
"       figure 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef52959 \" href=\"UTD.htm?16/42/17061\">",
"       figure 10",
"      </a>",
"      ). The phrenic nerve is left intact adherent to the scalene muscles while the tissue superior to the nerve is resected.",
"     </li>",
"     <li>",
"      Preserve the cervical plexus nerves as possible while dissecting the nodal tissue from level III (",
"      <a class=\"graphic graphic_figure graphicRef54142 \" href=\"UTD.htm?17/25/17814\">",
"       figure 11",
"      </a>",
"      ). The cervical plexus nerves cross the field of dissection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113142004\">",
"    <span class=\"h3\">",
"     Dissection of Level II and Level V",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify the hypoglossal nerve at the superior extent of the lateral dissection, as it crosses superior to the bifurcation of the carotid artery, near the facial vein (",
"      <a class=\"graphic graphic_figure graphicRef86991 \" href=\"UTD.htm?32/36/33350\">",
"       figure 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Identify the spinal accessory nerve at the lateral extent of the superior dissection (",
"      <a class=\"graphic graphic_figure graphicRef86991 \" href=\"UTD.htm?32/36/33350\">",
"       figure 12",
"      </a>",
"      ). The spinal accessory nerve is the landmark that divides level II into levels IIA and IIB, where it can be identified superior to the greater auricular nerve, which originates posterior to the sternocleidomastoid muscle. Avoid retraction or dissection along the nerve, which is particularly vulnerable to injury during levels IIB and IVA dissections.",
"     </li>",
"     <li>",
"      Continue the dissection posteriorly into level VA and superiorly to level IIA. If no further disease is identified, the dissection is concluded here. However, if macroscopic nodal disease is identified at level IIA, proceed with the removal of level IIB nodes.",
"     </li>",
"     <li>",
"      Insertion of a drain should be done selectively, as they will not prevent bleeding or seroma formation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. If there is any suspicion of injury to the thoracic duct, a drain should be placed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7044954\">",
"    <span class=\"h1\">",
"     REOPERATION FOR RECURRENT NODAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distortion of the tissue planes due to scar tissue makes a reoperation for metachronous recurrence of nodal disease technically challenging. The keys to minimizing the morbidity of a reoperation are preoperative ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/58-61\">",
"     58-61",
"    </a>",
"    ] and intra-operative localization of disease. Ultrasound guidance can be used preoperatively to inject either blue dye [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/56\">",
"     56",
"    </a>",
"    ] or a charcoal suspension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/57\">",
"     57",
"    </a>",
"    ] to mark or &ldquo;tattoo&rdquo; the location of the pathologic nodes, which allows the surgeon to localize the pathologic nodes amongst the scar tissue within the neck. Intra-operative ultrasound can also be used if required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Management of recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to the ATA guidelines, we favor a compartment-oriented neck dissection for nodal recurrences in a nonoperated field. If the recurrence occurs in the clinical setting of a previous neck dissection, we favor a more limited dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We use the following guidelines for managing nodal or local recurrence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the clinical setting of a biopsy proven recurrence &gt;7 mm in diameter, we advocate surgical resection of the lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with nodal recurrence in a field that has not been dissected, we perform a formal compartment neck dissection.",
"     </li>",
"     <li>",
"      For patients with biopsy-proven nodal recurrence following thyroidectomy or formal neck dissection, we proceed with a focused removal of the involved lymph node(s).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the clinical setting of a biopsy proven recurrence &lt;7 mm in diameter, we perform a formal compartment neck dissection if the patient has not had a prior lymphadenectomy. If the recurrence is in a reoperative bed, we favor observation and serial imaging until the lesion enlarges to &gt;7 mm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since reoperation for small isolated lymph nodes is associated with risk, nonoperative management may be a reasonable option for patients with a low risk of recurrence. In a series of 166 patients with nodal recurrences who were followed without a lymphadenectomy, only 29 percent of the lesions grew by &gt;3 mm in 3.5 years of follow-up, and 14 percent resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/72\">",
"     72",
"    </a>",
"    ]. This suggests that, in properly selected patients, nonoperative surveillance may be appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16738442\">",
"    <span class=\"h1\">",
"     INTRA-OPERATIVE CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intra-operative challenges for a central neck dissection are similar to those for a thyroidectomy and include identification and preservation of nerves (eg, RLN, phrenic nerve, superior laryngeal nerve), vascular pedicles (eg, superior thyroid artery and vein), parathyroid glands, thoracic duct, trachea, and esophagus (",
"    <a class=\"graphic graphic_figure graphicRef58086 \" href=\"UTD.htm?14/53/15193\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/41,73,74\">",
"     41,73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link&amp;anchor=H27#H27\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Postoperative complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During a lateral neck dissection, the vagus, phrenic, spinal accessory, hypoglossal, greater auricular, and cervical sensory nerves are at risk of injury. The spinal accessory nerve is at greatest risk, particularly when levels IIB and IV are dissected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/75,76\">",
"     75,76",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef86991 \" href=\"UTD.htm?32/36/33350\">",
"     figure 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ). Densely adherent nodal disease to the internal jugular vein can require ligation and resection of the vein; however, this procedure can only be safely performed unilaterally in one operative setting because of obstruction of cerebral venous outflow [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27139949\">",
"     'Technique for a selective lateral neck dissection'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    However, the greatest technical challenges to avoiding injury to vital structures are encountered in the reoperative setting secondary to distortion or obliteration of the anatomic landmarks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16738449\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative care includes management of pain, nausea, and observation for hypocalcemia, chyle leak, and hematoma formation, similar to that described for patients undergoing a thyroidectomy. Patients are typically admitted for overnight observation, but are discharged home for less extensive dissections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link&amp;anchor=H23#H23\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Postoperative care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients are educated regarding the symptoms of hypocalcemia (eg, peri-oral numbness, paresthesias of the hands or feet, muscle cramps). After discharge, all patients are often instructed to take 1 to 2 grams of oral calcium supplementation (elemental calcium given as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    ). A typical dose is 2 grams BID, but dose is adjusted to control symptoms and maintain a low-normal serum calcium concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of hypocalcemia\", section on 'Acute manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of hypocalcemia\", section on 'Oral calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients undergoing a central neck dissection, serum calcium and parathyroid hormone (PTH) levels can be obtained in the recovery room for outpatients or on the morning of postoperative day one prior to discharge. Calcium supplementation can be based upon the postoperative PTH level using the following algorithm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PTH &gt;10",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      give calcium 1 to 4 gm orally daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PTH between 5 to 10",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      add 0.25 mcg of calcitriol twice daily to the calcium supplementation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PTH &lt;5",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      add 0.5 mcg of calcitriol twice daily to the calcium supplementation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If PTH testing is not available, then symptoms or an algorithm based upon serum calcium levels can be used (",
"    <a class=\"graphic graphic_table graphicRef59019 \" href=\"UTD.htm?28/57/29596\">",
"     table 2",
"    </a>",
"    ). Alternatively, given the minimal risks and cost of routine calcium supplementation, this may be the most cost effective way to manage patients in the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link&amp;anchor=H25#H25\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Calcium supplementation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H16#H16\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Hypoparathyroidism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link&amp;anchor=H10949435#H10949435\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\", section on 'Hypocalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If used, a drain is typically removed on postoperative day one. If it was placed to observe for a chyle leak, the patient is given a fatty food challenge and the drain contents examined for milky, opalescent appearance of lymphatic fluid. If a small chyle leak is identified, it may cease with conservative management, such as medium chain triglyceride diet or parental nutrition. If the output cannot be controlled by diet modification, reoperation with ligation of the thoracic duct, fibrin sealant placement, or flap closure may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\", section on 'Chyle composition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31241?source=see_link&amp;anchor=H1067386#H1067386\">",
"     \"Management of chylothorax\", section on 'Dietary control measures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroid hormone replacement following a thyroidectomy for differentiated thyroid cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H18#H18\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Postoperative thyroid hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7046574\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MORTALITY AND MORBIDITY RATES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7048866\">",
"    <span class=\"h2\">",
"     Mortality rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 30-day mortality rate after thyroidectomy and neck dissection for differentiated thyroid cancer is less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7048874\">",
"    <span class=\"h2\">",
"     Morbidity rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of the surgical procedure, the experience of the surgeon, and prior neck surgery all contribute to the risk of surgical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. The most common complications following a neck dissection for differentiated thyroid cancer are similar to those following a thyroidectomy and include nerve injury, hypocalcemia,",
"    <span class=\"nowrap\">",
"     hematoma/seroma",
"    </span>",
"    formation, and injury to the trachea and esophagus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=see_link&amp;anchor=H27#H27\">",
"     \"Initial and reoperative thyroidectomy\", section on 'Postoperative complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a review of 17 retrospective studies including 1929 patients undergoing a central neck lymph node dissection (CLND), the range of complications reported included [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient hypocalcemia &ndash; 3.6 to 60 percent",
"     </li>",
"     <li>",
"      Permanent hypocalcemia &ndash; 0 to 14.4 percent",
"     </li>",
"     <li>",
"      Transient recurrent laryngeal nerve injury &ndash; 0 to 25 percent",
"     </li>",
"     <li>",
"      Permanent recurrent laryngeal nerve injury &ndash; 0 to 11.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While some authors suggest that there is no increased risk of complications when a central node dissection is performed in conjunction with a total thyroidectomy, others have found higher complication rates with an added CLND [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/36,40,86,87\">",
"     36,40,86,87",
"    </a>",
"    ]. The following reviews and retrospective studies illustrate the range of complications based upon extent of the operation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a systematic review and meta-analysis of five retrospective studies that included 1132 patients with",
"      <strong>",
"       benign and malignant",
"      </strong>",
"      histologies, patients undergoing a thyroidectomy with a CLND (n = 398) had a similar risk of permanent hypoparathyroidism compared with patients undergoing a thyroidectomy without CLND (8 versus 6 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/40\">",
"       40",
"      </a>",
"      ]. Patients undergoing a thyroidectomy with a CLND had a nonsignificant increased risk of vocal cord palsy (5.5 versus 2.3 percent).",
"     </li>",
"     <li>",
"      However, in a retrospective review of 504 consecutive patients with",
"      <strong>",
"       differentiated",
"      </strong>",
"      <strong>",
"       thyroid cancer",
"      </strong>",
"      , patients undergoing a total thyroidectomy and CLND were significantly more likely to sustain an injury to the recurrent laryngeal nerve compared with patients undergoing a thyroidectomy alone (21 of 732 versus 1 of 276 nerves at risk) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/86\">",
"       86",
"      </a>",
"      ]. In addition, patients undergoing a CLND also had a significantly higher rate of permanent hypoparathyroidism (13.2 versus 3.6 percent). Transient hypoparathyroidism ranges from 14 to 60 percent, while permanent hypothyroidism ranges from 0 to 16 percent following a CLND [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/40,73,88\">",
"       40,73,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A bilateral CLND is also associated with a high rate of complications. In a retrospective review of 103 patients with papillary thyroid cancers &lt;2 cm, patients undergoing a bilateral CLND were significantly more likely to develop transient hypocalcemia compared with patients undergoing a unilateral CLND (48.0 versus 20.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A lateral compartment lymph node dissection when performed by an experienced surgeon is associated with a low risk of permanent hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/87\">",
"     87",
"    </a>",
"    ], as well as risk of injury to the spinal accessory, hypoglossal, and vagus nerves and the thoracic duct. Reoperation for nodal disease in the lateral neck is not associated with a higher risk of complications if the lateral neck was not dissected during the original operation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reoperation in the central neck is associated with more complications, but when performed by an experienced surgeon, the risks are not significantly different from similar surgery performed at the initial operation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/36,38,44,80,89\">",
"     36,38,44,80,89",
"    </a>",
"    ]. Based upon a retrospective review of 295 patients undergoing a CLND, patients undergoing a reoperation (n = 106) had a similar rate of permanent hypocalcemia compared with patients undergoing an initial CLND (0.5 versus 0.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/89\">",
"     89",
"    </a>",
"    ]. In addition, patients undergoing a reoperation had similar rates of hematoma formation (1.1 versus 0.9 percent) and permanent hoarseness (2.9 versus 1.9 percent). Only transient hypocalcemia was higher for patients undergoing a reoperation (41.8 versus 23.6 percent).",
"   </p>",
"   <p>",
"    A postoperative seroma is common after a lymph node dissection and typically peaks four to five days after the operation and then resolves spontaneously. Seromas are not prevented by drain placement at the time of operation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Since a small seroma is difficult to discern from normal postoperative swelling, the incidence of this complication is difficult to define. However, occasional seromas become large and symptomatic and require percutaneous aspiration for symptom relief. Seromas requiring percutaneous drainage are uncommon, occurring in &lt;7 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7046801\">",
"    <span class=\"h1\">",
"     NODAL RECURRENCE RATE AFTER THERAPEUTIC DISSECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nodal recurrence rate following a therapeutic neck dissection ranges from 28 to 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/16,37,89\">",
"     16,37,89",
"    </a>",
"    ]. For example, in a retrospective review of 45 patients undergoing a therapeutic neck dissection for recurrent thyroid cancer, 17 patients (38 percent) developed a second recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/37\">",
"     37",
"    </a>",
"    ]. If the nodal disease was located outside a previously dissected level at the time of the therapeutic neck dissection, the overall nodal recurrence rate was 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/7/27770/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27140051\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The central compartment neck dissection extends superiorly to the hyoid bone and inferiorly to the innominate (brachiocephalic) artery (",
"      <a class=\"graphic graphic_figure graphicRef58086 \" href=\"UTD.htm?14/53/15193\">",
"       figure 1",
"      </a>",
"      ). The lateral border of dissection is the ipsilateral carotid artery, the anterior border is the superficial layer of the deep cervical fascia, and the posterior border is the deep layer of the deep cervical fascia, which may be deep to the carotid artery. It can be performed in conjunction with a thyroidectomy or as a separate procedure for recurrent differentiated thyroid cancer. (See",
"      <a class=\"local\" href=\"#H27139831\">",
"       'Central compartment neck dissection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extensiveness of a lateral compartment lymph node dissection is controversial. The extent of dissection generally depends upon the location of the nodal disease (eg, most commonly level III and IV), and surgeon preference. However, the technique of &ldquo;berry picking&rdquo; should not be performed. (See",
"      <a class=\"local\" href=\"#H27139926\">",
"       'Therapeutic lateral compartment neck dissection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with differentiated thyroid cancer and evidence of nodal involvement (ie, clinical or radiographic evidence confirmed by positive FNA biopsy results), we recommend a therapeutic neck dissection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28440921\">",
"       'Indications for neck dissection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H9#H9\">",
"       \"Surgical treatment of differentiated thyroid cancer\", section on 'Approach to neck dissection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients without nodal involvement but with a large primary differentiated thyroid cancer or high-risk features for recurrence (eg, BRAF mutations, extrathyroidal tumor extension), we suggest a prophylactic central neck dissection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28440921\">",
"       'Indications for neck dissection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H9#H9\">",
"       \"Surgical treatment of differentiated thyroid cancer\", section on 'Approach to neck dissection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a nodal recurrence following a thyroidectomy with a previous lymphadenectomy, we recommend a therapeutic regional neck dissection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15405244\">",
"       'Therapeutic neck dissection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a recurrence following a therapeutic neck dissection, we suggest an excision of the lesion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If the recurrence is located in an anatomic level not previously dissected, we recommend a therapeutic lymph node dissection of that level (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7044954\">",
"       'Reoperation for recurrent nodal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/1\">",
"      Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/2\">",
"      American Thyroid Association Surgery Working Group, American Association of Endocrine Surgeons,, American Academy of Otolaryngology-Head and Neck Surgery, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009; 19:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/3\">",
"      Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with \"berry picking\" than neck dissection in thyroid cancer. Am Surg 2003; 69:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/4\">",
"      Grubbs EG, Evans DB. Role of lymph node dissection in primary surgery for thyroid cancer. J Natl Compr Canc Netw 2007; 5:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/5\">",
"      Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/6\">",
"      Kim E, Park JS, Son KR, et al. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid 2008; 18:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/7\">",
"      Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006; 141:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/8\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/9\">",
"      Arturi F, Russo D, Giuffrida D, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab 1997; 82:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/10\">",
"      Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 1970; 26:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/11\">",
"      Qubain SW, Nakano S, Baba M, et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 2002; 131:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/12\">",
"      Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008; 144:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/13\">",
"      Caron NR, Tan YY, Ogilvie JB, et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary? World J Surg 2006; 30:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/14\">",
"      Chung YS, Kim JY, Bae JS, et al. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid 2009; 19:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/15\">",
"      Wada N, Suganuma N, Nakayama H, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg 2007; 392:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/16\">",
"      Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/17\">",
"      Moreno MA, Edeiken-Monroe BS, Siegel ER, et al. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid 2012; 22:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/18\">",
"      Smith VA, Sessions RB, Lentsch EJ. Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database. J Surg Oncol 2012; 106:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/19\">",
"      Howell GM, Nikiforova MN, Carty SE, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol 2013; 20:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/20\">",
"      Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab 2012; 97:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/21\">",
"      Koo BS, Choi EC, Yoon YH, et al. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg 2009; 249:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/22\">",
"      Roh JL, Kim JM, Park CI. Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence. Ann Surg Oncol 2011; 18:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/23\">",
"      Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003; 237:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/24\">",
"      Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 2004; 28:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/25\">",
"      Wada N, Masudo K, Nakayama H, et al. Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age. Eur J Surg Oncol 2008; 34:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/26\">",
"      Gemsenj&auml;ger E, Perren A, Seifert B, et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003; 197:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/27\">",
"      Schneider DF, Mazeh H, Chen H, Sippel RS. Lymph node ratio predicts recurrence in papillary thyroid cancer. Oncologist 2013; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/28\">",
"      Bardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol 2008; 158:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/29\">",
"      Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006; 106:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/30\">",
"      Scheumann GF, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994; 18:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/31\">",
"      Shah MD, Hall FT, Eski SJ, et al. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 2003; 113:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/32\">",
"      Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/33\">",
"      Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005; 71:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/34\">",
"      Noguchi S, Murakami N, Yamashita H, et al. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 1998; 133:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/35\">",
"      Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/36\">",
"      Sippel RS, Chen H. Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer. Thyroid 2009; 19:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/37\">",
"      Uruno T, Miyauchi A, Shimizu K, et al. Prognosis after reoperation for local recurrence of papillary thyroid carcinoma. Surg Today 2004; 34:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/38\">",
"      Schuff KG, Weber SM, Givi B, et al. Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer. Laryngoscope 2008; 118:768.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/40\">",
"      Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 2009; 119:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/41\">",
"      Ondik MP, Dezfoli S, Lipinski L, et al. Secondary central compartment surgery for thyroid cancer. Laryngoscope 2009; 119:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/42\">",
"      Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 2009; 94:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/43\">",
"      Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 2009; 19:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/44\">",
"      Alvarado R, Sywak MS, Delbridge L, Sidhu SB. Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity? Surgery 2009; 145:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/45\">",
"      Clayman GL, Shellenberger TD, Ginsberg LE, et al. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck 2009; 31:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/46\">",
"      Lee YS, Kim SW, Kim SW, et al. Extent of routine central lymph node dissection with small papillary thyroid carcinoma. World J Surg 2007; 31:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/47\">",
"      Cavicchi O, Piccin O, Caliceti U, et al. Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. Otolaryngol Head Neck Surg 2007; 137:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/48\">",
"      Tisell LE, Nilsson B, M&ouml;lne J, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996; 20:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/49\">",
"      Barczy��ski M, Konturek A, Stopa M, Nowak W. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg 2013; 100:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/50\">",
"      Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002; 26:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/51\">",
"      Choi JS, Kim J, Kwak JY, et al. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 2009; 193:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/52\">",
"      Kaplan SL, Mandel SJ, Muller R, et al. The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thyroglobulin levels. AJNR Am J Neuroradiol 2009; 30:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/53\">",
"      Buerba R, Roman SA, Sosa JA. Thyroidectomy and parathyroidectomy in patients with high body mass index are safe overall: analysis of 26,864 patients. Surgery 2011; 150:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/54\">",
"      Roy M, Rajamanickam V, Chen H, Sippel R. Is DVT prophylaxis necessary for thyroidectomy and parathyroidectomy? Surgery 2010; 148:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/55\">",
"      McCoy KL, Yim JH, Tublin ME, et al. Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer. Surgery 2007; 142:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/56\">",
"      Sippel RS, Elaraj DM, Poder L, et al. Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg 2009; 33:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/57\">",
"      Hartl DM, Chami L, Al Ghuzlan A, et al. Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence. Ann Surg Oncol 2009; 16:2602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/58\">",
"      Desai D, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography for localization of recurrent thyroid cancer. Surgery 2001; 129:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/59\">",
"      Karwowski JK, Jeffrey RB, McDougall IR, Weigel RJ. Intraoperative ultrasonography improves identification of recurrent thyroid cancer. Surgery 2002; 132:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/60\">",
"      Zimmerman P, DaSilva M, Izquierdo R, et al. Intraoperative needle localization during neck reexploration. Am J Surg 2004; 188:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/61\">",
"      Triponez F, Poder L, Zarnegar R, et al. Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease. J Clin Endocrinol Metab 2006; 91:4943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/62\">",
"      Nobori M, Saiki S, Tanaka N, et al. Blood supply of the parathyroid gland from the superior thyroid artery. Surgery 1994; 115:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/63\">",
"      Sakorafas GH, Sampanis D, Safioleas M. Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol 2010; 19:e57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/64\">",
"      Khafif A, Medina JE, Robbins KT, et al. Level V in therapeutic neck dissections for papillary thyroid carcinoma. Head Neck 2013; 35:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/65\">",
"      Stack BC Jr, Ferris RL, Goldenberg D, et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid 2012; 22:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/66\">",
"      Farrag T, Lin F, Brownlee N, et al. Is routine dissection of level II-B and V-A necessary in patients with papillary thyroid cancer undergoing lateral neck dissection for FNA-confirmed metastases in other levels. World J Surg 2009; 33:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/67\">",
"      Merdad M, Eskander A, Kroeker T, Freeman JL. Metastatic papillary thyroid cancer with lateral neck disease: Pattern of spread by level. Head Neck 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/68\">",
"      Lee J, Sung TY, Nam KH, et al. Is level IIb lymph node dissection always necessary in N1b papillary thyroid carcinoma patients? World J Surg 2008; 32:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/69\">",
"      Koo BS, Seo ST, Lee GH, et al. Prophylactic lymphadenectomy of neck level II in clinically node-positive papillary thyroid carcinoma. Ann Surg Oncol 2010; 17:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/70\">",
"      Khanna J, Mohil RS, Bhatnagar D, et al. Is the routine drainage after surgery for thyroid necessary? A prospective randomized clinical study [ISRCTN63623153]. BMC Surg 2005; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/71\">",
"      Sanabria A, Carvalho AL, Silver CE, et al. Routine drainage after thyroid surgery--a meta-analysis. J Surg Oncol 2007; 96:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/72\">",
"      Robenshtok E, Fish S, Bach A, et al. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 2012; 97:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/73\">",
"      Henry JF, Gramatica L, Denizot A, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998; 383:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/74\">",
"      Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 2007; 245:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/75\">",
"      Lima LP, Amar A, Lehn CN. Spinal accessory nerve neuropathy following neck dissection. Braz J Otorhinolaryngol 2011; 77:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/76\">",
"      Cappiello J, Piazza C, Nicolai P. The spinal accessory nerve in head and neck surgery. Curr Opin Otolaryngol Head Neck Surg 2007; 15:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/77\">",
"      Beahrs OH. Surgical anatomy and technique of radical neck dissection. Surg Clin North Am 1977; 57:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/78\">",
"      Weiss KL, Wax MK, Haydon RC 3rd, et al. Intracranial pressure changes during bilateral radical neck dissections. Head Neck 1993; 15:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/79\">",
"      Chai PJ, Skaryak LA, Ungerleider RM, et al. Jugular ligation does not increase intracranial pressure but does increase bihemispheric cerebral blood flow and metabolism. Crit Care Med 1995; 23:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/80\">",
"      Kim MK, Mandel SH, Baloch Z, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg 2004; 130:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/81\">",
"      Youngwirth L, Benavidez J, Sippel R, Chen H. Postoperative parathyroid hormone testing decreases symptomatic hypocalcemia and associated emergency room visits after total thyroidectomy. Surgery 2010; 148:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/82\">",
"      Shaha AR. Complications of neck dissection for thyroid cancer. Ann Surg Oncol 2008; 15:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/83\">",
"      Gupta PK, Smith RB, Gupta H, et al. Outcomes after thyroidectomy and parathyroidectomy. Head Neck 2012; 34:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/84\">",
"      Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/85\">",
"      Friedman M, Pacella BL Jr. Total versus subtotal thyroidectomy. Arguments, approaches, and recommendations. Otolaryngol Clin North Am 1990; 23:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/86\">",
"      Toniato A, Boschin IM, Piotto A, et al. Complications in thyroid surgery for carcinoma: one institution's surgical experience. World J Surg 2008; 32:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/87\">",
"      Cheah WK, Arici C, Ituarte PH, et al. Complications of neck dissection for thyroid cancer. World J Surg 2002; 26:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/88\">",
"      Rubello D, Salvatori M, Casara D, et al. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer. Eur J Surg Oncol 2007; 33:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/89\">",
"      Shen WT, Ogawa L, Ruan D, et al. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg 2010; 145:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/90\">",
"      Lee SW, Choi EC, Lee YM, et al. Is lack of placement of drains after thyroidectomy with central neck dissection safe? A prospective, randomized study. Laryngoscope 2006; 116:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/7/27770/abstract/91\">",
"      Mekel M, Stephen AE, Gaz RD, et al. Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer. Am J Surg 2010; 199:485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15033 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27770=[""].join("\n");
var outline_f27_7_27770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27140051\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27139731\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1138017\">",
"      ANATOMIC NECK LEVELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18534097\">",
"      DEFINITION OF NECK DISSECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1137809\">",
"      INCIDENCE OF METASTATIC DISEASE TO REGIONAL NODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1138097\">",
"      PATTERN OF NODAL METASTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27139738\">",
"      SIGNIFICANCE OF LYMPH NODE INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27139745\">",
"      Local nodal metastasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19166492\">",
"      Local nodal recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27139752\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28440921\">",
"      INDICATIONS FOR NECK DISSECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15405244\">",
"      Therapeutic neck dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15405236\">",
"      Prophylactic central neck dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19167149\">",
"      Prophylactic lateral neck dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27139780\">",
"      STAGING EVALUATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1138723\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1138731\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1138747\">",
"      Venous thrombosis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2892454\">",
"      Preoperative localization of recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2892462\">",
"      INTRA-OPERATIVE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27139831\">",
"      CENTRAL COMPARTMENT NECK DISSECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1140098\">",
"      Extent of central neck dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27139898\">",
"      Technique for central neck dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27139926\">",
"      THERAPEUTIC LATERAL COMPARTMENT NECK DISSECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16738719\">",
"      Extent of lateral compartmental dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27139949\">",
"      Technique for a selective lateral neck dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113141971\">",
"      - Incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113141996\">",
"      - Dissection of Level III and Level IV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113142004\">",
"      - Dissection of Level II and Level V",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7044954\">",
"      REOPERATION FOR RECURRENT NODAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16738442\">",
"      INTRA-OPERATIVE CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16738449\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7046574\">",
"      POSTOPERATIVE MORTALITY AND MORBIDITY RATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7048866\">",
"      Mortality rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7048874\">",
"      Morbidity rates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7046801\">",
"      NODAL RECURRENCE RATE AFTER THERAPEUTIC DISSECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27140051\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15033|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/8/2178\" title=\"diagnostic image 1\">",
"      Elliptical lymph nodes on thyroid ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15033|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/53/15193\" title=\"figure 1\">",
"      Thyroid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/9/1173\" title=\"figure 3\">",
"      Lymph node compartments of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/50/2852\" title=\"figure 4\">",
"      Anatomy for central neck dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/37/24146\" title=\"figure 5\">",
"      Dissection of recurrent laryngeal nerve lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/47/9972\" title=\"figure 6\">",
"      Parathyroid location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/22/31076\" title=\"figure 7\">",
"      Lateral neck dissection anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/20/19778\" title=\"figure 8\">",
"      Incisions for lateral neck dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/21/16725\" title=\"figure 9\">",
"      Left phrenic nerve course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/42/17061\" title=\"figure 10\">",
"      Right phrenic nerve course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/25/17814\" title=\"figure 11\">",
"      Cervical plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/36/33350\" title=\"figure 12\">",
"      Hypoglossal nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/45/1758\" title=\"table 1\">",
"      TNM staging thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/57/29596\" title=\"table 2\">",
"      Management of hypocalcemia after thyroid surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14599?source=related_link\">",
"      Clinicopathologic staging of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31642?source=related_link\">",
"      Initial and reoperative thyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31241?source=related_link\">",
"      Management of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=related_link\">",
"      Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=related_link\">",
"      Overview of follicular thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8440?source=related_link\">",
"      Overview of papillary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44310?source=related_link\">",
"      Surgical anatomy of the thyroid gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=related_link\">",
"      Ultrasound-guided thyroid biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_7_27771="Probability of thromboembolism";
var content_f27_7_27771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Probability of thromboembolism in pregnant women with inherited thrombophilias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Lesion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence if no history of thrombosis, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probability of thrombosis per pregnancy in carriers, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor V Leiden",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin gene mutation",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Both factor V Leiden and prothrombin gene mutation",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antithrombin (ATIII) deficiency",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein C deficiency",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein S deficiency",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No abnormality",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gerhardt, AG, Scharf, RE, Beckmann, MW, et al, N Engl J Med 2000: 342:374.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27771=[""].join("\n");
var outline_f27_7_27771=null;
var title_f27_7_27772="RF in nonrheumatic diseases";
var content_f27_7_27772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The major nonrheumatic diseases associated with rheumatoid factor (RF)-positivity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency of RF, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Aging (&gt;age 60)",
"       </td>",
"       <td>",
"        5 to 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial endocarditis*",
"       </td>",
"       <td>",
"        25 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis B or hepatitis C*",
"       </td>",
"       <td>",
"        20 to 75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Syphilis*",
"       </td>",
"       <td>",
"        Up to 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parasitic diseases",
"       </td>",
"       <td>",
"        20 to 90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leprosy*",
"       </td>",
"       <td>",
"        5 to 58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other viral infection*",
"       </td>",
"       <td>",
"        15 to 65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis*",
"       </td>",
"       <td>",
"        3 to 33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interstitial pulmonary fibrosis",
"       </td>",
"       <td>",
"        10 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Silicosis",
"       </td>",
"       <td>",
"        30 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asbestosis",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Miscellaneous diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary biliary cirrhosis*",
"       </td>",
"       <td>",
"        45 to 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignancy*",
"       </td>",
"       <td>",
"        5 to 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        After multiple immunizations",
"       </td>",
"       <td>",
"        10 to 15",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Refers to disorders that may cause symptoms suggestive of rheumatoid arthritis. The best documented examples of viral infection (in addition to hepatitis B and C)&nbsp;are rubella, mumps, influenza, and HIV. Chagas' disease, Leishmaniasis, onchocerciasis, and schistosomiasis are major parasitic diseases. B cell neoplasms are the most common malignancies.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from the publisher from: Shmerling RH, Delbanco TL. The rheumatoid factor: An analysis of clinical utility, Am J Med 1991; 91:528. Copyright &copy; 1991 by Excerpta Medica Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27772=[""].join("\n");
var outline_f27_7_27772=null;
var title_f27_7_27773="Mechanisms alcohol HCV";
var content_f27_7_27773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Potential mechanisms by which alcohol affects hepatitis C virus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 228px; background-image: url(data:image/gif;base64,R0lGODlhewHkAMQAAP///4CAgAAAAEBAQMDAwODg4NDQ0KCgoPDw8DAwMCAgIGBgYLCwsHBwcJCQkFBQUBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAB7AeQAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b73gsYc/v+/+AgYKDgHmGh08CA4uMjY6PkJGSk44CiJeYRpZbm5menzudWaKgpaYwpFepp6ytJatVsK6zprJTtrS5mLgmCAQFLgQGLMIqvLrIeLgFiwwiBAIBLoos1CnHydlzuA4CAg/P0SMGBAgivsAi1L8j6CPWKNja8264CvcCwNDSBgreAgYO/FugTgEEb84EeiMIAN4JefQiprFlQECDBgIcANgHYABAAA6gDQAQQIAzAQoY/3QbgIBayZMjr0mcScfWgozdFGwUB48jR2uKfPKMGY+mUTiyEBz8J2CPuHvmyAkgKPBAw5iKCkwFUPWqsaNg2cgSqBHkVI4CFXgkcHMAhATmgI5s+zYu0Ydh86KRxSBAugIBHAAmIKKAgwBWAfQ9YI5kYsQiFjeGLFOv5TEQmWS+zDkRl82dQysBnYS06NNETB9Rjbq1D9ZFYLuejUP2ENu0c8uIFqC379/AgwsfTrz4b9y6k7cwzlz4oubQfSufLqY39euIrGPffkc79+9yvIMf30Y8eTiAo6tfz769+/fRn8OfT7++/d+EcxFQcL+///YKLPDfgPAtwB+BCBo3gP80+t1VygD5xUGAg2iY18qErUA4B4ZsWMgKh6doKAeIanh4CokPRggHihUySAuLn4goIYVnmAhKXwb2Nown6QVIWRsHBJCjXy3K50o3TKXjCVNbuYERU42Z4c8/NH5S0T86geLRP864Ac0/CaTxpDcusrJUk58g6U2UbTDVQBoMMLVjKzchVMqVAoQJx5ZNpdGSNxDQopAAbHqy1JtwqLlGAt6AM4tWeZ7ygDcqtnGlo2mUlFEu/iBaikJzHFRWGl8q6QpGlfL4zRyTzpkGBFnSEmcrCowKxwGBsvEAQ7QgUGUmDbj6RgG8quFAl7kIC4qyb6R6RgGFnifttNRWawT/AQlmqy1zOQS5bW+m0vDtuL45C0B65KpnQwALpuvugLINIOC2CpiLyrvZLojCfvgyp5qNtMRrbw8y1oCcFCbCGMW/ZWYjsBEF03BwFAn/6lkNAM/ycBERzzAxFBVjwXBEGxPR8W5uhKzKug0nU/IQJ8fw8RMqWzEyPS8HUyk54ZYQMyopt/yMxU7cfIIvxZySMwmKDJDAjgckEEADTwOAQAICYp3Czy/M7ETNMiT9g9EmEKtAYrWoYIADDxD98yYHgFMABI3tB5KnzIrAdQABMlbZDgegHVMBDyTgNAHHjhDAwDKAvcIiTBNtA9kmcEgAAwsMYAAD8opwAAMPPIAA/7sa7SECg5+Hng67CxTql18IZM4g5wM4c3nmUMsLTAFBDlAWuw8ME7u+ijXzVQm8L3Cm2/ZuAjpIxSoQUNWPD6ypNwk0gOw7PXhnCQL1FsbA8yLQzYPjxsjjS94tUF4Ch+wWYAAEVj1g1QANIOBAAuUokJ46esufAwjSAGlw7hULKgD/AFDAfiCAdyRhyfy4Ijq77ad/hgHH5gCwwAYq4IFow4vVGNCAKTHpQMQJXzymVjXxaCgAjNLc1uY1HD4xaUE7Opj3KGgC85FvB+i7hiiowSgEtCRMuMKeL75huGmwTAXwY9AmrKMhDkFIO5uo4kgg4BtSbKIfvcnc3EJyOv8GQegB+dGcFQkQtQMMA4xCGsAYGbcJBBzAQEzyBgqHo8KHYCsmDvAUAKRHAlzNsDg2/AcE7JcOHaplEZaw0AKsMsnuCW0jknvHEEfSjc9lpCXg6CQ0pBbC44nrkkMrIwBJIg0t6g1bUnwlJhvSh1c8g397GAZgmqgdCIkIQmvcSAkXh8ti7NJiqVjbA5ZXvcos4E1zq5tO5qSUrVmPKb5Tlg5dFElBRgYc5jvfJRX2kE1a7Rs3WSJTFieOrj0xBVFcJRUJs8ZAniuL9ByJ70QgrDpCYEcGKAAwWsJKqwXKnuCbZUeEYQ7OKQWgAj2nKU/wR+ZV5mpWiRoLh3EABRT/MAGlJMHesjewbXKvHyRoDBcxBcRxZlId5gTAMhd5T0wVgCPuxBgqDZAACLwJi6p05ULBhz98zhIBhUsASxsyDsNJTYFOswrfnOaM2CUgAbaLCYQY4NQ3OtUvTg0p03Lwswj5YgSma8ceoiVSxrXPktwDQOYYwBYGKW97OghiPJjiFa7YSa4ocQs7USnCU9aIsEBYGhC45kQepJUk4+hNhADzA72eADiOUVyZDNAbxgwGaDo97GjI6lYdMPat5XGpyN45D8X+4LTVCNq+Xjra0OKMtBAr7Qq81gTLXsywL+BDEBDAPhxENAeu9QFsdytbilqMHJph7XLaKQPGGsCb/zwI3EJvkFyC6Xai2RUrDK47A996JLq2zSnvSHc6zjHkAM85l4+sJjvkWeV2mnOv50AnOvZCkCvASN0D9PELHwWkMLaKLQ7k9a0+GgyKPSPBWtGan+M+9lwqEttGhLcjd/CzHCjQqzDOCwBypIodN1UrO84BYgmby33M3Ui9wAcMAdTvvuaw39XI2MEyYSh+87txRwTIPxoHE3/6I0hvdlwO800NtDfw1np8xJ4IywwFCmzATRSqoWfyDVrZW4CSA3A1LSs5e7uyGv7EbLUwLwBDPGUXJR9AtRCrtgRX4+v1IAAMjzCKi95AlJtKzMx+AEqb0kVtMKcoDcAMgD/bhf9j5iQ8EqAWVKjA1CphXDlPEVTSf1BWwnJfg4IGlMUSwXyGgAigJ3NIttUFHWQBGpCYpxWQxSNJwEADRSir2Xm2JsCIRs77i+uKwyNBCoo/PIcABizbH8Mg4gcrUqxVAjeniy5jAVJyaXoW01U/jmW3ubwHTW833NstcUqWquAljLoHsBARqs1NNXZJQ3m1Kyi+ndHLCRluEQaQEYaaBjkHQIB4JkAfic+Lq7ccG9UPV3OeDtJXatzQBDA+XrZZyWpPt7Kq/+QnpWPN6HNrmqdt3nQ+L42sR3/X2qJ+OQ9g8YAuzfuVHY+1YgLlHQbwnEH+sx8JhJ5KPpugH8xC36T/+myJSHGE2BF/SUcsASt1jAQqhcF4oh+3DnOXfAGGe4ABm8hTp/m40uLudDALVziVz9I6XI1J1FDGhHfPHAVcxdb3UsK3AjNAo2xBXJgk++b9RfCP6j4AARqwh5SQEENRGx84aufsCKMPGgpglCVieJBWQtzzikGJ5hmYJ3+MRCAHV4vW04uISl657jIPBTz9sglssREYnFU8YfriAHOYjveuFhDaDBOALgFGMP/lbADeCK5fO5eiiAmS1SS7OK40uvrSV0z0UVf8VZ3rMIJZ/bUPsW2PNcHuso9xDjK2/jsPAYZuMQlqx++w88deB7xALAwuDATf7iA94Td/5aV//63AW820BAa4BP7XBBlHUWx1dGzFOOTVBQloTejVIe4XC1uHAhWBStoRLCdANOSkgbB3gWuwgCbYOAQoV3yjOPrVEQl0AAVAV8/Ab+eieH6ROcGjUCPgRmTEOg1lPPiVOwuwO71TFrTTJUAogEmAfvjXXJVDW6WxgSdAN9RjYzJFSW/mK2zkKEKHaovkF2+kEyjyaItza5zjQBDELsQVKHHjC2Q4Y/6jhlaBhplUgSjghMgFhe8jhUjQgCTwPPbEVAXVbwDAZ+XHVCByR8TmICLCRb2RDxBARrF2RmlEDpo2R+XTRUyIBHpYG4QQiqI4iqQoigKyL8VUiqq4ik5Bhf8lYCBOkyUlZ4i9cRgAxCFaVmM8KEu0JFzHVIkTkkblJku/2BTC1W4xV3eUsIzMuAg91YzQOAniFXDRWI3W+AiuSALhVDWziCgasm2gpoha5QxasYvptk8lFlEEZR3VhFBkmIkDZQnoWFxx5W73BwYjaBTs90P2VHJQFXD5kWa3GBP9UFTmKCJIdVUDFlYkoRZYRV9XlVWvBFUgZTVJxW6FlYwj4odK8IA84JE3wH5dIJLpZ48bwpFJUG0/oJJ5tYJbQJJPWIIbqQXONgRaAZKsV38yOSNagBH0GGXy5wMwmTY7uSIoeQSMkmA9MCnY1X4kY38nmQV/gpE7cBCxIk7/T1mUzXKURaAQufIDeGJl2agxUDmTWFAnfVJZ/yBeY+kKeBiC9/gF+egEJuSSMcAnLBmSebSXfNmXfvmXgBmYgjmYgFmWPHkFkOINXLlbimQGQzkLn+gFc8kEarImPhAnclIGj3kKPSJ8h2kF7PKMMtQD8OURxkMGmxkDOLkXTJGXpLKYRDCZ3NUiQ0CVa2BDbIkGsskEu/lgojVc+RAeUPKZV9CbEkObQRAnuYkGeKInRqkFxml+vwkEGGGbanAoZqkHsNmJ1WGXMuAPXwkHkxKUz5kF0Ul3jumdMJCYP2kGSBKV5rmdyIia6vkCg1KfX6AV8gmd+wkE5/l66RkE/2jZn1gAadlZnARaFNPpA2fylkywAO1pBv95LQmakfQJBHjyVytCBxNaBB3aWAH6A7TTNMtpLR86BCc6n2OQmqFmLVBUoY4Fo7a0oGNzBF9CmDiaozqqozIahfyZGsgZBG+ZovjYo334o7cRpIllo0aKoBSKpELgoP2HnznloU1qBURKDFdqA1n6N5pJpSAam1tKBV36olAqpEpao0+KB2UKT2NKA20qfl+apGt6B3H6fPEJpDRKanVaSH+RGAjQAIvQe703AoU6gADGAgbQGDIYNmN6pzoAqfU4p1HKpHCZSuBjFaPDFomRiIjaqAcIqvv3qG86A5IKcxdaqX06Av8igiEXUQLkM4ismoZlxxIM1AAPQEjWAYJRo1QM9G9t2EQgCENSE0CPFi2nilal6qh6GqJouqp6829N1DHmQz3vwHjgYw531BH3NXitJAwfVGK+xkDDJowBpzfRBgym5qNWeqZLuqfwZqkm0Kr6lCqT5KlxRQAH5zT1CkDzJB60A2m/BEuqVHJH2q55SqfO+q4I6zP54arYxTlPNqM5x6qEUU3/ijfh2mkLNYiBQYgWkqyplLCqurBq2rBtlUrbpqnVd4jhOFYikAAaAUEDIFVjtlBzAwwOoIb6omM46z/bpos6p6zQSqZXKqWVBabc6Z80AoIlhiizNgAPcKgDFIL/7SCoNdcRbUNmXFGHw0AAbaMR8LUADmAVBhA6DPS1oZNGnhNSImuOVZCsSCuUSquiQfC2KcubpOquJ0upz4qyRuC0S/C2eGuqR5umfAq4HLq3JPu3fsuwYpoHhLusMSC3iBuvRXugQlC4zKqwj9u3KEq5TzC5fJu4n2u6KJqKrLi6rNu6fOAAjKudzXq6mFsE1HiNuNsIb5G7vIs/mSsFlguvd0cHkdkFnFu5hyu8JSkHxcsFxzuqs5uqjhsHzbsFzxtcyWuyqLsncSmZoou90buidat+zNu9xvu9wZC9tDu8c1C9pTsFwau9tVu+8Cm7niu9kEu95uu86NsC8bu+/8urv/XrpPcrvgX8Bu7buFiqvvgLutw7wAscvt15wG6QwPZ7wdNrwCVLv5obtwyswRmMwPtrvf2rpRIcBixapRxMnBFMwWCQwmEqwB1stCf8wuMLXg88w/D7wRO8wTLMwh5cw18Aw0vbBhZMwBicvyCsxCIMwUHswkN8w176w+WZxA7cwyG8Bp35I15Swivwvw28vW3SmkBMw1DsBURst2yAm2W8w0KMxlKsoHFQmatZBtebvm88knFsoW7QnDoMvDyMwnssp3CAnW0MyHnMBWlMvuJJKX8cBWC8xFcMJN7gxGbsw5Isxm2gn5bsxmesx5+cBrXSyYgcyi85yDM6B/8QSsqQHMg2bMpnEKES6sVmCstZsMg47KJ4asWa/MqYrMvsysvzG8bDDMk7esw7Sssjp8CT7MtZ7AR3jMeXjMTPHMW2/Lul7MnCzL4AHJPTTM2t/L7cTMzjHM7ivDZrIa/bHMCZXMxQEM3+6yC8s0xMMcLSvM7e3M17+MQJizkmxCT/1rvN2ETM3MvW/Muji5LaYXuFIai+8z/PsHzIi2D0nEch4bqlKMuD68oHXc0/8DlfjJKVTBLiMD95wij7kZZLN9ElwFk2ZM+vmcinfM0LppgSHcyoMEXiMCllEVAlQRCczNJ4RzUwrZscDcc0fQOJtEgBCLft0zT+IA0jPQL/WnFQWCjUyRDJWJxYyNzVedQ6Tl0NUM0TqTApUROe4KsNWi3IRgzQ2hMl5znSJeF5PR1gKIEm0KvWRw3KaywAEHCvu5zTpyMOX3JVabkUGk20ei3TWoDLU8AA9HiekMMVNctPmeM7jQG7rhnS87DWzmynyuymnb3XiozKJGy9+yrQqr3arC0JBI3Qn20H8EwMqovRtn3buA0IiS2d8svK5jwecwtXkhvawEYewY2Vw33axn25vv3OxF0Kx91ShnCjXl3dffncoBDdLQnM26HdTsnd1+HdOODY4C0R4h2Spl3eLsPc6t0a592W7d0Z752T8e0a801/9e3e7J3f8r3fP/x9GfddXtY94ARe4AZ+4Aie4Aq+4AH+39VS1A4e4RI+4RRe4RZ+4Rie4Rq+4Rze4R7+4SAe4iI+4iRe4iUeAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HCV: hepatitis C virus; ROS: reactive oxygen species.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27773=[""].join("\n");
var outline_f27_7_27773=null;
var title_f27_7_27774="Anatomy of the nipple";
var content_f27_7_27774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the nipple",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, 8th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27774=[""].join("\n");
var outline_f27_7_27774=null;
var title_f27_7_27775="Cho stitch";
var content_f27_7_27775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Cho stitch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 382px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF+AgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiql5f2dkAby6ggz08xwufzNA0m9EW6K5+XxhocT7DfBz6ojMPzAqxZ+I9JvGCw30O4/wudhP4HFJST6lujUSu4s2KKOtFMzCiigEHpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAxXViwVgSpwcHODT68q8Y2lxoevzXkE08VveHf5kbsuG7qSD+PNY0uuX0ybRf38o9FnY/ng1i6tnZo9GGXupFSjLRnsd7f2lkm68uYYAehkcLn86xJvGmixZC3EsxHaOFz+uMV5avn7i4tAWPJZyCT+OamWa6H34AB7CpdZ9DeOWwXxO/wByPSIvHGkv94XUY9XiOP0zWtp+uabqLbbO8ieQ/wABO1v++Tg15XblZuCuG9OlJcWJ4deGHII4IPsaFVkKWBpbJtHtNFeaeHvF9xYSrbauzTW5OBMeXT6+o/WvRoZY54lkicPGwyrKcgitoyUtjz6+HnRdpfeS0UUVRgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDdXENrbvNcSLFEgyzscACsnxH4jstBtw102+Zh+7hX7zf4D3rzHUtT1LxRdL9qPl2ynKQITtHufU1nOoo6dTsw+DnW956R7mz4i8cXV9I1toAMMHQ3BHzv/ujsP1+lc7BpU88hluGaSRuWdySSfc10enaRDBGCw5q66oi/LismnLWR6UZworlpI5l9OEQye1VJGjVtrqcDvjitq+V2yBWSzzQ5WaIOnqBzj6VDVjeEnJXZqaVrF3Y7TZ3T+WP+WbHK/l2/Cr9x441iHrDYlD0YRuf/AGauY8lJAZLF9rDkoehohug+6KdcHoymmpNaEyw9OTu43Ni/8Yand27K9wkCEc+Qu0kfXJI/Cu1+H9hNYeHo/tGQ07mYIf4AcYH6Z/GuP8HaTpdzqafbrpzKrhoYCAEf6nuR6cfjXq9a0037zPOxs4QXsqat1CiiitjzQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKytd1u10WCKS6EjGRtqJGASTj3IrVrH8T2en3mmOuquIoEO8S7tpQ9iDSd7aF0+VzSlsef+JvEU+sAxP8A6PYf88Qcs/8AvEfy6fWsOJ55VC2kYSMcBiMDHtSSQ2qXM0okle1DHyhLjcR6kYqRGubk4jAhi7E9SPpXI227s+ihCNONoLQcLdwQZrkk9wOK0bdE2hQ24e9U002L7087v7E1chW2gHyN+tCRM5X2NK2s4mw2OaumzQrWPFqCKcA1dj1AEda0TRzTjMz9VsBg8fjUnhDxE+i3gsr1ibGRsAn/AJZHPX6ev51ZnmWUVg6tbAqWA5qXo7o1glUj7Opse1AggEHIPcUtcF8Ntfa6ibSrtsywLuhY/wASeh+n8vpXe10RkpK6PFrUZUZuEgoooqjIKKKKACiiigAooooAKKKKACiiigAooooAK5bxp4oi0G18qHEl/KD5addo/vH2/nWtr+qw6Npc15cchBhVHV27AV4hLLPqmoy3d026WZyzeg9APbHFZVZ8ui3PQwGEVZ88/hX4li0guNTu2ub2VppXOSzHJNdPZQxWqjgZFZ1qy20YCjmm3N2ccmsFoepO9R2WxtS3y9AarvdEjg1zkl6d2F5PoOTTPtbggPvTPTIxT5wWHSNW7mn5aNd3tVNdSZW23MRUdMkcfnUcd7LHzsdl9RzViO9t7kbHAyeDmpbLULLYbcRKQLi0Pzrycdx6GmSol9B5sfyzKOo6596imU2L742zATgj0pEmFvceav8AqZOvsaLlJPdFi00/UpbOO4itZZ4ixGYQXKMD0IHIPevSvBFxqk+nSDVY5RsbbE0ylXZcdx/XvXM+CdTWw1kwO2La9wo9Fk/h/McfXFemVvSj1TPJx9Zv3HFeTCiig+netjzAopgYg4YU8HI4oAKKKKACiiigAorD1/xJp2hqBdylpW6Qx4Ln3x2HvXn+s+PdTvSyaei2UPQEfM5/E8D8PzqJVIxOqhg6tbVKy7s9Tu7u3tE33U8UKesjBR+tc9f+OdDtCVW5a5cdoELfrwP1ryKZp7uYy3Usk0p6u7Ek/jU0dqfSsXWb2PShldOOtSV/wO9n+JUWT9k0yZx6ySBP5A1Sf4j3xP7vTrdR/tOzf4Vy6WhPapvsRx0qeeb6mywmGj9n8zoF+I2oj71han6Fh/WrEPxLlH+v0oEeqTY/TbXKGyb0pjWh9KXPPuP6rhn9n8z0G0+I+lyELc291bnudoZR+Rz+lb9h4k0e/wAC21CBmP8AAzbG/I4NeMSWpHaqsluPSqVaS3MpZbRn8LaPooHNFeC6Tr2raOQLK7fyh/yyf51/I9PwxXe6H8RLK52RarEbSY4HmLloz/Ufr9a1jWi9zhrZdVp6x95eX+R3tFRQTRzxLLC6yRsMqykEH8alrU88KKKKACiiigAooooAKytf0W31u0SC6aVFRw6tGQCDgjuD61q1l3muWFqSrTiRx/BF8xpNX3HGTi+aL1PMfFuj2ejanBDBPLLtjMrmVgcEnCjgDHQmqMNrf3S7ooyqHoXO3P4f/Wreu7RL7xDdahKZGSRw0ccgHy8Ac8+1WtU1KDTbThQ1w4Plp2z6n2rH2a1ctj1FjJtRp09ZdzjrmG7hnMLNGzAZO1ydv14pscWDmebp2T/GtfTNCv8AUI/tDHy4pCWMsgyXPqB/jirV1pthpMTSXUb3T9FV2xubsAP8c1moN69DreKjC0G7y8jDN1AmAoAPuealS5O4Y3jPqCBUcjwRu0zJEJW6LGoCoOwArX0fSDeHzL3OSMrH0wPf39qUYuTsi61WFKPNIginJ6HNOnPmRkGrGsaP9mUzWq7HUZKjgOPTHrVeBhNArjowzVSTWjM6VWNVc0THtLuTSdYt7yHIMUgYgdx3H4jIr3eKVZokkjOUcAqR3BrwXVlxJXsXgmf7T4W01yckR7P++SV/pVUXq0YZnBOEanyNyiiiug8cKKKKACiiigAooooAKKKKACiiigAooooA8s+KV81xq1vYIw8qBBIw/wBtvX8MfnXOWMGMGrGvSG98V6k+f+W7IPop2/0q8tt5UOfauN+9Js+kpr2VKMPIp3EoQYFJp2ny6kxckpApxkdWPoP8aqBWu76OBeC7YJ9B3P5V6BBbpa2IVFCqq4AHYVdOHM7vYwxmIdCKjHdmJZ2EcD7EQKB+Z+p71tNaWzwbJ0R1I5DAEVnxykyHaMsa07W2km+9zXTZWseI5Sb5m9TktZ0tNPzcWJLQD78ZOSo9QfSsya3iuYvNh+V8ZyOv416BdaaVXkcGuZvNBlRnfTvvDkwE4BH+ye30rCdPqj1MLjb+7Uevf/M56YTpYK1wAY5UJRxyMg4I+tWrzTZYYQ8MbvBIASg5KcdvUV1GjaQBogg1OIEvKZTG/OzsB19s/jWwlqsnyqBjoMURpXWoq2YOM7Q6N+jPOIoLlYE7hgMhvlKn19q9o0E3B0e0N5Kktx5Y3upyGPrnvXHajpSqDlcH1qx4KvpLW+ewmf8AcOCUDH7reg+taRgo7HHXxU66tJI7uiiirOYCARg1HtKn5elSUUAIpz2waWig4xz0oAK4Lxh4ya0lkstJ2NOMrJMeQh9FHc/Xil8a+J/LX7Dpc/7w/wCtljP3R6A+v0rz0rn3rCpU6RPVwWDT/eVV6IgZJJ53mndpJXJZncklj61ahtS3apraHcelbVhabiOKxjE9SpV5UZ9rppYjiti30sYHFbVnYgAHbWisAUdK1UDz6mKZgppgHah7ADtW8VFMZQRVcpj7aVznWsx6VE9mMdK6BohVedABS5TSNVnNXFqBnisq4t8E8V01woJNZ88IOeKzaOqnUZzrw1WlhFbksI9KqzQgA1DR1xqB4c8QX+gTH7M3mW5OWgcnafcehr13w3r9pr1oZbZtsq8SRMfmQ/4e9eJSpg1JZXNxZXKXFnM0M6dGT+R9R7GqhUcdOhz4rBQrrmWkj6Dorm/CPiSHXbRQ5SO+QYkizjP+0vqK6SutNNXR89OEqcnGS1CiiimQFNZgqlmOABkk9qdWL4kvIorGW2EyC4kUAJuG7aTycenvQFjD1C+uNWmZFcx2eSFReC49W/wqW00tAOFqpaERsg7Vv2k6KuCRQBU+xqvBUVTutBsry+guLhXdowBszhWGeMjvzWpdXCE8cmqrTkNmk0nuVGUou8XY1liQoe3Fcd4o0yO9ljcyyIYsgBMYOcdePatxr7C4zis+ZhK2eo7mhpPRhCcoPmi7MxNN8OojhwpeQdGk5x9B2rUhhezn+fpWnbvtX5TVXUWPl5OM+tCSWw51JVHebuyHVJVaJcdTXI2L7bcqDkBiB9M1o6jfCOB3duEBIHqewrAsptluqsecZP1rGq9Uj0sug3GT6aDNUO5q9W+HOf8AhErLP96T/wBDNeTXTB+a9g8DReV4U09fVC35sT/Wpo/EzfMnagl5m/RRRXSeGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeK2cO/xHfK/3hcPn67jXRanbBYfl9KyteiOleNbsEYSV/OU+obk/rkV0chW5tA454rmit0e7Vm/cmtrHE6MRHr8QfuGA+uDXaSOWtzzniuN1W1kgulnhOHVgwPvW1pWrJdwkH5JRwyf1HtVUXa8Wc2YU3O1VbWszQsYwZCTW7C4RRiuftWxKSDwe1akMmTitzyzXlkEkYz2qjFCDcZ7dqlVS69eKY58o5BoA0HtkaI5ArLjzBcYH3c0kuqFBs7npjms97qWRv3UUjE9yMD86BqLeyL+rXaMv0HNcw1rcXazPbL8x4BJx+taxs5bg5uXwv8AcTr+Jq5GixIFQBUXoKzlNW0Oyhhpc3NI5aH/AISa2OElvSo6bbhSPwBNW11rxNAMO96QPWCN/wBQK0LzWrC0BDzBnH8EfzH/AOt+NY1x4nuHJFpaBF7NKcn8h/jWF7dT1FTU94L7i4PGGtQj97Gxx3ks2H8iKafiBqKA71tBjkkwuMf+PVkm+1W4P7y7KKeyAL+uP609bWJxm5uJJT33sT/Wjml3E6FFbxXyC6+IetTcWflZPQpbnH5kmsm71DXNTO7Vr6YwdfJVsBvqAAK3VWyjHyrnFUNUlh2jYMe1J36sunGmnaELGOXIb2qWJtxFQSMCeKmth8wqDrktDbsYgcV1Gk2ucHFeTeDLye4+IGppFcan/ZyRMpiu0k2SzeZktGSuFRVO3GRnrg4yfWdFk1Dy9QbULSCC3jBNu9pO00si85JQxrtbAXgF+TjPHPRGOp5NerdHQLGEQcVFIwFeM2Gv+JtMl1ltMOrX+kyXlpHFe39nczfZYWEnmuImVZHcYj3BfkBYEAAEF8/irxvNrYgs/sjWDXltZJNLpE6llktfMacqZAQquMbT0zgkGtDgjK56xJKAagaaub8F6rf6x4T0q/1i3+zahPCGni2FNrcg/KeR0zg1sFjUNnTGN1csGaq80uaaWqNyKVzRRRDIRk1VlxU8lVZTUM2iV5QKz58cirsrcGs+c9alnTAoT9agLYqxNVRzzWbOuJLBPJDKHgd0kXlWQkEH2Nb1l451+2UBhJOo/wCekasf0OTXOQt+8ratb+OJArKCKqMmuplWpRl8UbmwPidfLxLawI3q0bgfnmrK+O9XuI8wRWuG6FIJH/k1Ykv2K7HK7G9qrQTXulSbrKciPP8Aq25U/h/hV88u5zLDUXtHU35tW8TaiuxXuo1PXZGsI/M8/lTdO0W5s5Jru6kXey4IDFyeRklj34pLDxah+XUYGib++mSv5dR+tbMWtabMuVvIcHs7bT+RoTV7tkzpNQcFGyfYjRgygZww71KryjjdWfci0GXtdStkB/heQEfge1Z76oYW2vLbv7pKpH866VOL6njTw1SPQ6q2I5aR+lCzJJPsBzXMw6kZR8h3fQ5qzZ3XlOWc4Y1Ri1bc6d7eLGTVC7mSJCBVCXUw3G6qFxcGTnd8o70CNqGfEW4nrWbqt+BEVzk1l3WrJEuwuMjsOT+VZUks9821VKIepPU/T0qJTUTpo4WpV2Vl3G3DPezBVz5an8zT5Lcxrk1r6Vph2gAcVa1OySGAlj2rnacveZ7NOUaSVOOxyEzYzXvGjW5s9IsrduGihRD9Qorxzw3Yf2l4gt4CMxK/mSf7oPT8eBXuCnIFXQW7OTNZ/DD5i0UUV0HkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHFfEfRjfWsV7bAm6twRgdXXrj6965PQ9Y2RiOQ/L05r1i/QPARXnPiDw0sszXFiwilY5ZT91j6+xrnqKzuj18HUjOn7OfTYZdtBOvBBzXO3lpiXdESrDoVOCPxouUu7BsXMToOm7qp+hqMXoPes27noQpuO2pLa397bNjcJF/wBoc/nWkniGZQN0HPsf/rVn20qO3zd61YdNWcZQiqjKXRnPVw9Bu8o2/Ami8UOo/wBRJ+lNk8QPM3Mcir3IwT/OiXSii5I6VXitAXwarnmZLDYd7L8WWF1wQA/Z7Usx6vI/P5Yqrca7qsg/ciGIf7K5P6n+lXTYoq5OKzbl0icqDxUO+7Z0U1BaRiVHv9VlbD3ko/3SF/kKUW9zcn9/PNID2dyR/Oo3uV31bttRSL0NSrG0nJLRFyx0n0TA9cVJcWsUBO7GRULeIgibVqi8l7fsWSMqp/jfgf8A1/wptpIyjCpJ3lsLeXCJwpqvC1zcHEEMjj1A4/OrkVhbW2JL6YSv1CHhfy6mrRv3lG22idgOB/CMVN7m6SiismmXrjMksMI9CSTWbqcMttMI5JBIpGQy8fpWw63jLl3ii+nJ/wA/hWDqGfNy0hkboSaGmVBxb0K4GTVuAYIqoh5pdJ1G31DzxbsfMt5TFLG4IeNh6j0PUHuORSQ5tbG5pOoxTo0lmr3Ko4TMeAGOQCVYkAgc5x6EdeK7nTJ7rypBFBESHQIXkIDrxuJwpwRlsDuR1Gcjyz4dMV8H6G5PzSWcUrfV1DH9Wr0nSbnCAZreOjPLxEeaKZq30l1tmCC3GHXyyxJyvG7cMcH72MZ7VkXMl1mbZHC+HURhpCMpxuLHacH72AM545GeLtzOSOKpEkmrbOanCxRsdSgv576ODeHspzbShxjDbEfj1GHU5q0xrnNM/wBH8ea9ABhLi1tbsHsXzLG3/jsaVvs1SzaOoMawzqM914ivtMgIiitbe3maYAFi7u/y4PGNsf8A49xVXW9ZutC1Pz9RQPoEqqv2lFwbN+mZeeYzx84+6evHIp+Fbu3vtc8UXdrPFPH9sihV4n3ghbeI9Rx1dh9QaRW7sb88G/zd002HdWADkbMY4BHbjkd8ntVSeBG83LTDzHVziZhgjGAOeBwOBgHnOcmrsjVTmbmpubxRUnhDebiWVTI6scOeMY4HoOOg681hXd5PbeJLa0dw9rdwyyLuABjkQx/KD3BDOecnIPOOBuytzXMeJcLrPhyXv9seIn0DW8v9VWpNrWVzSlPNVJDg1akxVSbrWbOuIRKXkVV4ZiFH1ziuu/4R20EYVpZS4HJBGCe/GK5CEESAg4IOQfeumtrq9ZATsmGOp4P50IKjt1IrrQriDLWknmqOdp4P4etQ2spLeVcKVYcEMMGtNNSaP/XRSIfbkfnT55bLUFG5wsvZwcEfh3pmb95CR6VHcJlQDUcmgj+5Ulst7a8xkTIOm04OPpVhtaeHieJ0P+0pFWuVnNL2sXoZE2j+X0X9Krtpxx92tS412N89Kz5tVMnyxKWPoozSaiaQdV7lX7CgfkYPqOKuRWc7gBLiTHYHBqrsv5PmSyuSvr5bf4VJBqD2rgSo6MOzAg0J2KqQc1Z2ZZawvV6znH+6P8KqvaSsSsksrexJA/KtIa8jLgjmqM2pK77hTcr9TKnScX8KXyQ2GxVCDgVs2cSKBkCsNr7J4p8Vzc3B228ckh9EBNJNI0lCUlqdYl9BaxHkbq57UL241S6+z2ql2Y4AXsPU+gp9toOo3jBrhhbxnruOWx7D/E11el6fb6fDstkwTjcx5LH1Jp3b9DFRhSd92WvCGix6XBjh7l8GR/U+g9q7JegrJ0xeBWsOldNNWR42Kk5TuxaKKKs5gooooAKKKKACiiigAooooAKKKKACiiigCOcZjIrn79cFhXQv0NYWpjD1nM68K/esZCgEkMMg8EHpWTf6BY3Mh/deSx/ii4/TpWqeH/GiY8g1zs9hNp6HHXfhu6gYtZzJKB0VvlP/ANf9Kqi7v9ObE8EqY7lTj8DXayN8xp8rZhBpW7GnNeykrnFSeI3kXaxqBdWct8gLN2Art3UNDuIBPqRUbMEUAcewodxxUOiOWQ6tdriO2kC+r/KP1qe28O3E+WvrjYOyx8n8+1dEJP3ZJ4FVbrUY4E2lwpPr1/AUvUavtFWIY9E0+FAGh3kdWdiSf1pktvpdupb7LCcdSw4qrJc3NyT5KlEP8b+nsP8AGmiGCI77mQysP7xyAfYUWuDklu7set0X40+1jUf3lQIP5c08Ws8w33NxsHdY+P1qncasqfLCAAOmKqG4vbs4jVyD3AOPzp6IlKcttDUZbK2yQAW7k8mqs2rIo2wj8qZDpEsmDcTbc9hya0odJtUUfu959WJNHMUqSWstTnp72WU9cfSqUu48k59a7mK1iRQFjRR6AAVna/YJJatNEgEqcnb3HepeprFpaI5XDlHEbBXIIUsMgHHBIyM/nXIeILHxUYmu9KtbNdbjTYl3aXAUSrnlXikXB7kZY4PfGa6+Nvmq/CeacZWIrU+dWvYzPhiZ/wDhB9DFzgSx2qRkAYwFGAD7gAD6139jIVArhPBjfZpNV0tuGs7x2QHvFKTIhHtlmX/gNdpbnGK06nG17qRrl9wpuaijbinE1Rz2OeJA+IZPrpQz/wB/eP51uu1c9bkz+PtQkAPl22nwQhuxd5JSwH0Cp+dbjtQxwMHU9BOoXc0l1q+q+Q+AttDOIUQYwQCgDHnJ5Y1y/wAO/C+m+EfEHiXT9LSVUkNvcL5j7iI2DhV+gYSc9fUnFd+7VzGoZsPGNrqDI/2W5s5LeeUAlYzGfMjLHHAw03J74HelfoVyJNSOgkNVJTzSz3ttH5geeJPLi859zAbE5+Y88Dg8+1VJ7u3Qyb54l8uPzn3OBtTn5jzwODz04qTpiEhrmvEhDan4ejB635Y+oC28x/nt/Oty4uoU8zdIMpH5rAckLzg49ODWHfwy3PifS5BGfs1vBNKXI48xtiqAfXaXpGj1X3GjIarPy1TyHmoGrJnXESMfMK0oLx4enIpvh+BZ9SRXUMiqWIPI9v511ptIHGGhjI/3RTiRUtszAj1TtIlPMtpckBlC5/CtW40m1Yf6rafVSRVGXQVIJhkIPo3NVdmXJHoEdqVw1rduvoCcj8qm+0X8H+sjEq+qHB/KsuWxvbbkAsvqhzS2+pTwnbLnj1ougcZrZ3NmHUoC2HAR/R1wfzrQS6yOMY7Vire29wAJVQ565p62aN81pMY29AePyp27E86+0rHQRz7lIzzUgCTQlXUOB2YAiueWe5tWxcJvX+/Hz+YrRsr6NmyjhlPBHp9aE7bg4pq8Rz6dYSHLWcOfUKBSro+nEE/Y4/1/xqd2Ab2NT27g8etBLva5Rj06yjOUtIcjoSgNXwoRFVFCr2AGBSEAGpWxtWmiWx8YITNSx9FoUAxU5ANq1Ri2bemj92K0hVDTh+7FXxXRHY8es/eYtFFFUYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFIaAGueKxdVIBrWkY5rF1Qkms57HXhl7yMeU/vKSb7gpJjhqbK2VArnZ7KWxHIw3fhT34txUT4zSztlFXoO9Iu2wSviBQO9Ubm4SIFnYADqTUGoXwVxFEN79gP5k9qqfZSzCW9fcRyF7D6Cjcq6gtRZL2e7Gy0QqveRxgfgKhZYLU75m8yU9S3NMvdSEaeXDgfSqdtZ3F++4/Kndm6fh60aISUp76IkuNTZiVjzilg068vMMw2Ie78fkK1LLToLZlIXe4P3m5P4VvbNyA0LUp2haxz9vo8EBBceY3q3T8q10gHljaMAdAKleKp7dcrihImU9CgY8VNGuVxU8sfNMRSDRawc90RFcVGyg5BGQeCKuSR8Zqu64pNDjK555PGYLqSM9UYr+tW4D0NP8AEcPlao7DpIAw/kf5VDbNkCpRvJ3Rcitbc3i3flgXAUKZFyCy84Df3gNzHByATkVp2kCoIsSSnyiSN0hO7OevPPXv0qhC1X4GrRM4pxLkECoIsSTHyiSN0hO7Ofvc89e/SnxW8MflYDkxEspd2YgnOcknnr3pI2p+atMw5ULGkUEQjgjSONckIgAA5ycD6nNMdqVmqFmpDSBjUTHilJqJ2wKRokMkbrVZzUjtUMh4pM0SIJDVeQVO/Won71LNkVGHJqGTirTrVWXrioZtE2vCUebid/7qBfzP/wBaushHNYPhGHFnNJ/efA+gH/166OFeatGNSW5HMe1LAoNSSpk06JMECn1Mr6CTQjy8gVnTWcU3EkYb6jmtyRf3dVNnNDQoVDnrzQUxvtnKH0bkfnWXLDe2ByynZ6jkV3ToCoFQTxDbgjINFi41L7nJW+qnhZeRVsxQXBDwsYpuzLx+dWrrRYLhiVHlt6r0/EViXFtdadLk5ZAeGHIP+FF+43BN+7ozZS9eBVS9XA6CVeh+vpWhBMFYHOVPIIrEs9SSVdkygg8EGpGV7cb7T95D1MZ6r9DQ1fYSlb3ZHSSMMhh3qQtmJTWVY3S3MHynkcEHqD6Gr0L5jKntRcTiXA37nIqS3kDKB71BF80DCmW5IfFUZOKaZ1mnH92KvKaztNP7sVoJ1rpi9Dw6y95j6KKKoxCiiigAooooAKKKKACiiigAooooAKDRRQBBIOTWTqa8Gth+tZeprmM1Etjqw795HMztl8UyRsYpJeJDVe4lAP8ASuRnvxjsO8wbsk8Cs65uZbuYxWmQBw0nZfp71CWlvpCsR2QDhn9fYe1PubuKyh2Q4GKaXVkzlZ2juI/kafGSfmkPJLHJJrInup7yXZCCxPQClihn1OctyEB5J6V0lpp8dvCFiXnue5obvsOMFHWW5maZpCKd9zh39OoH+NbKQ4IwMAdBToU2vV5ItwoSCc7FJocHNaFqu6PaetKYvlNLbfK1NKxjOfNEa6YpIVIerjoCc9qjK4bNVaxmp3QskQPNQtEB0q0OaYy0NExk0VscYqrOpFXXUjmoJFDDHepZvCVmcj4rgzHFOB0JU/TtWHatiu01W1NxaSw/xEcfXqK4mLKuVIwQeRUM64u6NOM1chaqETZFWojVIxmjRibipt3FUo2qYNVXOdxJWao2amM1MLUDSHlqhkahmqFmyaCkhrNk1G1ONMapNEiFutRN3qVj3qJjSZoiOTpVNxlqtStxUEMbTSqiDLuwUD36VDNVodxoEQi0i3GOWUsfxJNa9uvGarQRCOOOJPuooUfTFXlXaoFao5KkhCoxmkhXL09umKfAuBmmjJvQdIPlquE5q0wzTQtBKdkRlar3C1e29TUEiEmhjjLUpRrgEmqssYcnvnqD0rRlTauBVQqc1LOiEupz+o6SCd9qNjjqo6H6VRtb2SCTZKCCOCD1rsBHnORWPq2npdZI+WQdD/Q0tjRNT0YxVWX9/bNsnHJx0b2Iq3ZXqyPsb5JB95D1+o9q5uGWWzn8uXKlTWqQl4FeM7LheVYf1p7mdnDR7HR2suGKnoalTHmcetYtldlztkGyVeGH9R7VqwSAyj3oTFKPU6zTD+7FaK1maYfkFaiV1R2PArfEx1FFFWYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAET9ao6gv7pvpWgw5qpfLmJvpUy2NqbtJHC3smyRsdaxJXe9naFDiMHDv6n0FaOuK73PkRHDNyzD+Ef41mXM8dnB5UOBjvXJbW7PoVP3Uo7j767S1i8mHjAxxWdY2r38peTIiHU+p9BTbC1e/uNz5EYPJ9fYV1lvarGioi4UDAApN3LjFQWu4lpbpHEqooVR0Aq9GvGKbCuDjFWUXFUkYzmVvLw9XbUcYNMKZOaeo2ninYyk+ZErrjPpVcDa9WwQy1DIvOabREH0JEbK4NIaYpxT+vNMTVhVNDUCloERkBhiq0qEdKtMKjb3pM0i7GfMAw964fXbb7NqTEfdk+cfnzXoEsSsOK5nxVZl7UTAfNEefoeKiSOulJbGFA3SraHvWbA3NXo2yKSZU0XUapQ3FVEbiplbiqMWh7NTC1IzUzdTBIVmpueaCabmkMGqF2zUjNxULUmWkRueMVCxqR+tQu2Kk0RFK1anhS287UfMI+WJd349v61jucmu08H2wh00yuMNK5YeuOg/rRHVjqPlib9vHgbjUvU5pAcjA6UhPYVocLu2KPmNTqMCo41qWmiZPoJSikpw60yWOA4ppUU+mscCglFaZc1XMfNXdu6lEQqbXNFPlKbLtjJ71QZdzVq3Q421TCDNJo2pysrmTqWnR3UJyMOv3W9K5yOSWzuCknBFdzMny4rH1XT0uoyMYdejVL0NoyUlZlbi7jWWFtk69D6+xq9pt0Jgu75ZFO1l9DXN20slrOUfKsDgitqJS0qXMP3xjeB/EKe5m/c06HoukHMY+lawrI0QgwKRyCMg1r11Q2PBxHxsdRQKKs5wooooAKKKKACiiigAooooAKKKKACiig0AIagnXKEd6nqNhSZS0OA8TxC0R2UfOxyTXF28Et/cYz8gPzH0Feq+INNS8t3356cYrkrfTxZpsUEc5JPUmuaotT3cFUUoa7haQLDGqRjCrWpbruAHpUcEIIqzEuxqiKN6kr7DtuDVlF4pjrxmpIm4xVo5ZO6GEc0MKkYDOaQjimK4iHtTmXIpo4NSDmgTK5FOU9qc60zoaRW4/oadTOopQaYh1RutPzSNzQCK0inFZ1/EZoJIm6OpX9K1HYrVWcgjpUM3pt3PNVUpKUYYYEgj3q7F2p2tw+TqsvGFYhh+XNFuMioR1yd1cnTing00cGngVaMGJmmFuaeQcVGRzQxoXNITRikakMaxpjU41G54oZSIXPWq0jVLIxFVHY5qGbQRLbRNcXMcS/edgo/OvRraERRoi8KihQPbGK43wnCZNS8wj5YlLZ9zwP612ykmnFGVZu9iZTxgVNGvc1HEmasAYFaI5JO2goGKU0lIx7UzMUcmnAU1RUlCEwpj8048UgGTTEhyLT24FA4prtgUyd2VZ+TUSLlqlbk0+NeCag3vZFeVapSL1rRlHWqUi80ma02YOtWPnJ5kY/eL+oqHRbgrOit64Nb7KCKr6fpAbUlZR8hOT7GlHcurJcjudxpEeyBcdDyK0xVW0Ty4wvoKtrXYkfOTd3ccKKKKZmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNIzTqKAIJkDKQRXOana4ckCuocVRvIQ4NRJXOrD1eSRzMSbTUrLjmp5ovLY1F1GKwtY9Pm5tUEbArg0gO1qYcqaf94Uh2Jd2RS1ErVKpzVENWEIpVNBFIDQIeRmo2WpAaRhTEnYipaUim1Je44GkZfSkzTgaYtiJxkc1TnXrWgWHeq8wQ1LNISszjPFUWJIJcdQVJ/l/Os61bgVv+LEBsUYDlZB/I1zdq3as+p2J3iaFPQZpiDIqeJatGTEKVGV5q4E4pjJTJTKuKYwqyVFROuKVikyswqGSrDjFQsKRoinLVVx81XpRVOQYaoZtBnW+DogthJJj5pJCM+wAx/M11MMWeTWN4YQQ6PbA9SCx/Ek1vREtWkUcdaTuxwAHAp3WjbgU0tiqMNxWOKQc00ZY1Mq4oB6ABThRRTIEPJpyigCn0ITEPAqGVqe7VAeTQ2VFDQKsKAFqNBzmnsaSHLUhl5zVV1q4wzULrSZpF2KuzmtzRbYY3Ec1nQQl3ArpbCHy4xV046nPi6to2LWMYqRaKFGK3R5LHUUUUyQooooAKKKKACiiigAooooAKKKKACiiigAooooAaajcZqWozSZSM29t9wJArJddprpXUEVl3tv1IFZSXU7qFXozMKhhTBlTUjLtNBAIrM7UxnuKkjbBqPpS+4oBq5ZwCKYwxSRtTzzTM9hqmpKjPFKGoBistRlalBzSEZpgmV2yKQNjrUrLUDqak0TTJeGFVplIzS7ippTKCOaRSTWxg+I49+lTeqkMPzFcjAcNXe6nCJ7OdF5LIQB744/WvPo2+YVD0Z109YmtC2cVbhHNULdulX4W5qkZyL0agimyJRG9OZgRVGGtyq61XcVbeoHApGiKMnWoWFWpFqBhipNYsqy8A1Sk61cnNV4EEl1Ch6NIFP54qGdEdj0PTIStrboBjEajH4CtdFESZY81TSZYxhRz2pDI8p74rVWRwyTmyw8u48UKpNNjTHWpgABQQ7LRDlUAU7NN3UoNUZsdS0gpwxQSwAoZsCkZgKiZiaGwSuIxzSAEmnBc08LgUi72E6Cmk0rGkoYIKYVzT6lgjLsKAbtqT6fBlskVuxrhQKq2kQVRxV1a3irI8uvPnkGKXpRTWqzAdS01adQDCiiigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUlLRQAwioJowwq0RTGWk0VGVmYd3bYJIFUCCprpJogwrJurfBJFZTiehRrX0ZQIzSdKcy7TSdazOu4A1IrVGBzThQhMkPNNPFLRTJEBp4YGo8UmcUBa5IcU1l4pu6gP60DsyN0BqB1wKuEAioZF4pNFxkUmrz3VIvsupTxAYUOcfTqP516JKuK4/xfblbmK4A+V12k+46fp/Ks5HZSepn20vStKF+KwoHwa0IZsd6ExzgaqyYp3miqaSgjmnFxVGLiWGkFRM47moXkHaoy1Fx8pK7A1XlbihmFV5ZBUtlpEM7VNoMPn6xbL2Vi5/AZH61SlYnJrofB1od0t444I2J7+pqeps/djc6uJATzVxFAHAqGBe9T5Nao4Zu47gUhak5pdtMzEBJp4pAKcOKBMcDQW9KaTSUxWA5NAWlC1Iq0rA3YRVoY0rNgVExzTEtRCaWilRdx4pFCxoWNa1nBgAkVHZ2vQkVqRoAK1jE4q9bohY1wKkoAxS1qcLYYpKWigQlLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA0jNV5oQwPFWqCM0NFKTRhXNsecCs912munliDCsy7te4FZSgd1GvfRmVS0skZU02stjs3HilqMGnhqYmhaTilK00jFAhGUHpTMGpB1peKB3sRgkUbgRzTioNRuMUilqRzRhhxWTqdiLu2eCTjPKn+6exrUaQrUE0oIqXY2p8yPNbqCS1uGimXa6nkdj7j2ojlIruL+0t76PZcJkjow4I+hrnLnQLiMkwMkq9hnB/Ks7WOxSUtymk9SecPWq0trcQHEsMie5Bx+dR7sdadxOCLplJ700yGqnm47ZFKspY4VHJPQAZouHISySmoGcnqeKnWzvZj8lrLz3KkD860bPw5cSkNdyJEndV5NIrSO5m2FnLqNysMA46s56KPU16BZWyW0EcMQwiDA/xqPTbW3sIfKgTavUk8lj6k1pRlD7VcUc1Wo3p0HRrgVJinApijIq7HK3cQClpCaTmgQtGaTFOC5oAaKeq1IkfrTjhadiXLsNC4pGbFIz1Gcmi4JdwLZopVjJ6CrMNozEcUJNg5xjuVkQscAVqWdr0JFT21mF6ir6IFFaRgcVbEX0QkcYUVJiiitTjbuFFFFAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApjxhhT6KATsZ1xZhs4FZc9qyHgV0uBUUkKOORUOCZ008Q47nLMpHWkyRW7PYA8qKz5rNlPSsnBo7YV4yKyvTwQaY0LDtTORSNLJ7ExjB6VG6laA5FNkm4obBJjWbAqpNOQafJIW4FVxC7ngE1DZ0wilqxhl3HmmsCelaNtpM0mMIce9acOhtxvIFNQkyZ4mlT6nMiFj2qRLVzXXxaRAn3hk1aSygXpGKpUTnlmUVsjixYyHopP4UpsnA5U/lXciJFGAo/KkaGNuqj8qr2Jj/aUr7HB/ZSO1MaBh2rvDaQHrGv5VG+n27f8ALMUexNFmS6o4MxuD0pQpFdq+k27dsVXl0OI/cOKj2LNVmNN7nLx+9SbsVrzaLIn3BuFUJrR4zhlIpcrRrGvCezGRMSasjJFU9rp0pyTMDzSTHKN9i6q1II6himzU281ZhK44RjvTsqvSo+TThGxpkPzBpPSoyS1WUtie1WorP2p2bIdSMTOSEtVqK1J61pR2oHap1hAqlAwniexThtAO1XI4QoqULilrRJI5ZVHIQLiloopmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMZFbqKfRQBWktI2HTFU5tP/u81q0VLimaRqyjszBawf8Au1G2lyN2rosCil7NGyxc0YcGijOZDx6VpQWUMIG1Bn1q1RTUUjKdec92IFx0FLRRVGQUUUUAFFFFABRRRQAUUUUAFRyQpIMMoNSUUAnbYzLnSopASnymsy40qROQNw9q6agjNQ6aZ0QxVSHU5OOzkB5U1ehsnPUVubF9KULjtSVNIuWLlIzo7H1qwlogq1RVKKMHVk+pEsSjtUgXFLRVENthRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cho described a technique in which a straight number 7 or 8 needle with #1 chromic catgut is  used to place sutures in a small rectangular array to compress the anterior and posterior uterine walls  against one another at sites of heavy bleeding. The through and through sutures extend from the serosa of the anterior wall to the serosa of the posterior wall. After creating a square, the ends are tied down as tight as possible to compress the myometrium. Two to five squares/rectangles are made, as needed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Cho, JH, Jun, HS, Lee, CN. Hemostatic suturing technique for uterine bleeding during cesarean delivery. Obstet Gynecol 2000; 96:129.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_7_27775=[""].join("\n");
var outline_f27_7_27775=null;
